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Abstract 
 
 
Work described in this thesis shows the design and synthesis of functionalised, triple 
stranded, dinuclear, supramolecular helicates. Click chemistry has been utilized to 
functionalise the parent ligand with dansyl and coumarin moiety’s. These ligands have 
been used to successfully form four novel metal complexes upon reaction with iron(II) 
chloride. The stability and fluorescence of these complexes has been monitored. 
Imidazole ligands has been functionalised by the addition of alkyne and azide side chains 
to allow them to undergo click reactions. This modification has not been shown to impede 
complex formation, as the ligand have been utilized to form novel triple stranded iron(II) 
and nickel(II) complexes. 
Synchrotron imaging has been used to produce elemental maps of cells treated with the 
parent metallo cylinder. This has allowed the uptake of the complex to be monitored. Two 
novel bromine functionalised cylinders has been developed to allow co-localisation 
experiments to be undertaken using XRF imaging. Cryo-SXT experiments have been 
undertaken to examine the morphology of HeK cells after treatment with parent metallo 
cylinder. 
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1 Introduction 
 
 
Deoxyribonucleic acid (DNA) carries the genetic information used in the growth, 
development and reproduction of all living organisms. The nuclear genome is comprised 
of approximately 3.2 billion bases in human DNA[1]. This information is stored in 23 pairs 
of chromosomes in diploid cells. The mitochondrial genome is a circular piece of DNA 
comprised of approximately 16.5 thousand bases, with approximately 10 copies of this 
DNA per mitochondria and 8000 copies per cell [1].  
 
DNA mutations and damage can be caused by a number of factors including, copying 
errors during replication, mutagenic chemicals and certain types of radiation [2]. If these 
mutations and changes in DNA sequence are not repaired somatic cells may accumulate 
so many mutations that they can no longer function. Carcinogens and mutagens can cause 
tumors by changing the sequence of DNA and by the errors that are introduced into the 
cell during its efforts to repair this damage [2]. UV and ionizing radiation such as X-rays 
and atomic particles cause modifications in the DNA.  This is evident from the rise in 
leukemia in survivors of World War II who were near atomic bomb drops, and also in the 
development of melanomas from the prolonged and repeated exposure to sunlight [2]. 
There are a number of DNA lesions that require repair including missing bases, altered 
bases, incorrect bases, bulges caused by insertion or deletion of a nucleotide and single or 
double stand breaks. Ineffective or error prone DNA repair mechanisms can perpetuate 
mutations, inducing tumour formation [2]. As such, DNA has long been viewed as a target 
for cancer therapeutics, either in its ability to detect these lesions or to induce them, such 
as the stand links caused by cisplatin. By causing these lesions in cancer cells it is hoped 
that the cell will induce DNA repair mechanisms. The DNA damage at the site of the lesion 
can be too great and the repair mechanisms fail, leading to the programmed cell death of 
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the cancer cell by a number of mechanisms including apoptosis. However these agents, 
such as cisplatin can be very genotoxic, leading to subsequent tumours, commonly 
leukemia later in life [3]. A move towards more specific DNA targets and DNA processes 
has been seen in recent years, hopefully lessening the toxicity to normal cells. An example 
of this would be the development of trastuzumab emtansine (Kadcyla), an antibody drug 
conjugate made up of the monoclonal antibody trastuzumab (Herceptin) linked to the 
cytotoxic drug emtansine (DM1) [4]. This has been used to treat HER2 positive breast 
cancers, where Herceptin binds to the HER2/neu receptor of the tumour and stops the 
growth of cancer cells and DM1 enters cell, binds to tubulin and destroys cells [5]. 
 
1.1 DNA  
 
 
DNA was first isolated in 1869 by Friedrich Miescher [6]. Its molecular structure was later 
determined in 1953 by James Watson and Francis Crick [7], whose names describe the 
Watson Crick base pairing observed in duplex DNA (Figure 1.1). DNA is formed from 
repeating subunits of deoxyribonucleotides. These nucleotides are comprised of a 
phosphate group, a 2-deoxyribose sugar and a nucleobase. The nucleobases Adenine (A) 
and Guanine (G) are heterocyclic purines, whilst Thymine (T) and Cytosine (C) are 
pyrimidines [8]. Watson Crick base pairing denotes that adenine binds with thymine via 
two hydrogen bonds, and guanine binds with cytosine via three hydrogen bonds [9].  The 
sugar phosphate backbone is made of alternating phosphate and ribose groups. DNA is 
very rarely found as a single strand, and instead hybridises together to form a double helix 
with a hydrophobic core, formed by hydrogen bonding between the bases[9]. It is this 
hydrogen bonding combined with solvation of the external polyphosphate backbone that 
stabilize DNA.  
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Figure 1.1 Shows the duplex structure of DNA, the alternating phosphate and deoxyribose sugar 
units forming the sugar phosphate backbone. The structures of the DNA bases adenine (A), thymine 
(T), cytosine (C) and guanine (G) are shown with the Watson-Crick base pairing and hydrogen bonds 
between the bases depicted as red dotted lines. (Taken from reference [7]) 
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Figure 1.2 Conformational shape Of B-DNA, A-DNA and Z-DNA (from left to right) ((Taken from 
reference [1]) 
 
There are many possible confirmations of duplex DNA, with A, B and Z forms being the 
most common (Figure 1.2). B-DNA is the most prevalent form of DNA found in organisms. 
It is a right handed double helix and has 10.5 bases per rotation. The site of attachment 
for bases to the backbone leads to the formation of a deep, narrow minor and a shallow, 
wide major groove. These are both used as targets for therapeutic agents.  A-DNA is also 
a right handed helix, but with a wider diameter that B-DNA and also more base pairs per 
rotation, leading to a shallower, wider minor groove and a deeper, narrower major grove.  
This A-form of DNA is also the conformational structure that RNA duplex and RNA-DNA 
hybrids take, as observed during transcription. Unlike A and B-DNA, Z-DNA is a left 
handed helix. It has a greater number of base pairs per rotation, 12, leading to little 
difference in its major and minor grooves, and a narrower helix diameter than B-DNA. 
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Figure 1.3 Model of the major groove in A-DNA which id deep and narrow and B-DNA that is wider. 
(Taken from reference [10]) 
 
Figure 1.4 The Schematic diagram shows Hoogsteen base pairing with hydrogen bond formed 
between the purine bases (A and G) and the pyrimidine bases (C and T) (Taken from reference [11]). 
 
As well as duplex DNA, other structures are possible, such as triplex DNA, junctions and 
quadruplex structures. The triplex conformation arises when a third strand of DNA wraps 
around a B-DNA structure, filling the major groove of the double helix. This third strands 
usually targets purine rich areas and is held in place by forming Hoogsteen pairs with the 
purine bases (Figure 1.5). 
 
Many junction structures have been observed in DNA such as Y-shaped junctions, three 
way junctions (3-WJ), four ways or Holliday junctions (4-WJ) and B-Z transitions. Y-
shaped junctions are formed whenever DNA is processed, commonly during transcription 
or replication, when the enzyme helicase unwinds and opens the DNA duplex leading to 
the formation of a transcription/replication fork/Y shaped junction. Since cancer cells 
have an increased replication rate, Y-shaped junctions can be an advantageous target for 
therapeutic agents. Three way junctions are formed when three strands of duplex DNA 
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converge towards a junction point (Figure 1.5). At this junction point, one strand from 
each duplex of DNA pairs with another strand from a different duplex with a 
complementary sequence, producing the three-way junction. Holliday or 4 way junctions 
are important in genetic recombination. They are formed when two duplex structures 
converge and one stand from each duplex, pairs with a complementary strand on the 
opposing duplex, forming a box like junction (Figure 1.5)  
 
Quadruplex structures are commonly found in guanine rich areas of DNA, particularly in 
the telomeres and nuclease-hypersensitive promoter regions. Four guanine bases are 
held in a coplanar fashion by the formation of Hoogsteen bonds, forming a guanine tetrad 
(Figure 1.6). One strand of DNA folds up, stacking three or more tetrads, leading to the 
formation of a G-quadruplex (Figure 1.6). There can be loops of DNA above and below the 
face of the quadruplex. The quadruplex can also adopt a parallel or anti parallel 
conformation depending on the direction of the strand that forms the tetrads. The tetrads 
can be further stabilized by a sodium or potassium cation occupying the central channel. 
The small size of sodium allows it to sit between the middle of one tetrad; potassium’s 
increased size means it has to occupy the space between two tetrads. 
 G-quadruplex structures are thought to be functionally important in transcription 
regulation and DNA replication. The extension of telomeres is inhibited by the formation 
of a quadruplex, as it stops the enzyme telomerase. The extension of telomeres is up 
regulated in cancer cell, making quadruple structures an important target for anti-cancer 
drug design.   
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Figure 1.5 3D models that show the structure of triplex DNA, three way junction DNA, G-Quadraplex 
DNA and four-way/Holliday Junction DNA. (taken from reference [12]) 
 
   
Figure 1.6 (Top) Schematic diagram showing a guanine tetrad stabilised by a metal ion in the central 
channel, with dashed lines depicting the Hoogsteen bonding between the guanine bases [13]. 
(bottom) Schematic diagrams depicting three guanine tetrads staked on top of each other, with a 
DNA strand forming loops around G-quadruplex, (left and centre mixed parallel/antiparallel 
qurdruplex, right antiparallel quadruplex) [14]. 
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1.2 Molecular DNA recognition 
 
Due to the variety of conformational forms DNA can adopt there are a number of 
structural targets for therapeutic agents to bind to and interact with. Such as the major 
and minor groove, junction points, replication forks, quadruplex structures, backbone and 
bulges. The components that make up DNA can also be targeted: alkylating agents bind to 
DNA bases, whereas backbone binders attach to the highly anionic DNA phosphate 
backbone. 
1.2.1 Major and minor groove binding 
 
 
The major groove of DNA is wider and deeper than the minor grove; this increase in size 
allows it to accommodate larger molecules. The major groove is a common binding site 
for protein molecules. They bind non-covalently using DNA sequence recognition, 
forming hydrogen bonds with the edges of base pairs [15]. Naturally occurring zinc finger 
proteins are relatively small protein motifs that bind in the major groove of DNA. Their 
alpha-helix regions form base specific interactions with DNA[16].  Oligonucleotides also 
reside in the major groove of DNA, forming a triplex. Their recognition can be used to 
regulate gene expression, as the strand can recognize a sequence specific target of the 
duplex [17]. The synthetic drug ditercalinium (Figure 1.7) interacts with DNA by a non-
covalent interaction, resulting in the chain linker sitting in the major groove of B-DNA [10]. 
Neomycin is a non-aromatic aminosugar antibiotic. The lack of aromatic rings limits its 
binding to the major groove of DNA, with it preferentially preferring A-form over B-form 
DNA [10]. Synthetic supramolecular structures such as the metallo-cylinder developed by 
Hannon also bind in the major groove. The metallo-cylinder is a similar size to naturally 
occurring zinc finger proteins (~2nm by 1nm)[18]. (Discussed further in section 1.5.1 
Metallo supramolecular helicates) 
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Figure 1.7 Structure of ditercalinium which interacts with the major groove of DNA. (reproduced 
from reference[10]) 
Due to their small size a large proportion of synthetic agents preferentially bind in the 
minor groove over the major groove. Diarylamidines compounds such as DAPI, berenil 
and pentamidine all bind to the minor groove of DNA and are effective at treating 
protozoal diseases [19]. DAPI has had limited clinical use due to its undesirables side 
effects, however due to its fluorescent nature it has been used as a chromosomal stain for 
fluorescence microscopy. DAPI has a high affinity for the ATT sequence in DNA. It binds 
in regions high in A-T base pairs as these form a narrower minor groove in the DNA, 
leading to a snug fit around the DAPI molecule[20].  
 
  
 
Figure 1.8 Structures of the diarylamidine minor groove binding drugs DAPI (top left), Berenil (top 
right) and Pentamidine (bottom). (reproduced from reference[19])  
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1.2.2 Intercalation 
 
 
Intercalation occurs when an aromatic planar molecule slides between two base pairs in 
DNA. The drug is held in place by forming π-π stacking interactions with the bases 
situated above and below the binding site[21]. As the aromatic molecule inserts into the 
DNA it causes the double helix to unwind slightly causing the DNA strand to lengthen by 
3.4 Å[22]. This lengthening leads to conformational changes in the sugar molecules present 
in the sugar-phosphate backbone and overall nucleotide structure at the intercalation 
site[22,23]. As the DNA backbone is relatively inflexible, once one molecule has intercalated 
onto the DNA, another molecule can’t insert into the adjacent site as it would result in too 
much strain in the DNA. This is known as the ‘neighbour exclusion principle’[15,21].  
Doxorubicin (Figure 1.9) is an anthracycline antibiotic that was developed in the 1960’s. 
It has been very effective at treating solid tumours and acts via intercalation. Ethidium 
bromide and Rhodamine (Figure 1.9) are further examples of planar aromatic molecules 
that bind via intercalation. They are both fluorescent dyes that are used in fluorescence 
microscopy[24]. A range of inorganic intercalators have also been developed, including 
ruthenium(II)[25][26] and rhodium(II) octahedral[27] complexes and platinum(II) square 
planer complexes[28]. Ethidium bromide has also been attached to a platinum(II) complex 
(Figure 1.9) as a potential intercalator, resulting in a molecule able to bind to DNA via 
intercalation and coordination[24]. 
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Figure 1.9 Structure of the intercalating agents Doxorubicin (top left), Ethidium Bromide (top right), 
Rhodamine 123 (bottom left) and an ethidium bromide platinum complex (bottom right) 
(Reproduced from reference [24]) 
 
 1.2.3 Alkylating agents 
 
 
Alkylating agents act by forming covalent bonds with DNA bases. They normally favour 
binding at the N7 position of the purine bases. Nitrogen mustards are a class of cytotoxic 
chemotherapy agents and are based on the chemical warfare agent mustard gas. 
Chlorambucil and bendamustine are chemotherapeutic nitrogen mustards. They form 
aziridinium rings via displacement of a chloride ion. The aziridinium ring then attacks at 
the N7 position of a guanine bases [29]. The formation and attack of another aziridinium 
ring results in an interstand crosslink. Cyclophosphamide is the most commonly used 
nitrogen mustard, it requires metabolism by hepatic cytochrome P450 enzymes for it to 
become active and is used to treat leukaemia and Hodgkin’s disease [30].  Another classic 
example of a successful alkylating agent is cisplatin and its counterpart’s oxaliplatin, 
nedaplatin and carboplatin (discussed further in section 1.3.1).  
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Figure 1.10 Structure of the nitrogen mustards Chlorambucil (left), Bendamustine (centre) and 
Cyclophosphamide (right) (Reproduced from reference [31]) 
  
1.2.4 Backbone binders 
 
 
Backbone binding molecules recognize functional groups on the sugar phosphate 
backbone of DNA. The sugar phosphate back bone is oxygen rich and polyanionic, making 
it a target for cationic molecules that can form hydrogen bonds with the phosphate 
oxygens. Few synthetic molecules act as backbone binders. However, the triplatinNC 
complex designed by Farrell et al. binds selectivity to the oxygen rich backbone. The 
complex binds by forming hydrogen bonds between its amine groups and oxygen 
molecules of the phosphate backbone [32]  (Figure 1.11). Recently a range of non-steroidal 
anti-inflammatory drugs have been bound to copper to enhance their anti-cancer activity. 
It is thought that these molecules act by binding to the DNA backbone, their sensitivity 
changes with alteration to the backbones structure and hydration. 
 
Figure 1.11 Model of triplatinNC binding to oxygen molecules in the sugar phosphate backbone. The 
dashed lines indicate hydrogen bonding between the NH3 molecules of triplatinNC and oxygen-
phosphate molecules on the DNA. (Taken from reference [33]) 
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1.2.5 Targeting DNA quadruplex structures 
 
 
As previously discussed the vast majority of DNA in the body exists in the B conformation, 
with some adopting the A, Z, quadruplex and junction forms. These unusual structures are 
all advantageous targets for DNA recognition. Quadruplex recognition can be achieved by 
loop binding, π-stacking, or central channel binding. Randazzo et al. have shown that 
distamycin A (Figure 1.12) can selectively bind to the groove of the quadruplex in a 4:1 
binding mode with the parallel quadruplex [(TGGGGT)]4. π-Stacking ligands sit on top of 
the quadruplex. They are generally large flat aromatic compounds, such as TMPyP4 which 
is able to stabilize a G-quadruplex structure. Thiazole orange is another π-stacking 
molecule; it also sits on the face of the quadruplex. Due to it fluorescent properties it is 
used in displacement assays for testing new compounds as quadruplex binders. Metal 
based quadruplex binders have also been developed, such as the platinum based 
complexes by Che et al. (Figure 1.13). The platinum metal center keeps the ligands in a 
square planar geometry allowing the molecule to bind externally in an end-stacking mode 
at the terminal face of the quadruplex.  
 
Figure 1.12 (Left) Model of the G3 tetrad showing the 4:1 binding of distamycin A, whose structures 
is depicted in yellow and green. (Taken from reference [34]) (Right) Structure of TMPyP4, a π-
stacking quadruplex ligand (Reproduced from reference [35]) 
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Figure 1.13 Sturcture of the platinum complex designed by Che et al (A), models of this complex 
binding to the face of a G-quadruplex of c-myc DNA, side view (B), top view (C) (A - reproduced; B 
and C - Taken from reference [15]) 
 
1.2.6 Targeting DNA junctions 
 
 
The Holliday junction is important in genetic recombination, although few synthetic 
agents bind to the four-way junction. The proteins responsible for this recombination of 
genetic material are the Ruv proteins A, B and C[36]. RuvA consists of four sub units (Figure 
1.14), this tetrameric protein binds to the Holliday junction and targets the hexameric 
RuvB protein to the junction[37]. It is these proteins that are responsible for branch 
migration of the Holliday junction. The heterodimeric DNA-binding protein Integration 
Host Factor (IHF) is able to bind to the Holliday junction[38]. IHF is found in E. coli, it 
regulates around 120 genes and many DNA-protein interactions[39]. IHF is also able to 
bind to the minor groove of DNA and the phosphate backbone.  
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Figure 1.14 Model showing the protein RuvA (grey) binding to a Holliday junction. (Taken from 
reference [40]) 
 
Targeting of three-way junctions can be achieved by the supramolecular helicates 
discussed further in section 1.5.1. The metallo-cylinder has an unprecedented mode of 
binding as it binds non-covalently to the center of three way junctions (Figure 1.15). The 
cylinder does not undergo any significant conformational changes upon binding in the 
hydrophobic cavity of the three-way junction. The cylinder has twelve aromatic rings, 
resulting in a large aromatic surface, leading to the formation of π-stacking interactions 
with DNA bases in the junction. The cylinder is also tetracationic resulting in electrostatic 
interaction between the cylinder and the polyanionic backbone. These forces along with 
van der Waals interaction’s and short range hydrogen bonds give rise to the cylinder’s 
ability to bind non-covalently to the DNA. 
17 
 
 
Figure 1.15 Model showing the electrostatic interactions between the iron metal centre and the 
phosphate group of the backbone (A). Model showing the π-stacking interactions between phenyl 
groups in the cylinder and the bases in DNA, as indicated by the double headed arrows (B). (Taken 
from reference [41]) 
 
1.3 Metallo anti-cancer drugs 
 
 
 This most successful chemotherapeutic agent used to date is cisplatin. Cisplatin is a 
platinum based complex whos effects on E. coli were first was discovered in 1965 by 
Barnett Rosenburg. Its clinic application was approved in 1978 for the treatment of 
testicular and ovarian cancer. Cisplatin has a number of side effects and drawbacks which 
have led to the development of a number of platinum analogues and interest in other 
metal centers as discussed below. 
1.3.1 Platinum based anti-cancer drugs 
 
 
The first platinum based metallo drug to be discovered was cisplatin, in the 1960’s[42]. It 
is comprised of a Pt(II) metal center with two ammonia ligands and two labile chlorine 
ligands. This small molecule is able to enter cells by diffusing across the cell membrane 
and also via Cu transport proteins. Cisplatin is an alkylating agents (although it platinates 
rather than alkylates, is it referred to as an alkylating agent in clinic) and forms 
intrastrand links on the N7 position of purine bases in DNA (Figure 1.16). It has a 
preference for binding to guanine adducts over adenine adducts, with the majority of 
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intrastrand crosslinks being formed between GG bases (60-65%) and GA bases (22-
30%)[43]. It is these DNA adducts that cause inhibition of DNA replication, arrest of the G2 
phase of the cell cycle and apoptosis[44]. The distortion it induces in DNA structure (a 45ᵒ 
kink) is recognized by DNA binding proteins, which either initiate DNA repair 
mechanisms or signal to initiate apoptosis[45]. The discovery of cisplatin revolutionized 
anticancer treatment and gave rise to an increase in testicular cancer survival rates [46][47]. 
 
Figure 1.16 Schematic diagram showing how cisplatin forms intrastrand crosslinks at the N7 
position of two guanine bases on the same strand of DNA, resulting in inhibition of replication and 
apoptosis. (Taken from reference [48]) 
 
However, cisplatin causes a lot of unpleasant side effects which are thought to be due to 
the complex binding to proteins [42]. Some cancers are also resistant to the effects of 
cisplatin whilst other tumours develop resistance after prolonged exposure to the drug. 
All of these pit falls have led to the development of new platinum based anti-cancer drugs 
including Carboplatin, Satraplatin, Oxaliplatin and Nedaplatin [49] (Figure 1.17). 
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Figure 1.17 Structure of cisplatin (top left) Nedaplatin (top centre), Carboplatin (top right), 
Satraplatin (bottom left) and Oxaliplatin (bottom right) (Reproduced from reference [49]). 
 
1.3.2 Non-platinum metal based drugs 
 
 
Due to the success of platinum based anticancer drug in clinic other metal based 
complexes were developed. Changing from platinum to a different transition metal allows 
different geometric complexes to be developed. This could alter the metal complex’s mode 
of action overcoming one of the main drawbacks with cisplatin, which is that cells become 
resistance to the drug. Changes in coordination number and geometry could also have the 
potential to increase specificity for cancer cells. The use of a metal complex over organic 
complexes is the ability to easily impart a charge to the complex. This can be useful for 
electrostatic binding to the DNA.  
1.3.3 Iron based anti-cancer drugs 
 
 
Iron is an abundant metal found in vivo and is required for many biological processes; 
including DNA synthesis, cell growth and proliferation and is vital in the oxygen transport 
chain. Iron is also regarded as a DNA damaging metal. This feature makes it a popular 
20 
 
target for synthesizing anti-cancer agents[50]. Iron’s biological compatibility and low cost 
makes it a useful metal center for developing metallo-drugs. Cancer cells also have a 
higher requirement for iron than normal cells. Depletion of iron in tumors leads to 
hypoxic areas and ultimately cell apoptosis[51].  
 
A novel approach to chemotherapy developed by Richardson et al.  is to administer iron 
chelators, which bind to the free iron in-situ in the cancer cell, causing the cell to go into 
apoptosis, but limited damage to free normal tissues[51] .  
 
The mononuclear polypyridyl complexes developed by Chen et al. (Figure 1.18) are 
fluorescent, allowing their cellular localisation to be monitored[52]. The increase of 
planarity in the polypyridyl iron(II) complexes leads to a increase in lipophilicity and 
cellular uptake[52]. The ability for the complex to be uptake more effectively leads to 
improved anticancer efficacy.  
 
 
Figure 1.18 Structure of the monocular polypyridyl iron(II) complexes developed by Chen et al. 
(Reproduced from reference [52]). 
 
A range of pentadentate pyridyl iron(II) complexes have been developed (Figure 1.19). 
They show higher cytotoxicity in a range of human cancer cell lines than cisplatin[53]. The 
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complexes have been tested on HeLa cells and induced apoptosis after 18 hours of 
treatments[53]. An iron(III) complex has been developed with two 5-nitro-8-
hydroxylquinoline ligands and is thought to bind to DNA via an intercalative binding 
mode[50]. In T-24 cells it shows lower cytotoxicity that cisplatin and is thought to act via a 
mitochondria-mediated apoptotic pathway[50]. Iron complexes formed with the 
glycopeptide bleomycin been shown to cause double stand breaks in DNA[54].  
 
 
Figure 1.19 Structure of the pentadentate pyridyl iron(II) complexes developed by Che et al. (Taken 
from reference [53]) 
 
1.3.4 Ruthenium based anti-cancer drugs 
 
 
Ruthenium has the ability to mimic iron in biological systems by binding to biomolecules 
such as human transferrin, serum and other proteins[55]. This property makes ruthenium-
based drugs less toxic than platinum based drugs. Ruthenium can exhibit a number of 
oxidation states, has ligand exchange rates comparable to platinum and favors an 
octahedral geometry[55]. This is in contrast to the square planer geometry of platinum in 
cisplatin, hopefully leading to a different mode of action and reactivity.  
 
A range of polypyridyl-Ruthenium based complexes have been developed, with a view to 
the polypyridyl ligand intercalating with DNA. A number of these complexes are also 
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photoluminescent allowing their localisation to be monitored, leading to the creation of 
DNA-targeted anticancer drugs[56]. 
 
The ruthenium based complex trans-[tetrachlorobis(1H-indazole)ruthenate(III)] 
(KP1019) has been shown to be affective against a range of cancers (Figure 1.20). Clinical 
trials have been undertaken with KP1019[57]. The complex induces DNA damage and 
apoptosis in colon cancer cells as well as inhibiting proliferation in ovarian cancer cells[58]. 
KP1019 is thought to bind to transferrin once it is administered. This could be useful in 
targeting tumour cells due to their high expression of transferrin receptors[55]. 
 
Figure 1.20 Structure of the ruthenium complex KP1019 (Taken from reference [58]). 
 
A tetrapyridyl ruthenium based prodrug has been developed that is activated in-situ by 
green light (Figure 1.21). Treatment of A549 and A431 cells show a 22 fold increase in 
cytotoxicity after irradiation with green light at 520nm compared to cell treatment in the 
dark[59]. The trans-ruthenium complex is activated by a ligand photo-substitution 
reaction, its trans monodenate sulphur ligands are replaced by water molecules upon 
irradiation[59]. 
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Figure 1.21 Structure of the ruthenium prodrugs developed by Bonnet et al. (Taken from reference 
[59]). 
 
1.3.5 Nickel based anti-cancer drugs 
 
 
Nickel has been used as a metal center for the development of novel anti-cancer drugs as 
it is a first row transition metal and can support a multitude of coordination numbers and 
geometry’s. These changes in geometry from the square planar geometry of cisplatin will 
hopefully lead to complexes that act via a different mode of action, overcoming the 
resistance mechanism that arise from long-term cisplatin treatment. 
 
Two novel nickel based complex’s containing disalicylidene chelating ligands have been 
developed by Bal-Demirci et al[60]. (Figure 1.22). These complexes where tested against 
K562 leukemia cells and are shown to be cytotoxic against these cells, whilst being 
nontoxic to normal mononuclear cells at their IC50 doses[60]. These complexes induce their 
cytotoxic effect by triggering apoptotic pathways, as they are shown to cause between 75 
and 78% DNA fragmentation in K562 cells[60]. 
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Figure 1.22 Structure of the nickel(II) complexes designed by Bal-Demirci et al. (Reproduced from 
reference [60]). 
 
A courmarin based nickel(II) complex has been developed by Zhu et al. (Figure 1.23) and 
was tested against PC3, HepG2 and HL60 cancer cell lines, showing the greatest affect 
against HepG2 cells[61]. It is thought that the complex interacts with DNA by a form of non 
calssical intecalation, as there is a lack of red shift in the electronic spectra upon complex 
binding to DNA. There is however an observed hyperchromism in the electronic spectum 
showning the active participation of courmarin moieteies in associating with the DNA. 
The toxicity of the free ligand was also tested aginst the same cancer cell lines and the 
IC50 value was considerably higher than that of the metal complexes, showing that the 
inclusion of a metal improved the toxictiy and potentially alters the complex mode of 
action. 
 
 
Figure 1.23 Structure of the courmarin based nickel(II) complex developed by Zhu et al. 
(Reproduced from reference [61]). 
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1.3.6 Copper based anti-cancer drugs 
 
 
Copper is an endogenous metal and as such is thought to be less toxic to the body than 
non-essential metals such as platinum [62]. Copper is essential for the function of an array 
or proteins and enzymes that are involved in energy metabolism, respiration and DNA 
synthesis. Copper complexes have also been shown to poses antibacterial, antifungal, 
antiviral and anti-inflammatory properties[63]. Another advantage for designing copper 
based drugs is their ability to enter the cell by copper transporters, meaning they can be 
effectively internalized into the cell without the need to attached them to cell penetrating 
peptides. 
 
One hypothesis for copper complexes anti-cancer activity, is due to their ability to form 
reactive oxygen species. The hydroxyl radical (OH) is thought to be the main species 
responsible for causing DNA damage in cells under oxidative stress[63] [64]. 
 
The Marzano group have developed a range of copper(I) complexes with triazolyborate 
ligands (Figure 1.24). When tested against A549 cells these showed activity rates that 
cisplatin under the same conditions, with IC-50 vales up to 26 fold lower  than that of 
cisplatin [65]. 
 
Figure 1.24 Structure of the triazolyborate copper(I) complexes designed by the Marzano group [63]. 
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A range of copper(I) complexes containing hydrophilic alkyl phosphine ligands have been 
developed by Santini et al.[66] (Figure 1.25). Reducing the lipophilicity of the overall 
molecule increased the cytotoxic activity for this series of copper(I) compounds. These 
compounds were tested against a variety of cancer cell lines, but showed the highest 
cytotoxic effect if A549 and HCT-15 tumour cells, showing better cytotoxic activity than 
cisplatin. This result shows that these copper(I) complex are able to overcome intrinsic 
cisplatin resistance that occurs in these cell lines and acts via a different mechanism of 
action. It is though that the copper(I) complexes have a different target site that acts 
through impairment of ubiquitin-proteasome degradation pathways[66]. 
 
Figure 1.25 Structure of the hydrophilic copper(I) complexes designed by Santini et al. (Reproduced 
from reference [66]). 
 
1.4 Fluorescent probes. 
 
 
The addition of a fluorescent probe allows drugs to be monitored using fluorescence 
confocal microscopy. This allows the localisation and uptake of drugs to be observed over 
time inside cells. This can be achieved by the addition of an organic fluorophore or a biotin 
molecule - the biotin moiety can then bind to a streptavidin complex attached to a 
fluorophore. The use of a fluorescent marker has been used to achieve a greater 
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understanding in the mode of action of a number of drugs used in clinic including cisplatin 
[67][68][69][70]. 
1.4.1 Fluorescent dye-anticancer drug conjugates 
 
 
Carboxyfluorescein diacetate (CFDA) has been grafted into a cisplatin analogue (Figure 
1.26). The CFDA moiety is non fluorescent; after administration to live cells the acetate 
group is hydrolyzed by esterases and the complex becomes fluorescent [70]. After 2-3 
hours the complex accumulates in the nucleus as observed by fluorescence microscopy. It 
has been argued that a large lipophilic fluorophore would scientifically change the 
pharmacokinetic properties of the complex, meaning it can’t accurately be compared to 
cisplatin[71][72].  
            
 
Figure 1.26 Structure of the fluorescent cisplatin analogue CFDA-Pt developed by Molenaar et al. 
(Reproduced from reference [70]), and its localisation in cisplatin resistance A2780 cells (scale bar 
10µM) (Taken from reference [69]). 
 
Tamoxifen is used in the treatment of breast cancer; it has been covalently bound to the 
fluorescent dye nitro-2-1,3-benzoxadiazol-4-yl (NBD), forming the compound FLTX1[73], 
(Figure 1.27). NBM is commonly used as a biomarker in hydrophobic environments[74]. 
FLTX1 was designed so that the triphenyl moiety in tamoxifen can bind to the active site 
of the estrogen receptor protein, without being affected by the NBD moiety [73]. FLTX1 
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shows near identical pharmacological properties to tamoxifen, showing the addition of 
the fluorophore has little impact on its binding[73]. 
 
 
Figure 1.27 Structure of the Tamoxifen and nitro-2-1,3-benzoxadiazol-4-yl (NBD) dye complex 
FLTX1 (Reproduced from reference [73]). 
 
1.5 Supramolecular chemistry 
 
 
Supramolecular chemistry has been defined by Lehn as the chemistry of molecular 
assemblies and of the intramolecular bond [75,76]. Supramolecular chemistry studies the 
weak and reversible non-covalent interactions between molecules, including van der 
Waals forces, π-π interactions, hydrogen bonding, hydrophobic forces and electrostatic 
effects. Such structures are formed from organic ligands bound to metal cations forming 
a variety of shapes through self-assembly, including cages[77], knots[78] and helicates[79] 
(discussed below). These structures have been used in an array of applications including 
the formation of cages [80], MRI agents [81] and anti-cancer drug delivery systems [82]. 
1.5.1 Metallo supramolecular helicates 
 
Metallo supramolecular helicates are formed from the spontaneous self-assembly of 
organic ligand strands wrapping around cationic metal ions. These complex can be 
double, triple, tetra or multi stranded. The design of the ligand and its binding sites 
dictates the shape that is forms. The helicate ligand is made up of the desired number of 
binding site, which are separated by a spacer. The spacer must be flexible enough to allow 
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the ligand to form a helical complex, but also rigid enough to prevent coordination of other 
binding site to the same metal ion. Helicates can be formed using homo or heterotopic 
ligands. Homo topic ligands have the same metal binding sites; heterotopic ligands have 
different metal binding sites. The use of heterotopic ligands leads to the formation of two 
different isomers, head to head (HH) or head to tail (HT)[83] (Figure 1.28).  
 
 
Figure 1.28 Schematic diagram showing the formation of helicates using homotopic and heterotopic 
ligands (Taken from reference [83]) 
 
Metallo helicates are chiral due to the way in which the ligand wraps around the metal 
ions in a helical fashion. Helicity is a special case of chirality. When viewed down the 
helical axis the ligands can wrap round the metal ions clockwise and are called right 
handed (P or plus) or anti-clockwise, left handed helix (M or minus) [83]. The use of an 
achiral ligands leads to the formation of a racemic mixture of M and P enantiomers, which 
can be separated using chiral chromatography [84] (Figure 1.29). 
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Figure 1.29 Helicity of a dinuclear triple stranded helicate, P (left) and M (right). (Taken from 
reference [84]) 
 
A number of helical complex have been developed that interact with DNA and have been 
tested as potential anti-cancer agents.  Two novel double stranded helicates have been 
synthesized by Adamski et al. using quaterpyridine and copper(I) and silver(I) salts [79]. 
1.5.2 Supramolecular metallo cylinder. 
 
 
The Hannon group has developed a supramolecular helicate comprised of three bis-
pyridylimine ligands wrapped around two cationic metal centers (Figure 1.30). Its 
cylindrical shape gives rise to its name as a metallo-cylinder. The ligand is synthesized 
using inexpensive commercially available starting materials and can be made into a 
complex by the addition of an iron salt, in a one-pot synthesis reaction. 
 
Figure 1.30 The molecular structure and synthesise of the parent ligand and the triple stranded, 
dinuclear, tetracatioinc supramolecular iron(II) cylinder. 
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The size of the metallo cylinder is comparable to that of the naturally occurring zinc finger 
proteins, (2nm in length by 1 nm in diameter). The metallo helicate has a 4+ charge, 
causing the complex to be attracted to the anionic backbone of DNA. The size of the 
complex allows the cylinder to bind in the major groove of B-DNA, spanning 5 base pairs, 
and its strong cationic nature gives rise to a strong binding constant in excess of 107 M-1 
at 20mM NaCl with ct-DNA. When the complex binds in the major groove of B-DNA it 
induces a structural change in the DNA, allowing the cylinder to act as a cytostatic and 
potent apoptotic agent. Atomic force microscopy (AFM) has also shown that the cylinder 
causes dramatic intramolecular coiling of linearized plasmid DNA upon treatment with 
the cylinder [85] (Figure 1.31). The cylinder is also able to unwind duplex DNA with an 
unwinding angle of 27 °. 
 
Figure 1.31 AFM image of linearized plasmid DNA before treatment and after treatment with the 
iron cylinder, causing dramatic intramolecular coiling of the DNA (Taken from reference [85]). 
 
The metallo-cylinder was crystallized with a palindromic hexanucleotide sequence and 
showed an unprecedented mode of DNA recognition [41]. The DNA had formed a three-
way Y-shaped junction with a hydrophobic hollow center that was occupied by the 
metallo-cylinder, Figure 1.32. The helicate is held in place by an electrostatic-dipole 
interaction between itself, due to being tetracationic, and the anionic DNA phosphate 
groups. The phenyl rings in the central spacer of the ligands form π-stacking interactions 
with the thymine and adenine bases in the junction [41]. An example of a Y-shaped junction 
is a DNA replication fork. These are formed whenever DNA is processed, prodominently 
32 
 
during transcription and replication. The ability to block DNA processing leads to 
cytostasis at low molecular concentrations and apoptosis at slight higher concentrations 
in numerous cell lines [86][87]. The metallo helicate is also able to bind the central cavity of 
RNA three-way junction, stabilizing the structure [88].  
 
Figure 1.32 (Left) Schematic structure of the three-way junction formed using a palindromic 
hexanucleotide sequence. Model showing the metallo cylinder residing in the hollow cavity of the 
three way junction, top view (Centre), side view (right)  (Taken from reference [41]).  
 
 The metallo-cylinder is synthesised using an achiral ligand, leading to the formation of a 
racemic mixture or right handed (P) and left handed (M) enantiomers (Figure 1.33). Both 
enantiomers are rac isomers as the stereochemistry is the same around the metal ions. It 
is possible to separate these enantiomers by chromatography on cellulose using 20mM 
sodium(I) chloride as eluent, with the M enantiomer being eluted first [89] (Figure 1.33).   
 
Figure 1.33 Structure of the P (left) and M (right) enantiomers of the iron(II) metallo cylinder [88]. 
Enantiomeric separation of P and M enantiomers on cellulose paper, eluted with 20 mM sodium 
chloride (Taken from reference [89]). 
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The P and M enantiomers of the metallo cylinder have been shown to have different 
effects on DNA and hence different binding modes. Through static light scattering and 
AFM experiments it has been shown that the M enantiomer is more effective at 
condensing DNA than the P enantiomer [90]. The P and M enantiomers are both able to 
cause supercoiling of DNA, whilst having very little effect of the base to base interactions 
that are monitored by CD, as such they resemble histone that DNA condenses around to 
pack into chromosomes [91]. The P enantiomer of the nickel metallo cylinder has been 
shown to preferentially bind to G-quadruplex DNA over duplex DNA [92]. In the presence 
of sodium(I) ions, the P enantiomer can also convert G-quadruplex structures from an 
antiparallel to a hybrid conformation (Figure 1.34). 
 
Figure 1.34 Diagram showing the P enantiomer stabilising a G-quadruplex and its ability to change 
an antiparallel conformation to a Hybrid in the presence of sodium ions (Taken from reference [92]). 
 
A number of modifications have been made to the parent ligand structure to try and 
improve specificity and cytotoxicity, Figure 1.35. The parent ligand (1 in Figure 1.35) has 
been reacted with a number of metals including iron(II), nickel(II), cobalt(II), 
ruthenium(II), copper(I) and silver(I). Reactions with copper(I) and silver(I) salts leads 
to the formation of a double stranded dinuclear structure [93]. In solution these complexes 
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form an equilibrium of cyclophane (box) and helicate structure [94]. The addition of ethyl 
groups on the central spaced (ligand 7, Figure 1.35) lead to the formation of an exclusive 
helical structure upon reaction with copper(I) salts [95]. The copper(I) cylinders have a 
decreased 2+ charge, compared to the 4+ parent iron cylinder. Charge is in important 
factor for complexes binding to DNA, and as such the copper(I) complex binds less 
strongly than their iron(II) analogues [95]. The dicationic copper(I) cylinder doesn’t cause 
coiling of DNA like its iron(II) tetracationic counterpart. It is thought that charge is also 
an important factor in bending and coiling DNA [95].  
A silver(I) metallo-cylinder has also been prepared using ligand 8 (Figure 1.35). This 
double stranded dinuclear complex contains a major and minor groove within its 
structure [96]. 
 
An extended triple-stranded tetracationic iron(II) metallo-cylinder has been developed 
using ligand 6 (Figure 1.35). The addition of two ketimine groups in the spacer leads to a 
longer and slightly wider helicate than that formed using the parent ligand [97]. This iron 
(II) complex bind in the major grove of DNA, causing some bending and coiling of the DNA, 
but the effect is much less dramatic than that of the parent cylinder [97]. This effect shows 
that DNA coiling isn’t just a consequence of the complex change but also the size and 
shape, with the parent cylinder interacting more strongly with the major groove.  
 
Ruthenium based metallo-cylinders have been prepared using the parent ligand (ligand 
1) and a bisazopyridine ligand (ligand 9 Figure 1.35). The parent ruthenium(II) metallo 
cylinder is of near identical shape and size of the iron(II) based parent complex [87]. This 
complex is able to bind to the major groove or DNA and cause dramatic coiling like its 
iron(II) counterpart [87]. The ruthenium analogue is highly stable due to the kinetic 
stability of the ruthenium(II) to nitrogen bond, which allows its cellular affects to be 
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attributed to the complex rather than its constituent components. The synthesis of this 
complex is laborious and produces low yields of pure triple stranded product (~1%).  The 
parent ligand and cis-[Ru(DMSO)4Cl2] are heated to reflux for 5 days at 200°C, forming an 
array of products including triple stranded and polymeric stands products. Double 
stranded ruthenium complexes have been developed using a bisazopyridine ligand 
(Ru2Cl4L2), (ligand 9, Figure 1.35) with five possible geometric isomers (three cis and two 
trans) [98]. Out of the possible conformations cis-α and trans-γ show the highest 
cytotoxicity in HBL100 and T47D cell lines [98]. 
 
 
Figure 1.35 Structure of the parent ligand (1) and it modifications. (Ligands 5 and 10 contain a Me 
group in the 3,4,5 positons) (Reproduced from references  [99][96][93][98][95][97]) 
 
Chiral arginine residues have been grafted onto the parent cylinder (Figure 1.36), this 
enhanced the complexes recognition of DNA three way junctions [100]. These complexes 
have shown increased cytotoxic activity against cancer cell lines compared to their parent 
counterpart [100]. The addition of chiral moieties allows the formation of pure 
enantiomeric products.   
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Figure 1.36 Structure of parent ligand modified with L-arginine (top) and D-Arginine (bottom) 
residues (Reproduced from reference [100]).  
 
1.6 Thesis aims  
 
 
The work undertaken in this thesis is an extension of the research conducted on the 
supramolecular helicates discussed in section 1.5.2. The aim of the work discussed herein 
is to develop a novel supramolecular helicate functionalised with organic fluorophores. 
This is to allow the localisation and uptake of the complex to be examined and gain a 
greater understanding of its mechanism of action. Their stability with be monitored by 
UV vis experiment and their DNA binding properties will be probed using circular 
dichroism. 
The use of synchrotron imaging techniques will be employed to observe the localisation 
of the parent cylinder. Elemental maps will be produced, to obtain the location of the 
cytoplasm and nucleus of the cell. Iron maps with show iron rich areas within the sample, 
which can be overlaid with those of the cytoplasm and nucleus to allow the irons location 
to be determined. XANES scan will allow the oxidation state of the iron to be compared 
against a number or prepared iron standards, making it possible to check that the iron is 
still bound to the complex.  
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2 Pyridylimine cylinders 
 
2.1 Introduction and aims 
 
As discussed in Chapter 1, the parent metallo-cylinder designed by the Hannon group is 
comprised of three bipyridylimine ligands and two metal centres[1]. The complex is of a 
similar size to the naturally occurring zinc-finger proteins, and as such is able to bind in 
the major groove[2] of DNA and also three-way junctions[3][4]. Cell testing of the parent 
metallo-cylinder has shown it to be cytotoxic against several different cell lines and unlike 
many commonly used platinum based drugs, such as Cisplatin, it has been shown to be 
non-genotoxic[5]. 
  
The main aim of this work is to gain a greater understanding of where the metallo-
cylinder localises within cells and how quickly it enters them. One of the main drawbacks 
of the metallo-cylinder is its lack of traceability within cells. To overcome this its iron 
metal centers have been studied using synchrotron imaging (see chapter 4), but ideally a 
luminescent cylinder would be developed that’s localisation could be monitored using 
fluorescence confocal microscopy. Ruthenium analogues of the metallo-cylinder have 
been created, but only in very low yields (around 1%) and are weakly luminescent[6].  
 
2.2 Molecular design 
 
An attractive way to address this challenge would be to produces a scaffold ligand for the 
cylinder which could easily be functionalised with a variety of fluorescent groups. One 
way to add a catalogue of fluorophores to the ligand would be through click chemistry, 
which occurs when an azide and alkyl group react in the presence of a copper catalyst to 
produce a triazole ring. An alkyl or azide group would need to first be added to the end of 
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the ligands pyridyl group. A synthetic preparation for alkyl functionalisation has already 
been developed in the group and employs the use of a Sonogashira reaction[7]. The 5 
position on the pyridyl group was chosen as the site of modification. This increases the 
length of the cylinder but has the least effect on the complex DNA binding[8]. Modification 
in the 6 position was not considered, as this would add steric hindrance near the site of 
metal coordination and prevent octahedral coordination to first row transition metals. 
Modification in the 3 position increases the width of the complex and has been show to 
weaken the DNA binding[8]. Modification in the 4 position hasn’t been explored before as 
functionalisation as this site is synthetically challenging.  
 
 
Figure 2.1 Molecular design of a flourophore functionalised pyridylimine based metallo complex 
 
2.3 Sonogashira reaction 
 
 
The Sonogashira reaction was developed by Kenkichi Sonogashira[9]. It is a cross coupling 
reaction that forms a new carbon-carbon bond. The reaction occurs between a terminal 
alkyne and an aryl or vinyl halide[9]. It is a double catalytic cycle mechanism (Scheme 2.1) 
that employs a zerovalent palladium complex such as Pd(PPh3)4 and a copper(I) halide 
salt. Palladium(II) pre-catalysts can also be used such as Pd(PPh3)2Cl2, as they have a 
greater long-term stability for storage[10]. These are reduced in-situ by a phosphine or 
amine group[10]. The reaction is conducted under basic conditions using triethylamine as 
a solvent which neutralises the hydrogen-halide byproduct produced during the reaction 
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and facilitates in the formation of a key copper acetylide. If a Pd(II) catalyst is used it is 
first reduced in situ to Pd(0), this species then undergoes oxidative addition with the aryl-
halide. The CuI salt forms a π-alkyne complex, making the terminal alkyne proton more 
acidic. In the presence of triethylamine, the π-alkyne complex is deprotonated forming 
copper acetylide. The alkyne group then undergoes transmetallation from the copper to 
the palladium metal catalyst, reforming the copper halide catalyst. Trans-cis 
isomerization occurs on the palladium metal, followed by reductive elimination, leading 
to formation of the new carbon-carbon bond and regeneration of the Pd(0) catalyst. 
 
Scheme 2.1 Sonogashira reaction cycle 
 
 
 
46 
 
 
2.4 Click chemistry 
 
Click chemistry is a cycloaddition reaction between an azide and an alkyne, leading to the 
formation of a five membered triazole ring. Click reaction are generally catalyzed by a 
copper(I) catalyst, however copper(II) is usually used and reduced in-situ using sodium 
ascorbate as it is non-air sensitive and can be used in aqueous conditions[11]. Click 
reactions can also proceed un-catalysed (copper free click chemistry) by using a highly 
strained alkyne in an 8 membered ring, the reaction proceeds due to the ring strain of the 
triple bond being decreased when it is reduced to a double bond[12]. The advantage of click 
chemistry over Huisgen 1,3-cycloaddition is that only the 1,4-substituted product is 
produced. This is in contrast to the Huisgen 1,3-cycloaddition which proceeds under 
thermal conditions and produces a mixture of the 1,5 and 1,4 regioisomers[13]. Another 
advantage of the click reaction is that it can proceed under mild reaction conditions, in 
aqueous solution. If a Cu(II) catalyst is used it is first reduced to a Cu(I) species with a 
slight excess of sodium ascorbate. The excess stops the formation of oxidative 
homocoupling products. It has recently been proposed that the mechanism proceeds 
through a mononuclear catalytic species, π,σ-bis(copper) acetylide and a bis(metallated) 
traizole complex[14]. It has also been suggested that the bis(Cu) cycle is kinetically 
favoured but both the mono and bis pathways are active in the reaction[14]. 
 
Scheme 2.2 Copper catalysed click chemistry reaction cycle (redrawn from reference [14]) 
47 
 
2.5 Synthesis of coumarin ligand and complexes. 
 
 
Coumarin was chosen due to its small size and biocompatibility. The small size should 
give the least steric hindrance at the terminal ends of the metallo-cylinder, allowing the 
ligand to undergo coordination to the metal centers. The size of the fluorophore will also 
have an effect on the solubility of the final product, as the metallo-cylinder will be 
comprised of three ligands with 3 fluorophores at the end of the cylindrical structure, this 
increase is size has been shown to have an effect on solubility. Coumarin dyes can also be 
easily modified; it was shown by Wang et al. that functionalisation in the 7th position can 
affect the fluorescent properties of the molecule upon triazole formation[15]. The addition 
of a diethylamine group at the 7th position was shown to give a strong fluorescent signal 
upon triazole formation with variety of alkyl functionalised phenyl compounds[15]. The 
diethylamine group is electron donating and increases the fluorescence[15]. 
2.5.1 Synthesis of 5-ethynyl-2-formylpyridine. 
 
 
 
Scheme 2.3 Synthesis of 5-ethynyl-2-formylpyridine 
 
5-Ethynyl-2-formylpyridine is not commercially available so was produced through a 
two-step reaction using the literature preparation[16] (Scheme 2.3). Firstly, a Sonogashira 
reaction was employed; 5-bromopyridine-2-carboxaldehyde was reacted with 
68% 61% 
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trimethylsilylacetylene using a palladium bistriphenylphosphine dichloride catalyst, that 
was reduced in-situ using triphenylphosphine. Copper(I) iodide was used to catalyse the 
second part of the cyclic mechanism discussed above. Triethylamine was used as the main 
solvent to neutralize any acidic species produced during the reaction. Anhydrous THF was 
also used to help solubilized the palladium catalyst and 5-bromopyridine-2-
carboxaldehyde. The procedure was modified to use anhydrous triethylamine and the 
reaction temperature was dropped from 80°C to 60°C, with stirring under argon for 5 
hours. The work up conditions were also changed to eliminate the need for neutralization 
and extraction. Instead the solvent was removed in vacuo and the crude was dissolved in 
chloroform, filtered to remove the palladium catalyst and purified by flash column 
chromatography on silica with DCM as eluent. The product was triturated with petroleum 
ether to give pure product of 5-Trimethylsilylethynyl-2-formyl pyridine (68% yield). 5-
Trimethylsilylethynyl-2-formyl pyridine was then stirred overnight in methanol with 
potassium carbonate to remove the silyl protecting group. Pure product was then 
obtained via flash column chromatograph on silica using DCM with a 61% yield. Both 
steps were fully characterised by 1H NMR, 13C NMR and ESI mass spectrometry, which 
were both consistent with literature data[16]. The 1H NMR (Figure 2.2) confirms formation 
of the product by the singlet peak at 0.26 ppm, accounting for the SiMe3 (Figure 2.2, a). 
Deprotection of the alkyne is confirmed by the loss of this peak and the formation of the 
H5 peak at 3.5 (Figure 2.2, b), representing the alkyne proton. 
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Figure 2.2 1H NMR (300 MHz, CDCl3, 298 K) of 5-trimethylsilylethynyl-2-formyl pyridine (a) and 5-
ethynyl-2-formylpyridine (b). 
 
2.5.2 Synthesis of 3-azido-7-diethylaminocoumarin 
 
 
 
 
Scheme 2.4 Synthesis of  3-azido-7-diethylaminocoumarin 
a. 
b. 
77% 
76% 76% 
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3-Azido-7-diethylaminocoumarin was not commercially available. It was synthesised via 
a three step synthesis (Scheme 2.4)[15]. 4-Diethylamino salicylaldehyde and ethyl 
nitroacetate were heated at reflux for 24 hours in anhydrous 1-butanol, under argon with 
molecular sieves and a catalytic amount of piperidine and acetic acid. Upon cooling, an 
orange solid was collected and dissolved in DMF at 80ᵒC. The solution was hot filtered to 
remove molecular sieves, and ice cold water was added to the filtrate. 3-Nitro-7-
diethylamino coumarin precipitated out of the solution as an orange solid, 77% yield. 
The nitro group was then reduced to an amine by stirring in hydrochloric acid with 
stannous chloride dihydrate at RT for 4 hours. Yielding 3-Amino-7-diethylamino 
coumarin as a yellow solid in 76% yield. 
The amine group was then converted to an azide group using nitrous acid to give the 
diazonium salt and then treated in-situ with sodium azide to give a golden brown product 
in 76% yield. The compound was characterized by 1H and 13C NMR and ESI mass 
spectrometry and was consistent with literature data. The 1H NMR spectrum of all three 
steps is shown in Figure 2.3. All proton environments integrate correctly for all three NMR 
spectra. The formation of 3-nitro-7-diethylaminocoumarin is confirmed by the H6 proton, 
which shows the carbon ring in the product has successful formed (Figure 2.3 a). There is 
a peak shift in the 1H NMR spectra of 3-amino-7-diethylaminocoumarin, a broad NH2 peak 
also appears at 4.8 ppm, confirming conversion of the NO2 group to NH2 (Figure 2.3, b). 
The NH2 peak disappears in the 1H NMR spectra of 3-azido-7-diethylaminocoumarin, 
showing formation of the desired product (Figure 2.3, c). 
51 
 
 
Figure 2.3  1H NMR (300 MHz, CDCl3, 298 K) of 3-nitro-7-diethylaminocoumarin (a), 3-amino-7-
diethylaminocoumarin (b), 3-azido-7-diethylaminocoumarin (c) 
 
2.5.3 Synthesis of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-
1,2,3-triazol-4-yl)picolinaldehyde 
 
 
 
Scheme 2.5 Synthesis of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-
yl)picolinaldehyde 
 
a. 
b. 
c. 
85% 
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A click reaction was undertaken between 3-azido-7-diethylaminocoumarin and 5-
ethynyl-2-formylpyridine (Scheme 2.5). Both starting materials were dissolved in THF 
and water (5:1). A freshly prepared solution of copper(II) sulphate was added, followed 
by a sodium(I) ascorbate solution to reduce the Cu(II) in-situ to Cu(I). Upon addition of 
sodium(I) ascorbate the solution darkened. The flask was covered in foil and stirred in 
the dark for 72 hours. The reaction was monitored by TLC. After 48 hours there was still 
a mixture of starting materials as well as product, so the reaction was left for a further 24 
hours. After this there was still starting materials left, an aliquot of the sample was taken 
and checked by 1H NMR showing 15% starting material to product. The reaction was 
stopped and ice cold water was added. The resulting yellow precipitate was collected by 
filtration and washed with ice-cold water to remove residual copper(II) salts and 
sodium(I) ascorbate. The crude product was then purified by flash column 
chromatography. 5-ethynyl-2-formylpyridine was eluted off using ether and some 
product was eluted washing DCM. However, a lot of product stuck to the column, as 
evident from the yellow colour of the silica, after 2 L of DCM had been used to elute the 
column, the collected fractions were placed under a UV lamp and were fluorescent, 
showing they contained the clicked product, the yield collected was lower than expected. 
The purification was modified in subsequent reactions. After collection by filtration the 
solid was washed with water – to remove copper salts and sodium ascorbate, ethanol – to 
remove coumarin azide starting material, ether – to remove 5-ethynyl-2-formylpyridine. 
The product was then washed through using chloroform and the filtrate was concentrated 
to dryness to afford pure product as a bright yellow powder with an 85 % yield. The 
purified product was then fully characterised by 1H NMR and 13C NMR and ESI mass 
spectrometry. The 1H NMR spectrum confirms formation of the product (Figure 2.4). The 
loss of the alkyne proton peak and formation of the triazole ring proton, H7, show the click 
reaction has been successful. 
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Figure 2.4 1H NMR (300 MHz, CDCl3, 298 K) of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-
1,2,3-triazol-4-yl)picolinaldehyde 
3-Azido-7-diethylcoumarin isn’t fluorescent, as its fluorescence is quenched by the 
electron rich α-nitrogen of the azide group[15]. Upon ‘clicking’ the azide forms a triazole 
ring. The α-nitrogen is now in a ring and is unable to quench the fluorescence (Figure 
2.5)[15]. This characteristic allows the reaction to be monitored by TLC, viewed under UV 
light - a fluorescent spot is present on the TLC plate after successful ‘clicking’ of the staring 
materials.  
 
Figure 2.5 A coumarin azide, B clicked coumarin pyridine ring in 5th position, C - A exposed to UV 
light, D – B exposed to UV light. 
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2.5.4 Synthesis of LC5 
 
 
 
 
 
 
Scheme 2.6 Synthesis of  LC5 
 
The newly formed clicked coumarin product was then incorporated into a bidentate 
ligand, with the capability of forming an iron metallo cylinder complex (Scheme 2.6). The 
ligand LC5 was prepared by suspending 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)picolinaldehyde in methanol. Chloroform was added to aid 
dissolution. 4,4′-Methylenedianiline was dissolved in a small amount of methanol and 
added dropwise to the stirred solution. The reaction was stirred for 24 hours in the dark 
to prevent the possibility of photobleaching the coumarin dye. A yellow precipitate 
formed that was collected by filtration, washed with methanol to remove any unreacted 
4,4′-methylenedianiline, followed by further washing with diethyl ether to help dry the 
powder. The product was obtained in a 85% yield. The purified product was then fully 
characterised using 1H NMR that was fully assigned using 2D COSY and NOSEY 
experiments. ESI mass spectrometry and 13C NMR were then under taken and fully 
assigned using a 2D HSQC experiment. The 1H NMR spectra (Figure 2.6) confirms 
formation of the ligand, evidenced by formation of the imine peak at 8.7ppm and loss of 
the aldehyde peak from the starting material, proving that the condensation reaction has 
been successful. 
LC5 
85% 
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Figure 2.6 1H NMR (300 MHz, CDCl3, 298 K) of LC5 
 
2.5.5 Synthesis of (LC53Fe2)[ PF6]4 
 
 
The newly developed fluorescent ligand was then used to produce a triple stranded 
dinuclear iron complex. LC5 was suspended in methanol, a stoichiometric amount of 
iron(II) chloride in a 3:2 ratio, was dissolved in methanol. This solution was added 
dropwise to the stirred ligand. Upon addition of metal salt the solution turned green. An 
excess of metanolic ammonium hexafluorophosphate was added to precipitate the 
complex from solution. The solid was collected by filtration, washed with methanol to 
remove any unreacted iron salt and diethyl ether to dry. The product was obtained in a 
56% yield and characterised by 1H NMR and ESI mass spectrometry. The 1H NMR 
confirms formation of the product due to the broad nature of the peaks. The aromatic 
56 
 
protons of the ligand become inequivalent upon binding to the metal and are represented 
as two board peaks in the NMR spectrum (Figure 2.7). The formation of a multicharged 
species is also evident in the mass spectrum, where the M4+ peak can be observed at 
733.60. 
 
Figure 2.7 1H NMR (300 MHz, CD3CN, 298 K) of [LC53Fe2][ PF6]4 
 
2.5.6 Attempted Synthesis if (LC53Ru2)4PF6 
 
 
Previously in the Hannon group a weakly luminescent ruthenium(II) cylinder has been 
synthesised[6]. This has been shown to be more stable than the iron(II) cylinder due to its 
strong Ru-N bond. Unfortunately, during the reaction, a number of side products are 
formed, leading to a low yield of triple stranded product, of around 1%. An attempt to 
make a ruthenium(II) cylinder using LC5 was undertaken, to increase stability of the 
resulting complex compared to the iron cylinder, when in contact with aqueous solution. 
Ru(II) chloride was firstly converted to Ru(DMSO)4Cl2, to increase its reactivity. LC5 was 
dissolved in anhydrous ethylene glycol and heated to 200˚C. Ru(DMSO)4Cl2 was added to 
the hot solution. Upon addition of the metal salt the solution turned dark red. The reaction 
was heated in the dark for 5 days at 200˚C. Upon cooling methanol was added and the 
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solution was filtered to remove any polymerized side products. Ammonium 
hexafluorophosphate was added to covert the counterion from Cl- to PF6-. The resulting 
solid was collected by filtration and concentrated. Numerous attempts to purify the 
complex were under taken via flash column chromatograph with silica and alumina as the 
solid phase, with a variety of eluents; unfortunately, no pure product could be obtained. 
2.6 Synthesis and design of dansyl ligands and complexes. 
 
Due to the instability of the coumarin complex when in contact with aqueous media or 
solution, dansyl was explored as an alternative fluorophore, like coumarin, dansyl is also 
quite a small fluorophore. Large fluorophores on the cylinder are likely to adversely affect 
the cylinder’s formation and DNA binding. A short polyethylene glycol (PEG3) linker was 
also introduced between the fluorophore and triazole, in the hope of aiding solubility. The 
increase in distance between the ends of the metallo-cylinder and the fluorophore would 
decrease any steric repulsion caused from the close proximity of the three fluorescent 
groups at the ends of the cylinder, and might minimise any π-π stacking effects leading 
too self-quenching of the fluorescence. 
2.6.1 Synthesis of dansyl-PEG3-azide 
 
 
 
Scheme 2.7 Synthesis of dansyl-PEG3-azide 
67% 
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Dansyl chloride was dissolved in anhydrous DCM under argon with a small amount of 
anhydrous triethylamine[17]. 11-Azido-3,6,9-trioxaundecan-1-amine was added dropwise 
and the reaction stirred in the dark for 15 hours at room temperature. A saturated 
solution of sodium carbonate was added to quench the reaction. The solution was 
extracted using DCM and the crude product was purified using flash column 
chromatography using 2% methanol in DCM, giving a 67% yield. The bright yellow oil was 
fully characterised using 1H NMR, 13C NMR and ESI mass spectrometry, which were all 
consistent with literature data[17]. The 1H spectra confirms formation of the product as 
the peaks correctly integrate to the correct number for each proton environment (Figure 
2.8). The NH peak H7, correctly integrates for one proton, showing conversion from NH2 
to NH. The [M+Na]+ peak at 474.12 is also observed in the mass spectra, confirming 
product formation. 
 
Figure 2.8 1H NMR (300 MHz, CDCl3, 298 K) of dansyl-PEG3-azide. 
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2.6.2 Synthesis of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
 
The newly formed azide functionalised dansyl group was grafted onto the pyridyl ring via 
a copper catalysed click reaction (Scheme 2.8) 
 
 
 
 
Scheme 2.8 Synthesis of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-
triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
A click reaction was performed using dansyl-PEG3-azide and 5-ethynyl-2-formylpyridine 
were dissolved in ethanol and water (5:1). A fresh solution of copper sulphate 
pentahydrate in water, was added, followed by a solution of sodium ascorbate. Upon 
addition of sodium ascorbate the solution changed colour from yellow to orange-red. The 
reaction was stirred under argon for 18 hours in the dark. The solution was diluted with 
water, extracted with DCM and the organic fractions concentrated and purified by flash 
column chromatography on silica using DCM to produce the product as a yellow powder 
in a 67% yield. The pure product was then fully characterised using ESI MS, 1H NMR and 
67% 
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13C NMR. The 1H NMR spectra (Figure 2.9) confirms formation of the product by the 
formation of the triazole peak H17 and loss of the alkyne peak from the starting material. 
 
Figure 2.9 1H NMR (300 MHz, CDCl3, 298 K) of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
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2.6.3 Synthesis of LD5 
 
 
The newly developed dansyl functionalised pyridine ring was then incorporated into a 
bidentate fluorescent ligand (Scheme 2.9), with the potential to form a metallo-cylinder 
complex. 
 
 
 
Scheme 2.9 Synthesis of  LD5 
 
The ligand LD5, was produced by dissolving 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy) ethyl)naphthalene-1-
sulphonamide in a mixture of chloroform and methanol (1:2). A solution of 4,4′-
methylenedianiline in methanol was added dropwise to the stirred solution. The reaction 
was stirred at room temperature for 24 hours with the exclusion of light. After 16 hours 
of stirring an oily residue had stuck to the side of the round bottom flask, a small amount 
of methanol was added to the flask and the solution was sonicated for 5 minutes to 
dissolve the residue back into solution. Following this, the reaction was then stirred for a 
further 8 hours. An excess amount of diethyl ether was added to precipitate out the 
product, which was then collected rapidly via filtration and dried to afford LD5 as a brown 
solid with a 65% yield. The product was fully characterised using 1H NMR that was fully 
LD5 
65% 
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assigned using 2D COSY and NOESY NMR experiments. 13C NMR experiments were 
undertaken that were fully assigned using a 2D HSQC NMR experiment. ESI mass 
spectrometry was then analyzed and showed the product peak. The 1H NMR spectra 
(Figure 2.10) confirms formation of the ligand LD5, due to the formation of the imine peak 
H21 and loss of the aldehyde peak from the starting material, confirming the condensation 
reaction has been successful. 
 
Figure 2.10 1H NMR (300 MHz, CDCl3, 298 K) of LD5 
 
2.6.4 Synthesis of [LD53Fe2][ PF6]4 
  
The newly developed fluorescent ligand LD5 was used to form a triple stranded di nuclear 
metallo-cylinder. LD5 was reacted with iron(II) chloride in a stoicheometric 3:2 ration. LD5 
was suspended in methanol followed by the dropwise addition of iron(II) chloride in 
methanol. Upon addition of the metal salt, the solution turned a deep purple, the 
characteristic colour of the triple stranded parent metallo-cylinder, who’s colour arises 
from a strong MLCT band. An excess of methanolic ammonium hexafluorophosphate was 
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added to precipitate the complex. The solid was collected and washed with methanol to 
remove any unreacted ligand, water to remove excess NH3PF6 and diethyl ether to dry the 
solid. The product was produced in an 82% yield and characterised using 1H NMR and ESI 
mass spectrometry. The 1H NMR confirms formation of the product due to the broad 
shape of the proton peaks. The aromatic protons of the ligand become inequivalent upon 
binding to the metal and are represented as two broad peaks in the NMR spectrum (Figure 
2.11). The formation of a multicharged species is also evident in the mass spectrum, 
where the M4+ peak can be observed at 1023.8. 
 
Figure 2.11 1H NMR (300 MHz, CD3CN, 298 K) of [LD53Fe2][ PF6]4 
 
2.7 Functionalisation in the fourth position 
 
Complexes synthesised using LC5 were unstable in aqueous solution, this is thought to be 
due to the steric hindrance of the fluorescent groups being held in close proximity at the 
end of metallo-cylinder. It was hoped that moving to the fourth position would give more 
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room at the end of the metallo-cylinder and reduce any steric repulsion between the 
fluorescent groups and hence improve stability (Figure 2.12). Up until now 
functionalisation in the fourth position hasn’t been undertaken, this has been due to the 
synthetic difficulties of adding functional groups at this position. However, addition at the 
third position has been shown to increase the width of the cylinder complex and decrease 
its DNA binding ability[8]. It is hoped that the addition of a fluorophore at the fourth 
position will have a minimal effect on the DNA binding properties but improve the 
stability of the complex.   
 
 
 
Figure 2.12Structural difference of fluorescent modification at the 5th position of the pyridyl ring 
(left) and the 4th position of the pyridyl ring (right). 
 
2.7.1 Synthesis of 4-ethynyl-2-formylpyridine 
 
4-Bromopyridine-2-carbaldehyde was commercially available from Fluorochem, this was 
used to add an alkyl group via the same 2 step synthetic route described in Section 2.5.1 
(Scheme 2.10). 4-Trimethylsilylethynyl-2-formyl pyridine was successfully produced in a 
63% yield and converted to 4-ethynyl-2-formylpyridine, giving a 59% yield . The products 
were fully characterised using ESI mass spectrometry, 1H NMR and 13C NMR. The 1H NMR 
spectrum confirms the addition of the SiMe3 group, by the presence of the H5 peak at 0.25 
ppm (Figure 2.13, a). The successful deprotection of this group is confirmed by the 
formation of the alkyne peak H5 at 3.5 ppm (Figure 2.13, b).  
65 
 
 
 
Scheme 2.10 Synthesis of 4-ethynyl-2-formylpyridine 
 
Figure 2.13 1H NMR (300 MHz, CDCl3, 298 K) of 5-trimethylsilylethynyl-2-formyl pyridine (a) and 4-
ethynyl-2-formylpyridine (b). 
2.7.2 Synthesis of clicked courmarin product in fourth position. 
 
The newly developed compound, 4-ethynyl-2-formylpyridine, was used in the production 
of a fluorescent ligand precursor. A click reaction was undertaken using the same 
synthetic procedure described in Section 2.5.3. 4-Ethynyl-2-formylpyridine and 3-azido-
7-diethylaminocoumarin were dissolved in THF and water, the reaction was catalyzed by 
copper(II) sulphate pentahydrate, reduced in-situ to copper(I) using sodium(I) ascorbate 
b. 
a. 
63% 59% 
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(Scheme 2.11). The bright yellow product was produced in a 73 % yield and fully characterised 
by ESI mass spectrometry, 1H NMR and 13C NMR. 
 
Scheme 2.11 Synthesis of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-
yl)picolinaldehyde 
The 1H NMR spectra (Figure 2.14) confirms the click reaction has been successful by 
formation of the triazole peak, H7 and loss of the alkyne peak from the starting material. 
 
 
Figure 2.14 1H NMR (300 MHz, CDCl3, 298 K) of the pyridine ring functionalised in the 4 position with 
a coumarin fluorophore. 
 
 
 
2.7.3 Synthesis of LC4 
  
The newly synthesised pyridine ring functionalised in the 4th position with a coumarin 
fluorophore was then used in the formation of a ligand LC4 ( 
73% 
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Scheme 2.12). 
 
 
Scheme 2.12 Synthesis of  LC4 
 
LC4 was produced by using the same synthetic procedure described in Section 2.5.4. The 
condensation reaction between the coumarin clicked product in position 4 and 4,4′-
methylenedianiline was undertaken in methanol and chloroform. After stirring for 24 
hours, the product was collected in a 71% yield and fully characterised using ESI mass 
spectrometry and 1H NMR and 13C NMR. 2D COSY and NOESY experiments were used to 
fully assign the proton NMR. A HSQC experiment was used to fully assign the carbon NMR 
spectrum. 
Confirmation of the condensation reaction is evident in the 1H NMR spectra of LC4, by the 
formation of the imine proton peak, and loss of the aldehyde peak from the starting 
material. 
LC4 
71% 
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Figure 2.15 1H NMR (300 MHz, CDCl3, 298 K) of LC4 
2.7.4  Synthesis of [LC43Fe2][ PF6]4 
 
The newly developed fluorescent ligand LC4, was then used to produce a triple stranded 
dinuclear iron complex. LC4 was suspended in methanol, a stoichiometric amount of iron 
chloride, in a 3:2 ratio, was dissolved in methanol. This solution was added dropwise to 
the stirred ligand. Upon addition of metal salt the solution turned green. An excess of 
methanolic ammonium hexafluorophosphate was added to precipitate the complex from 
solution. The solid was collected by filtration, washed with methanol to remove any 
unreacted iron salt and diethyl ether to dry. The product was produced in a 58% yield and 
characterised by 1H NMR and ESI mass spectrometry. The 1H NMR confirms formation of 
the product due to the broad nature of the peak. The aromatic protons of the ligand 
become inequivalent upon binding to the metal and are represented as two board peaks 
in the NMR spectrum (Figure 2.16). The formation of a multicharged species is also 
evident in the mass spectrum, where the M4+ peak can be observed at 733.49. 
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Figure 2.161H NMR (300 MHz, CD3CN, 298 K) of [LC43Fe2][ PF6]4 
 
2.7.5 Synthesis of clicked dansyl in fourth position 
 
Dansyl-PEG3-azide was ‘clicked’ to 4-ethynyl-2-formylpyridine using the same synthetic 
procedure described in Section 2.6.2 (Scheme 2.13). The product was precipitated and 
collected by filtration, giving a 59% yield, followed by full characterisation using ESI mass 
spectrometry and 1H NMR and 13C NMR. The 1H NMR spectra (Figure 2.17) confirms the 
click reaction has been successful, due to formation of the imine proton peak, H16, and loss 
of the alkyne peak from the starting material. 
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Scheme 2.13 Synthesis of  4-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-
triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
Figure 2.17 1H NMR (300 MHz, CDCl3, 298 K) of 4-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
 
 
 
 
59% 
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2.7.6 Synthesis of LD4 
 
The newly produced pyridyl ring, functionalised in the 4 position with a dansyl 
fluorophore, was then used to produce a bidentate ligand, LD4 ( 
Scheme 2.14). This ligand will be used to produce a metallo cylinder complex. 
 
 
 
Scheme 2.14 Synthesis of LD4 
 
LD4 was synthesised via a condensation reaction between 4,4′-methylenedianiline and 
clicked dansyl product in position 4. The reactants were stirred in methanol and 
chloroform. The product was precipitated from solution using diethyl ether, collected by 
filtration and dried to give a 68% yield. The solid was characterised using 1H NMR that 
was fully assigned using 2D COSY and NOESY NMR experiments. 13C NMR experiments 
were undertaken that were fully assigned using a 2D HSQC NMR experiment. ESI mass 
spectrometry was then analyzed and showed the product peak. 
LD4 
68% 
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Figure 2.181H NMR (300 MHz, CDCl3, 298 K) of LD4 
 
2.7.7 Synthesis of [LD43Fe2][PF6] 
 
The newly developed ligand, LD4, was used to produce a triple stranded, dinuclear metallo 
iron complex. LD4 was reacted with iron(II)chloride in a 3:2 ratio following the same 
procedure described in Section 2.6.4. Upon addition of the iron(II) salt the solution turned 
bright purple. An excess methanolic solution of ammonium hexafluorophosphate was 
added, leading to precipitation of the complex, caused by counter ion exchange with the 
chloride. The solid was collected by filtration, washed with methanol to remove unreacted 
ligand, water to remove excess NH3PF6 and ether to dry the solid. The product was 
collected in a 72% yield and fully characterised using 1H NMR and ESI mass spectrometry.  
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Figure 2.191H NMR (300 MHz, CD3CN, 298 K) of [LD43Fe2][PF6]. 
 
2.8 Attempted synthesis of 5-azidopyridine-2-carbaldehyde. 
 
 
Attempts to convert 5-bromopyridine-2-carbaldehyde to 5-azidopyridine-2-
carbaldehyde were undertaken (Figure 2.20). This would potentially allow the metallo 
cylinder to react with a highly strained 8 membered ring copper-free click compound in 
vivo [18]. This could also lead to the cylinder being reacted with just one florescent group 
after cylinder formation, rather than having to functionalise the ligand prior to complex 
assembly. Another advantage of using copper free click chemistry, is the ease of 
purification, as there shouldn’t be any unreacted starting material due to the high 
reactivity of the DBCO (dibenzocyclooctyl) ring.  
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Figure 2.20 Conversion of the bromine group to an azide capable of undergoing copper free click 
reactions with DBCO modified fluorophores (depicted in pink). 
5-Bromopyridine-2-carbaldehyde was stirred with sodium azide in water at 60˚C for 48 
hours, followed by extraction into ethyl acetate. The solvent was removed in vacuo and 
the product analysed by 1H NMR and ESI mass spectrometry. Both were consistent with 
unreacted 5-bromopyridine-2-carboxaldehyde, no product peaks were observed. 
2.9  Attempted synthesis of [LTB53Ru2][PF6]4 
 
Attempted to click onto an alkyne functionalized iron metallo-cylinder have been 
previously made, but proved unsuccessful, as the cylinder wasn’t stable enough to 
undergo post cylinder-formation clicking. To overcome this, the synthesis of a ruthenium 
triple bond functionalised complex was undertaken, due to the increased stability of the 
ruthenium to nitrogen bond. 5-Ethynyl-2-formylpyridine was suspended in ethanol and 
a dropwise solution of 4,4′-methylenedianiline was added, producing a white precipitate. 
The solid was stirred for 18 hours at room temperature and collected by filtration. 
Washed with methanol to remove unreacted starting material then washed with ether to 
aid drying. The ligand LTB5, was produced in an 84% yield and fully characterised using 
1H NMR, 13C NMR and mass spectrometry. The 1H NMR spectra confirms formation of the 
product by the presence of an imine peak and loss of the aldehyde peak from the starting 
material.  
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Scheme 2.15 Synthesis of ligand LTB5 
The ligand LTB5, was suspended in ethylene glycol and heated to 200ᵒC. Ru(DMSO)4Cl2 was 
added to the solution, upon its addition the solution turned a dark red colour. The reaction 
was heated at 200ᵒC for 5 days. The reaction was cooled to room temperature, methanol 
was added and the solution was filtered to remove polymeric products. A solution of 
ammonium hexafluorophosphate was added to precipitate the product from the 
methanol, ethylene glycol mixture. The solid was collected and dissolved in acetonitrile. 
Numerous attempts to purify the product were undertaken, on silica, alumina and 
cellulose, with various eluents.  Unfortunately no pure product could be obtained.  
2.10 Attempted click reaction 
 
 
A number of fluorophores have been successfully functionalised with azide groups to 
allow them to undergo click reactions with 5-ethynyl-2-formylpyridine and 4-ethynyl-2-
formylpyridine (Figure 2.21). Numerous attempts to click Fluorescein isothiocyanate 
(FITC) have been undertaken, the solvent systems, catalysts and reaction times have all 
been altered but unfortunately no click products could be obtained. 
 
84% 
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Figure 2.21 A. FITC-PEG3-azide, B. FITC-C3-azide and C. dansyl-C3-azide 
 
Biotin azide has been synthesised, with the prospect of clicking it on to the alkyne 
functionalised pyridine ring. This will be turned into a ligand and subsequently a metallo 
cylinder complex. The addition of the biotin molecule will allow the complex to be located 
during cellular uptake by the use of a fluorescently tagged streptavidin molecule. 
Numerous attempts were made to click biotin-PEG-3 azide with 5-ethynyl-2-
formylpyridine. The solvent system and catalyst were both changed, but no product was 
produced. 
 
Figure 2.22 Biotin functionalised pyridyl ring 
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2.11 Stability studies 
 
The stability of the complexes, was monitored in a mixture of solvents – acetonitrile to aid 
complex solubility’s, and water – to mimic the aqueous cell environment. This was to 
examine how stable the complexes would be in an aqueous environment and how suitable 
they would be for cellular uptake studies. 
 
 
 
Figure 2.23 Stability of 100 µM [LC53Fe2][PF6]4 in acetonitrile/water in increasing gradient 
 
This complex [LC53Fe2][PF6]4 degrades when water concentration is increased, this is also 
evident in Figure 2.31, where the complex has precipitated out of solution. This means the 
complex cannot be used for long treatments in aqueous environments, and any effects 
observed from the complex may be attributed to the ligand or the release of iron within 
the cell. 
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Figure 2.24 Stability of 10 µM [LD43Fe2][PF6]4 in acetonitrile or acetonitrile/water (1:9) 
 
 
Figure 2.25 Stability of 10 µM [LD53Fe2][PF6]4 in acetonitrile or acetonitrile/water (1:9) 
The stability of the dansyl iron complexes was examined be a similar method (Figure 2.25 
and Figure 2.25). The complex was dissolved in acetonitrile and its UV-vis spectrum was 
compared to the sample dissolved in 10% MeCN and water. It can be seen that 
[LD43Fe2][PF6]4 has greater stability, this may be attributed to the increased distance 
between the fluorescent groups at the ends of the cylinder, reducing any steric hindrance 
and repulsion effects experienced by three fluorescent groups held in close proximity. 
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2.12 Fluorimeter studies  
 
Fluorescence studies have been conducted to examine if the iron based complexes are 
fluorescent after complex formation. The complexes were dissolved in acetonitrile and 
their excitation and emission spectra are shown below. Upon complex formation it can be 
observed that all four complex still exhibit an emission peak. 
 
 
Figure 2.26 Normalized emission and excitation spectrum of [LC43Fe2][PF6]4 in acetonitrile. 
 
Figure 2.27 Normalized emission and excitation spectrum of [LC53Fe2][PF6]4 in acetonitrile. 
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Figure 2.28 Normalized emission and excitation spectrum of [LD53Fe2][PF6]4 in acetonitrile. 
 
Figure 2.29 Normalized emission and excitation spectrum of [LD43Fe2][PF6]4 in acetonitrile. 
 
2.13 Imaging  
 
Imaging experiments were undertaken using the coumarin functionalised iron cylinder 
[LC53Fe2][PF6]4, to examine if the compound could be visualised using fluorescence 
microscopy (Figure 2.32). MDA-231 cells were seeded into MatTek dishes, at a density of 
300,000 cells per dish, and left to adhere for 24 hours. The media was removed, cells were 
washed with PBS and clear imaging media was added. The MatTek dish was placed on the 
heated stage of the Nikon A1R Inverted Confocal/TIRF microscope and the cells were 
focused. An image was taken of the cells before treatment to examine their morphology 
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and check they had an elongated natural shape before treatment and they were still 
adhered to the MatTek dish. The compound was added directly to the MatTek dish and 
time course imaging was under taken, with an image being taken every minute, for 20 
minutes (Figure 2.32). An increase in fluorescence in the blue channel was observed, this 
is from the coumarin moiety on the complex. It it believed that the complex enters cells 
and is then degraded. With the increase in fluorescence being attributed to the breakdown 
of the complex, leaving the free ligand being imaged. This is reminiscent of the work by 
Chen et al. discussed in chapter 1; where polypyridyl iron complexes were thought to be 
fluorescent[19], but as observed in other studies, these complexes have no emission 
profile[20]. It is assumed the fluorescence in their imaging studies is also caused by 
compound degradation, and it is in fact free ligand being imaged. 
 
The imaging experiment was repeated and cells were also stained with draq 5, (red 
nuclear stain), to examine if the complex enters the nucleus (Figure 2.30). After 20 
minutes, it was observed that the degraded complex remains located in the cytoplasm, 
with no co-localisation observed between coumarin and draq 5. 
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Figure 2.30 MDA-231 cells treated with 100 µM [LC53Fe2][PF6]4 with 3% MeCN in clear imaging 
media, over 20 minutes with the nucleus stained with draq 5. 
 
The degradation of the complex is further confirmed by precipitation of the complex in 
the MatTek dish at the end if the experiment as shown in Figure 2.31. 
 
Figure 2.31 MatTek dish containing MDA-231 cells after treatment with 100 µM [LC53Fe2][PF6]4 with 
3% MeCN in clear imaging media, over 20 minutes. 
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Figure 2.32 MDA-231 cells treated with 100 µM [LC53Fe2][PF6]4 with 3% MeCN in clear imaging 
media, over 20 minutes. A 0 min, B 1 min, C 2 min, D 3 min, E 4 min, F 5 min, G 6 min, H 7 min, I 8 min, 
J 11 min, K 15 min, L 20 min 
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2.14 Conclusions and future work 
 
In conclusion four novel fluorophore functionalised ligands have been created and 
characterised. LC5, LC4, LD5 and LD5 (Figure 2.33). 
 
Figure 2.33 Structure of LC5, LC4, LD5 and LD5 
 
These ligands have been successfully used to form iron based metallo-cylinder complexes, 
[LC53Fe2][PF6]4, [LD53Fe2][PF6]4, [LC43Fe2][PF6]4 and [LD43Fe2][PF6]4. There stability has 
been examined in aqueous solution using UV-vis experiments and their fluorescence has 
been examined with fluorimeter studies. The complexes are not stable over long periods 
of time when in aqueous solution. Fluorescence confocal imaging was undertaken using 
[LC53Fe2][PF6]4 in MDA-231 cell, however the observed fluorescence is attributed to 
degradation of the complex, with the released ligands fluorescence being observed. 
 
In future work stability studies would be undertaken for longer period of time, along with 
NMR experiments to examine complex degradation over time in aqueous solution. CD 
binding studies would be under taken to explore the binding properties of all complexes. 
Imaging studies using dansyl functionalised complex would be undertaken to explore if 
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complexes fluorescence can be observed using fluorescence confocal microcopy. 
Fluorimeter experiments would be undertaken following the addition of water to see if 
the fluorescence signal increase upon degradation of the complex, as observed in 
fluorescence microcopy. Further attempts to click biotin and FITC on to the cylinder 
ligand would be attempted.  
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3 Imidazolimine cylinders 
 
3.1 Introduction 
 
The parent ligand system (discussed in chapters 1 and 2) has been modified by swapping 
the pyridylimine system to an imidazolimine system (Figure 3.1). The addition of the NH 
groups on the ligand scaffold will allow functional groups to be added to the structure by 
utilising a simple condensation reaction. 4,4′-Methylenedianiline is used as the spacer in 
both ligand systems, meaning the distance between the binding sites in kept constant. The 
modification from pyridyl to imidazole rings causes little difference in the width and 
diameter of the triple stranded dinuclear complexes formed upon reaction of the ligands 
with metal(II) salts. As such they should both bind in a similar manner to DNA, with the 
ability to bind in the Major grove of B-DNA and DNA and RNA three-way junction. 
 
 
Figure 3.1 Pyridylimine parent ligand L and imidazoleimine parent ligand Lim 
 
The modified ligand is synthesized by the same simple condensation reaction in methanol 
at room temperature, with two drops of glacial acetic acid as catalyst (Figure 3.2). Upon 
reaction with an iron(II) or nickel(II) salt; a dinuclear, triple stranded, tetra cationic 
complex is formed (Figure 3.2, right). 
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Figure 3.2 Synthesis of the parent imidazole ligand (Lim) and formation of a dinuclear, triple 
stranded, tetra cationic complex [M2 im3]4+ [1] 
 
The bisimidazolimine ligands have additional hydrogen donor groups (NH), these are 
located at the exterior of the complex structure and engage in hydrogen bonding with 
anions and solvent molecules [1]. The most striking difference between the imidazole and 
pyridyl based systems is the spin-crossover property exhibited in the imidazole 
complexes.  
 
Spin-crossover is observed in d4, d5, d6 and d7 metal ions, two different electron 
configurations are possible in the octahedral ligand field, high spin and low spin. Changes 
between the spin states can be caused by temperature, pressure, light irradiation or 
influence of a magnetic field. The iron(II) metal center of the imidazolimine complex is d6 
therefore both high spin and low spin states are possible (Figure 3.3). 
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Figure 3.3 Crystal field splitting of a d6 electron configuration into high-spin and low-spin states. 
 
The overlay of the pyridyl (black) and imidazole (white) nickel(II) complex structures 
shows that their structures are very similar (Figure 3.4)[1]. d8 Nickel(II) complexes do not 
exhibit spin-crossover, eliminating the effects of spin transitions on the structure. The 
replacement of the six membered pyridyl ring to the five membered imidazole ring causes 
slight differences at the ends of the cylinder, due to the change in size of the rings[1]. 
However, this does not have a dramatic effect on the length or diameter of the nickel(II) 
complexes[1]. As there is very little change in the length and diameter of the complex and 
the charge is the same as the pyridylimine based iron and nickel systems, it is 
hypothesized that the complexes will bind in a similar fashion, residing in the major 
groove of DNA[2] and DNA[3] / RNA[4] three way junctions. 
 
Figure 3.4 Overlay of the structures of the pyridylimine Ni(II) (black)[5] and the imidazolimine Ni(II) 
complex (white)[1]. 
 
Δ Δ 
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3.2 Molecular design 
 
 
Azide and alkyne containing chains with be grafted on to the imidazole ring via their NH 
component. This will be achieved by a condensation reaction. This would allow a copper 
catalyzed click reaction to be utilized to add a fluorescent organic dye to the imidazole 
ligand (Figure 3.5). Incorporation of an azide chain will allows copper free click reactions 
to be undertake, using a highly strain triple bond in an eight membered ring. This would 
give the potential for the complex to bind to DNA and be tagged with a biotin molecule or 
fluorophore after binding. 
 
 
Figure 3.5 Addition of fluorophore/biotion molecules to the NH position of the imidazole rings. 
 
3.3 Synthesis of azide functionalised ligands and complexes 
 
 
The development of an azide functionalised ligand will allow fluorescent groups to be 
click onto the ligand, using cooper catalysed click chemistry or copper free click 
chemistry. It is hoped that the short carbon chain will allow larger fluorophores to be 
‘clicked’ to the imidazole complex. It is anticipated that the increased distance from the 
ligand will not impeded cylinder formation and reduce any steric hindered caused 
between the close proximity of bulky fluorophore or biotin moieties.  
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Figure 3.6 Synthesis of ligand LimN 
 
3.3.1 Synthesis of azide imidazole 
 
The three carbon chain linker was synthesized in a two-step reaction, Scheme 3.1. Firstly 
3-chloropropan-1-ol was heated to reflux was sodium azide and potassium iodide in 
water for 24 hours. The reaction was cooled and extracted with diethyl ether and the 
organic fraction dried over sodium sulphate. The solution was carefully concentrated 
under reduced pressure to afford the produce as a yellow oil in an 82% yield. The 
compound was fully characterised by 1H NMR and 13C NMR and MS. 
 
3-Azidopropan-1-ol was then converted to 3-azidopropyl methanesulphonate. The 
starting material was dissolved in tetrahydrofuran and triethylamine and the solution 
cooled to 0°C. Mesyl chloride was added dropwise to the reaction mixture and the solution 
was warmed to room temperature and stirred for three hours. Dichloromethane and a 
saturated sodium bicarbonate solution were added to the reaction mixture; the organic 
layer was separated, washed, dried and concentrated to afford 3-azidopropyl 
methanesulphonate as a colourless oil in an 76% yield; which was fully characterised by 
1H NMR and 13C NMR and MS.  
 
 
Scheme 3.1 Two-step synthesis of the short azido functionalised chain linker 3-azidopropyl 
methanesulfonate 
82% 76% 
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Imidazole-2-carboxaldehyde and potassium carbonate were dissolved in anhydrous DMF, 
Scheme 3.2. 3-Azidopropyl methanesulphonate was added dropwise to the stirred 
solution and the reaction was stirred at room temperature under an argon atmosphere 
for 18 h. The suspension was filtered to remove the potassium carbonate and the filtrate 
diluted with water. The solution was extracted with diethyl ether and the organic layer 
was separated, dried and concentrated to afford 1-(3-azidopropyl1H-imidazole-2-
carbaldehyde) as a yellow oil in an 67% yield. The compound was fully characterized by 
by 1H and 13C NMR and MS. The 1H NMR is shown in Figure 3.7 and shows loss of the NH 
imidazole peak, indicating product formation has been successful. The proton peaks also 
integrate correctly for each proton environment. 
 
Scheme 3.2 Systhesis of  1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde. 
 
Figure 3.7 1H NMR (300 MHz, CDCl3, 298 K) of 1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde. 
 
67% 
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3.3.2 Synthesis of azide functionalised imidazole ligand LimN 
 
The newly synthesised azide functionalised imidazole group was then incorporated into 
the full ligand, LimTB, which will allow formation of the metallo cylinder. The azide 
functionalised imidazole ligand (LimTB) was successfully synthesized via a condensation 
reaction.  1-(3-Azidopropyl)-1H-imidazole-2-carbaldehyde was dissolved in ethanol, and 
4,4′-methylenedianiline was dissolved in ethanol and added dropwise to the stirred 
solution. The reaction was stirred for 18 hours at room temperature. The white 
precipitate was collected by filtration, washed and dried to afford Ligand LimN in a 64% 
yield, Scheme 3.3.  
 
 
Scheme 3.3 Synthesis of the azide functionalised imadazole ligand LimN, through the reaction of 1-(3-
azidopropyl)-1H-imidazole-2-carbaldehyde and 4,4′-methylenedianiline. 
 
The ligand was fully characterised and the 1H NMR spectra is shown in Figure 3.8. The 
loss of the aldehyde peak from the starting material and the formation of the imine bond, 
(H4 Peak at 8.55ppm) confirm the formation of the product. The bridge protons of the 
spacer are clearly visible (H1 4ppm) and the azide chain is intact (H9, H7 and H8) 
 
64% 
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Figure 3.8 1H NMR (300 MHz, CDCl3, 298 K) of the azide functionalised imidazole ligand LimN. 
 
3.3.3 Synthesis of [LimN3Fe2][ PF6]4 
 
 
The newly synthesised azide functionalised ligand, LimN was used to develop an iron based 
triple stranded, dinuclear metal complex. The alkyne functionalised ligand LimN was 
suspended in methanol, a methanolic solution of iron(II) chloride was added dropwise to 
the stirred solution. Upon addition of the metal salt the solution turned a deep wine red 
colour (Figure 3.9), showing formation of the metal complex. This colour is characteristic 
of iron imidazole cylinders, due to the MLCT band observed at 550nm. The complex was 
precipitated from solution by the addition of ammonium hexafluorophosphate, collected, 
washed and dried to afford the product. The complex exhibits spin-cross over and is 
paramagnetic. Due to this property the complex was characterized using long range 
paramagnetic 1H NMR and MS.  Formation of the product is confirmed by the (M)4+ at 
418.02 (Figure 3.10), observed in the mass spectrum, showing the presence of a multi 
charge species. 
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Figure 3.9 Deep wine  red solution of [LimN3Fe2][ PF6]4 in acetonitrile. 
 
 
Figure 3.10 Mass Spectra of [LimN3Fe2][ PF6]4, showing the (M)4+ complex peak at 418.02. 
 
3.3.4 Synthesis of [LimN3Ni2][ PF6]4 
 
The Ligand, LimTB was also used to from a triple stranded nickel based metallo cylinder. 
LimTB was suspended in methanol and a solution of nickel(II) chloride was added. Upon 
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addition of the nickel slat the solution turned orange. The complex was precipitated from 
solution by the addition of ammonium hexafluorophosphate. The solid was collected and 
characterized using mass spectrometry. Formation of the product is confirmed by the 
(M)4+ at observed 419.80 in the mass spectrum. 
 
3.4 Synthesis of alkyne functionalised ligands and complexes 
 
The development of an alkyne functionalised ligand will allow fluorescent groups to be 
clicked onto the ligand 
 
Figure 3.11 Synthesis of ligand LimTB 
 
3.4.1 Synthesis of alkyne imidazole 
 
Imidazole-2-carboxaldehyde and potassium carbonate were suspended in anhydrous 
DMF. Propargyl bromide (80% w.v in toluene stabilised with MgO) was added dropwise 
to the stirred solution and the reaction mixture was stirred for 18 hours at room 
temperature under an atmosphere of argon. The suspension was filtered to remove 
potassium carbonate and the filtrate diluted with water. The solution was extracted with 
diethyl ether, dried and concentrated to afford 1-(prop-2-yn-1-yl)-1H-imidazole-2-
carbaldehyde as a yellow oil, in a 69% yield, Scheme 3.4. 
 
 
 
Scheme 3.4 Synthesis of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde. 
69% 
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1-(Prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde was fully characterised and the 1H 
NMR spectra is shown below. The loss of the NH imidazole peak confirms the reaction has 
been successful, the proton environments integrate correctly to show the alkyne linker is 
attached to the imidazole ring, Figure 3.12. 
 
Figure 3.12 1H NMR (300 MHz, CDCl3, 298 K) of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde 
 
3.4.2 Synthesis of alkyne functionalised imidazole ligand LimTB 
 
The alkyne functionalised imidazole group will be used to develop a bidentate ligand that 
will be utilized in the formation of a metallo cylinder complex. The alkyne functionalised 
imidazole ligand LimTB has been successfully synthesised via a condensation reaction. 1-
(Prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde was dissolved in ethanol, an ethanolic 
solution of 4,4′-methylenedianiline was added dropwise to the stirred solution. The 
reaction was stirred at room temperate for 18 hours, forming an off white precipitate, 
Scheme 3.5.  The precipitate was collected, washed and dried to afford the alkyne 
imidazole ligand LimTB, in an 82% yield. 
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Scheme 3.5 Synthesis of the alkyne functionalised imadazole ligand LimTB, through the reaction of 1-
(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde and 4,4′-methylenedianiline. 
 
The alkyne functionalised imidazole ligand LimTB was fully characterised and the 1H NMR 
spectra is shown below (Figure 3.13). The formation of the imine bond, H4, is shown by 
the proton peak at 8.5 ppm, the loss of the aldehyde peak from the starting material also 
shows the reaction has been successful. The bridging protons from the spacer are clearly 
visible around 4.0 ppm and the alkyne linker peaks are visible 3.4 ppm and 5.45 ppm, 
showing the linker is attached to the imidazole ring. 
 
 
Figure 3.13 1H NMR (300 MHz, CDCl3, 298 K) of alkyne functionalised imidazole ligand LimTB. 
82% 
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3.4.3 Synthesis of [LimTB3Fe2][ PF6]4 
 
 
The alkyne functionalise imidazole ligand LimTB was used to produce an iron based, triple 
stranded, dinuclear,  metallo cylinder complex. The alkyne functionalised ligand LimTB was 
suspended in methanol, a methanolic solution of iron(II) chloride was added dropwise to 
the stirred solution. Upon addition of the metal salt the solution turned a deep wine red 
colour, indicating formation of the metal complex. The reaction was shown to be 
successful by the presence of the (M)4+ observed in the mass spectrum at 350.81. 
 
3.4.4 Synthesis of [LinTB3Ni2][ PF6]4 
 
The nickel metallo cylinder was synthesised using the alkyne modified ligand LimTB. The 
triple bond functionalised imidazole ligand LimTB was suspended in methanol and reacted 
with a methanolic solution of NiCl2 6H2O (3:2, ligand:metal ratio). Upon addition of the 
metal salt the solution turned an orange colour. The ES mass spectra shows the complex 
peak (M)4+ at 352.13 (Figure 3.14).  
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Figure 3.14 Mass Spectra of [LimTB3Ni2][ PF6]4, showing the (M)4+ complex peak at 352.13. 
 
3.5 ‘Click’ reactions with imidazole ligands 
 
 
After confirming the modified imidazole ligands could successful form both the iron and 
nickel metallo cylinder, attempts were made to click a fluorophore to the modified 
imidazole ligand. 
 
 
A click reaction was undertaken with 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde 
and coumarin azide . The alkyne functionalised imidazole compound and coumarin azide 
was dissolved in THF and water (5:1). The reaction mixture was stirred, an aqueous 
solution of CuSO4.5H2O was added, followed by an aquesous soltion of soadium ascorbate. 
Upon additon of the sodium ascorbate the solution turned a deep red colour, indicating 
Cu(II) has been reduced to Cu(I) in-situ. The reaction was stirred at room temperature in 
the dark for 48 hours. Ice cold water was added to precipitate the product, which was 
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rapidly collected by filtration. The solid was washed with ethanol and ether then dried to 
afford the product as a yellow solid. The product was collected in a  33% yield and  
characterised using 1H NMR and MS. The product peak can be observed by mass 
spectrometry at 393.5, M+H+ peak. 
 
Scheme 3.6 The ‘click’ reaction of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde and coumarin 
azide. 
 
 The ‘clicked’ coumarin functionalised imidazole compound was reacted with 4,4′-
methylenedianiline via a condensation reaction, to form a florescent ligand. The coumarin 
functionalised imidazole compound was suspended in methanol, a methanolic solution of 
4,4′-methylenedianiline was added dropwise to the stirred suspension. The reaction was 
stirred for 18 hours in the dark, producing a pale yellow precipitate. The product was 
collected by filtration and washed with methanol and ether, then dried. The ligand was 
produced in an 82% yield and characterised using 1H NMR and mass spectrometry, which 
showed the product peak at 948.2 [M+H]+.  
 
33% 
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Scheme 3.7 Condensation reaction between the coumarin functionalised imidazole ring and 4,4′-
methylenedianiline to form ligand LimC 
 
The fluorescent functionalised imidazole ligand, LimC, was successfully used to form two 
triple strand dinuclear complexes [LimC3Fe2][PF6]4 and [LimC3Ni2][PF6]4. Both were 
synthesised by suspension of the ligand in methanol, followed by addition of the metal 
chloride salt, then precipitation of the complex with ammonium hexafluorophosphate. 
The addition of the fluorophore hasn’t hindered complex formation. Both complexes are 
paramagnetic, making them difficult to fully characterise using 1H NMR. The mass spectra 
of each complex shows the presence of the [M]+4 738.23 and 739.65 respectively for each 
complex. 
3.6 Copper free click reactions 
 
 
The modification of the imidazole ring with an azide linker allows to be used in copper 
free click (CFC) chemistry. This utilizes the high ring strain in the eight membered ring of 
dibenzocyclooctyne (DBCO), allowing it to form a triazole ring with an azide group 
without a copper catalyst. Two CFC reactions were under taken, one with a DBCO-PEG4 
biotin group and one with a DBCO-cy5 dye (Figure 3.15). 
82% 
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Figure 3.15 Structure of DBCO-PRG4-biotin (top) and DBCO-cy5 (bottom) 
 
1-(3-Azidopropyl)-1H-imidazole-2-carbaldehyde was dissolved in methanol followed by 
the dropwise addition of DBCO-PEG-4 biotin in methanol. The reaction was stirred for 12 
hours and the solvent evaporated to dryness. Mass spectrometry was used to analyse the 
sample, but unfortunately no product peaks could be found. The experiment was also 
performed with DBCO-Cy5, the reaction was stirred in the dark for 12 hours and the 
sample analysed using mass spectrometry. Unfortunately, no product peaks were 
observed; only 1 mg of DBCO-Cy5 was purchase due to its price, 1H NMR experiment were 
performed on the sample but the signal was weak and no clear product peaks were visible. 
 
3.7 Synthesis of [Lim3Ru2][PF6]4 
 
Attempts to ‘post click’ a fluorophore onto the alkyne modified imidazole iron cylinder 
complex have been undertaken, but the iron cylinder degraded during the click process.  
The ruthenium cylinder is highly stable due to the strong Ru - N bond between the d6 Ru 
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and the ligand. It was hoped that after the parent imidazole ruthenium complex had been 
formed, one side chain could be added to the complex. This side chain could subsequently 
undergo click reactions to allow just one fluorescent tag to be grafted onto the complex, 
as opposed to the six fluorophores that are present if they are attached during ligand 
synthesis. The reduction from six to one fluorescent group should reduce any steric 
hinderence and repulsion that occurs when three fluorophores are held in close proximity 
to each end of the cylinder. This reduction would also decrease the overall size of the 
complex enabling it to bind to DNA in a more similar manner to the parent complex, whilst 
also increasing its solubility and stability in aqueous solution. 
 
Figure 3.16 Proposed structure of the parent ruthenium imidazole complex functionalised by post 
complex modification to allow the addition of a single fluorophore or ‘tag (shown in pink)’ 
 
3.7.1 Synthesis of Lim 
 
 
The parent imidazole ligand Lim was synthesized via the condensation reaction between 
imadazole-2-carboxadlehyde and 4,4′-methylenedianiline (Scheme 3.8). Imidazole-2-
carboxadlehyde was dissolved in methanol, a methanolic solution of 4,4′-
methylenedianiline was added in a dropwise fashion. The reaction was stirred at room 
temperature for 18 hours, producing a white precipitate. The product was collected by 
filtration, washed with cold methanol and ether and dried, to afford the product as a white 
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solid. The ligand was produced in an 95% yield and fully characterised by 1H NMR, 13C 
NMR and ESI-MS. 
 
 
 
 
Scheme 3.8 Condensation reaction of imidazole-2-carboxadlehyde with 4,4′-methylenedianiline 
 
3.7.2 Attempted synthesis of [Lim3Ru2][ PF6]4 
 
 
Once the imidazole ligand Lim was synthesized, the formation of [Lim3Ru2][ PF6]4 was 
attempted. The imidazole ligand Lim was dissolved in ethylene glycol and the solution 
heated to 200ᵒC under argon atmosphere. Once the reaction was at 200ᵒC Ru(DMSO)4Cl2 
was added to the flask via a side arm. Upon addition of the ruthenium salt the reaction 
turned dark red in colour. The reaction was heated at 200 ᵒC for 6 days. The reaction was 
cooled and a solution of ammonium hexafluorophosphate was added; the solution was 
left to stir overnight. The solid precipitate was collected, washed with water to remove 
excess NH3PF6, followed by ether to dry the solid and remove water. The solid was 
dissolved in a minimal amount of acetonitrile and precipitated using ether to produce a 
fine powder that was collected, washed with ether and dried. The crude product was 
stirred in ethanol overnight and filtered to remove large polymeric compounds. The 
95% 
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filtrate was concentrated to dryness leaving an orange solid. Numerous attempts to purify 
this compound were undertaken using column chromatography. Varying both the solid 
phase (silica, alumina) and the solution phase (acetonitrile, water), no pure product could 
be obtained. 
3.8 Conclusions and future work 
 
 
 In conclusion three novel ligand systems have been developed, LimTB, LimN and LimC 
(Figure 3.17), each has been characterised by 1H NMR, 13C NMR and mass spectrometry. 
 
Figure 3.17 Newly synthesised ligand LimTB, LimN and LimC 
 
 These have been reacted with iron(II) and nickel(II) salts to form six new complexes, 
which have been charcterised by 1H NMR. 
Attempts to synthesize a ruthenium(II) parent complex has been undertaken but proved 
unsuccessful.  
Attempts to graft biotin and Cy5 onto the ligand precursor utilizing copper free click 
chemistry have been undertaken but proved unsuccessful. 
 
 
In future work, stability and DNA binding studies of the newly synthesised complexes 
developed in this chapter will be completed. 
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Studying the complexes stability in aqueous solution overtime will give an insight into 
their potentials for cellular work. Secondly, circular dichroism and linear dichroism 
experiments would be performed to examine the complexes ability to bind and interact 
with ct-DNA. 
A variety of different fluorophore can be grafted onto the alkyne and azide functionalised 
cylinder via click chemistry. The alkyne moiety could also be utilized in sonogashira cross 
coupling reaction to add a fluorophore. 
 
Scaling up the ruthenium(II) cylinder synthesis described in section 3.7.2, may yield 
enough product to attempt to couple the alkyne group onto the complex as proposed. 
 
A ruthenium(II) complex would be synthesized with ligand LimTB, with the intention of 
‘clicking’ a fluorophore onto the ligand, after complex formation. Unfortunately an azide 
modified ruthenium(II) cylinder cannot be attempted due to the explosive nature of 
azide’s at high temperature, the ruthenium(II) cylinder is formed at 200ᵒC, so this would 
be a dangerous experiment. 
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4  Synchrotron Imaging Techniques 
 
4.1 Introduction  
 
In this chapter the cellular accumulation and uptake of the parent iron pyridylimine based 
complex will be examined using synchrotron imaging techniques. How the light is 
produced and used for imaging is now explained  
4.1.1 Synchrotron systems and radiation 
 
Synchrotron light has a unique set of characteristics - high brilliance, high intensity, sharp 
focus and tenability - giving it a wide range of applications in a variety of research areas 
including health care, engineering, archaeology and astrophysics. 
The synchrotron light source consists of a circular storage ring, and a linear accelerator. 
A linear accelerator and booster is used to accelerate the electrons to their final energy 
before they are magnetically injected into the storage ring, where they are kept at a 
constant speed[1].  
The electrons traveling around the linear accelerator are produced by an electron gun. A 
high voltage cathode is heated under vacuum, this gives the electrons in the cathode 
sufficient energy to undergo thermionic emission and escape from the surface of the 
materials; these electrons are accelerated by earthed anodes. This stream of electrons has 
an energy of 90,000 electron volts (90 KeV), these electrons are accelerated by a linear 
accelerator to 100,000,000 electron volts using radio frequency cavities[1].  
Electrons with an energy of 0. 1GeV are injected into the booster synchrotron from the 
linear accelerator[1]. Dipole magnets are used to bend the electron beam around the 
curves of the stadium-shaped track, whilst radio frequency voltage sources accelerate the 
electrons around the straight sections of the track. 
Electrons are then magnetically ‘kicked’ out of the booster ring into the storage ring. The 
storage ring is made of twenty-four straight sections, which are angled together to form a 
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loop. Dipole magnets curve the beam between adjacent straight sections in the storage 
ring. The entire system is held under a vacuum to minimise electrons scattering off air 
molecules. Electrons are held in the storage ring at a constant speed with an energy of 3 
GeV. As electrons circulate the storage ring they produce synchrotron radiation, this 
radiation is projected at a tangent to the electron storage ring and is captured in 
beamlines. Beamlines can originate at bends in the storage ring or on the straight sections 
at insertion devices. Synchrotron light firstly enters the front end, where light is extracted 
from the storage ring and focused into a beamline, it then enters the optics hutch were 
the desired wavelengths are selected and focused. This focused light then passes to the 
experimental hutch where the X-rays interact with the sample and are detected using X-
ray cameras. 
 
Figure 4.1 Layout of the Diamond Light Source in Oxfordshire. 1- injection systems, electron gun and 
linear accelerator. 2 – booster synchrotron, 3 – storage ring, 4 - beam lines, 5 – font ends, 6 – optics 
hutch, 7 – experimental hutch, 8 – control cabin, 9 – radio frequency cabin[1]. 
 
4.1.2 XRF and XANES 
 
Two techniques are used to analyse the uptake and composition of the metallo cylinder -  
X-Ray Fluorescence (XRF) and X-Ray Absorption Near-Edge Structure (XANES). XRF is 
used to analyse quantitatively the composition of a material. The sample is bombarded 
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with high-energy X-rays, causing ionisation of the sample’s constituent atoms. During 
ionisation, one or more of the atom’s inner shell electrons is ejected from its shell, causing 
the electronic structure of the atom to become unstable. Electrons in higher energy 
orbitals fall down to fill the hole left behind. As the electron falls to fill the hole, it releases 
energy in the form of a photon i.e. a characteristic ‘secondary’ X-ray. These secondary X-
rays are detected and allow elemental maps to be produced. Each element has electronic 
orbitals with characteristic energies; there are a limited number of ways that the higher 
energy electron can fall to fill the lower energy level. The main transitions are called Kα (L 
to K transitions), Kβ (M to K transitions) and Lα (M to L transitions). Each of these 
transitions yield a fluorescent photon that has a characteristic energy equal to the 
difference in energy of the initial and final orbital. The wavelengths of radiation are then 
separated, allowing the intensities of each characteristic radiation to be directly related 
to the amount of each element in the material. An example spectrum so shown in Figure 
4.2. 
 
Figure 4.2 Wavelength dispersive XRF spectrum. 
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XANES is a form of X-ray absorption spectroscopy (XAS) which is used to examine the 
coordination structure of atoms. The energy of the synchrotron beam is tuned through 
the absorption edge of the element of interest and modulations in the absorption are 
measured. Modulations near the absorption edges are caused by photoelectron 
transitions. As discussed previously an X-ray interacts with the sample by photo 
absorption into a core level of the atom. This is followed by photoelectron emission, 
leaving a core hole in the atom that is filled by an electron from another level, releasing 
an X-ray or emission of an Auger electron. These modulations give information about the 
chemical state and local symmetry of the element. Using this information, the oxidation 
state of the element can be examined, for example Fe(II) and Fe(III) metal atoms can be 
differentiated between. As well as the geometry, for example allowing octahedral and 
square planar platinum centers to be distinguished between. For metal atoms in the 
absorption region, the photoelectron is excited to the first unoccupied level above the 
Fermi level. XANES spectroscopy allows the properties of an unknown sample to be 
compared against a set of standards. An example of this is from samples of soil and 
concrete that have been compared against a set of plutonium standards. XANES spectra 
of four plutonium standards at different oxidation states were recorder (Pu(III), Pu(IV), 
Pu(V) and Pu(VI)). The set of standards were compared against the soil and concrete 
samples, it can be seen from the spectrum, that the plutonium in the soil and concrete has 
a Pu(IV) oxidation state due to the alignment and identical shape of their individual 
XANES spectra (Figure 4.3)[2]. 
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Figure 4.3 XANES spectra of plutonium in soil and concrete against a set of plutonium standards at 
different oxidation states. (Image taken from reference[2]). 
 
4.1.3 Synchrotron XRF and XANES imaging applications 
 
 
Synchrotron imaging has been used to examine the cellular distribution of platinum(IV) 
complexes in A2780 ovarian cancer cells[3]. Micro-XANES of the treated cells was used to 
ensure the prodrug had been reduced in-situ for Pt(IV) to Pt(II)[3]. Cells were seeded and 
treated with freshly prepared platinum solutions. After treatment, cells were washed, 
trypsinised and re-suspended in ammonium acetate. Cells were mounted onto Fromvar 
film in a Teflon frame and frozen in liquid nitrogen cooled liquid isopentane. XRF imaging 
produced elemental maps of Cl, K, Ca, Cu, Zn and Pt were recorded, and show nuclear 
localisation of the Pt complex after 24 hours of treatment (Figure 4.4)[3].  
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Figure 4.4 Elemental maps of Cl, K, Ca, Cu, Zn and Pt respectively obtained by XRF imaging of A2780 
cells treated with cis-[PtCl4(NH3)2] (Image taken from reference[3]).  
 
The micro-XANES spectra on treated A2780 cells shows platinum is present in the cells. 
The Pt(IV) complex cis-[PtCl4(NH3)2] shows a single peak in the first derivative, similar to 
that observed for cisplatin, indicating the complex has been reduced to Pt(II)(Figure 
4.5)[3].      
    
Figure 4.5 XANES spectra (solid line) and first derivative (dotted line) of cis-[PtCl2(NH3)2] (a) cis-
[PtCl4(NH3)2] (b) through A2780 cells after 24 hours of treatment (Image taken from reference [3]). 
 
XANES experiments have also been used to probe the oxidation state and coordination 
environment of cobalt complexes, following treatment of cancer cells[4]. Cells were plated 
and treated. After treatment cells were washed with PBS, trypsinised and re-suspended 
in ammonium acetate, followed by dehydration in ethanol and 2 days of freeze drying. 
The solid cell pellet was then subjected to XANES experiments. It can be observed that 
[Co(diNOsar)]Br3 (diNOsar = dinitrosarcophagine) (Figure 4.6) possess the same shaped 
XANES curve before and after administration to cells; this indicates the complex stays 
intact after 24 hours in the cell environment, as it possess the same oxidation state and 
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coordination geometry (Figure 4.7)[4]. This is in comparison to [Co(acac)3] (Figure 4.6) 
which showed an altered XANES spectrum after cell treatment; indicating that the 
complex had lost ligands and potentially degraded inside the cell (Figure 4.7)[4]. 
 
Figure 4.6 Structure of [Co(acac)3] (left) and [Co(diNOsar]Br3 (right). 
 
 
Figure 4.7 XANES spectra of [Co(acac)3] before and after administration to A2780 cells for 24 hours 
(left). XANES spectra of [Co(diNOsar)Br3] before and after administration to A2780 cells for 24 hours 
(right)  (Image taken from reference [4]). 
 
4.1.3 Aims 
 
The aim of this experiment is to prepare samples of cancer cells that have been treated 
with different concentrations of parent metallo-cylinder (previously described in chapter 
2) for different periods of time. Samples will be examined using XRF imaging to produce 
elemental maps of – potassium(I) to distinguish outline of the cell (due to the high levels 
of potassium(I) in the cytoplasm); zinc, to observe the nucleus; chlorine, as this is the 
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complex counter ion, as well as a common ion throughout the cell; and finally, iron, the 
metal centre of the metallo-cylinder. These elemental maps will then be overlaid to 
determine if iron is inside the cell and subsequently inside the nucleus. 
XANES experiments will then be taken for iron containing areas of the cell and compared 
to iron containing standards that will be prepared, to analyse whether the iron metallo-
cylinder retains its structure once inside the cell. 
 
4.2 Sample preparation 
 
 
4.2.1 Iron(II) metallo-cylinder complex preparation 
 
Firstly, the parent ligand was prepared via a condensation reaction between 2-
pyridinecarbaldehyde and 4,4′-methylenedianiline in a 2:1 ratio[5]. The starting materials 
were stirred at room temperature for 18 hours in ethanol. The product was collected by 
filtration, washed with methanol and diethyl ether and dried. The compound was 
characterised by 1H NMR (Figure 4.8), 13C NMR and MS. The ligand was then dissolved in 
methanol. Upon addition of FeCl2 the solution changed to a bright purple colour, 
producing the metallo cylinder complex. The bright purple colour of the complex is due 
to the MLCT band at 575 nm.  NH4PF6 was added to precipitate the product, which was 
collected by filtration, washed with water, methanol and ether and dried to produce the 
product.  Dowex was used to change the counter ion from a PF6- to a Cl- counter ion. The 
product was filtered and the solvent removed to produce the parent metallo cylinder 
complex [Fe2L3]Cl4. The complex was characterised by 1H NMR (Figure 4.8) and MS. 
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Figure 4.8 1H NMR (300 MHz, CDCl3, 298 K) of the parent ligand (bottom) and 1H NMR (300 MHz, 
CD3OD, 298 K) complex [Fe2L3]Cl4 (top). 
 
4.2.2 Biological sample preparation 
 
MDA-231 (breast cancer) and A2780 (ovarian cancer) cell lines were selected for this 
experiment due to their large nuclei. This gave a large target area to be imaged for 
colocalisation studies. Both cell lines were removed from liquid nitrogen storage and 
placed into DMEM (Dulbecco’s Modified Eagle Medium) and RPMI-1640 (Roswell Park 
Memorial Institute Medium) respectively. After 12 hours the media was removed, cells 
washed with PBS, new media added. Cells where left to reach 80% confluency before cell 
passage. Cells were passaged twice before use.  
Round sapphire discs were used as the substrate to grow cells on as they have a good 
thermal shock resistance, low thermal expansion coefficient, extreme surface hardness 
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and low fluorescence. These properties make sapphire ideal for use in a cryostat as the 
extreme temperature doesn’t affect it. Sapphire discs also have excellent optical qualities 
and transmittance over a wide spectral range, allowing cells to be clearly viewed using 
the camera attached to the beamline. The sapphire discs were sterilised in 70% ethanol, 
and then left to air-dry in a laminar flow hood. A disc was placed into each well of a 6 well 
plate, before each well was seeded with 10,000 cells which were left to adhere to the disc 
overnight. The adherence of cells was checked using a Leica DMIL light microscope. Fresh 
solution of iron cylinder was prepared using DMEM and RPMI-1640 media. The media in 
each well was removed, the cells washed with PBS and fresh media added containing the 
desired concentration of metallo cylinder (20μM or 100μM). The treated discs were 
placed back into the incubator for their desired treatment time (30 min, 4 h or 24 h). The 
treatment media was removed and the cells were washed three times with PBS to remove 
any residual metallo cylinder from the surface of the disc. A super cooled slurry of dry ice 
and methanol was prepared. The discs were snap frozen by hovering them just over the 
surface of the methanol bath with tweezers for 1 second, then submerging them into the 
bath for 5-10 seconds, once removed the discs were placed in a clean, labelled, 6 well 
plate. Snap freezing was used to fix the cells to remove the need for a chemical fixative 
such as ammonium acetate. This was to allow the cells to stay in as natural a state as 
possible. Plates were stored in a -80°C freezer until they were needed (no longer than 1 
week) and then transported to the Diamond Light Source on dry ice. 
 
4.3 XRF and XANES beam line Set up 
 
All elemental mapping and XANES spectroscopy was conducted on beamline I18 at the 
Diamond Light Source in Oxfordshire. The schematic of beam line I18 is shown in Figure 
4.9. The beamline passes through 3 slits, toroid, monochromator, HR mirrors and KB 
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focusing mirrors before it hits the sample. These devices highly focus the beam, giving it 
a size and spatial resolution of 2µm x 2µm. 
 
Figure 4.9 Set up of beamline I18 as its focused onto the sample, giving it a beam size of 2µm x 2µm[1]. 
 
The sapphire disc was attached to an aluminium disc using super glue. The aluminium 
disc was subsequently mounted by a clip onto the face of the He/N2 cryostat (Figure 4.10). 
The copper back of the cryostat allows uniform heat distribution. 
 
 
Figure 4.10 Aluminium disc with a sapphire disc glued into place (left). The base plate of the cryostat 
showing the metal clip used to hold the aluminium disc in place during the experiment. 
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A cover is then placed onto the front of the sample. The cryostat is mounted to a motorised 
stage to allow movement of the sample in the X-Y plane so the sample can be focused from 
the control cabin. A stream of nitrogen is blown onto the face of the cryostat to stop ice 
formation on the front of the sample during the experiment. The detector is held at a 45° 
angle to the sample, with the beamline and camera directly facing the sample (Figure 
4.11). 
 
Figure 4.11  Experimental beamline set up on beamline I18 at the Diamond Light Source. The face 
plate of the cyrostat sample holder (A). Side view of the experimental set up (B). Front view of the 
experimental set up, with the blue top line blowing a stream of nitrogen across the sample to stop 
ice formation(C).  Arm of the cryostat, covered in ice. The X-ray detector at a 45°C angle to the 
sample. The camera and beamline are located directly opposire the sample. Experimental hatch (D). 
B A 
C D 
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4.4 XRF and XANES results 
 
 
MDA-231 and A2780 cells were used for the experiment as they have large nuclei and the 
results can be used in collaboration with previously obtained MTT data and hoechst 
displacement studies undertaken using these cell lines. During the experimental 
procedure, cells are firstly located using a camera, and an area of interest is selected and 
focused upon (the cells of interest are highlighted in red in the subsequent camera 
images). Areas are selected so that 2-4 cells, that have an elongated healthy shape are 
selected. Ideally the cells are spaced out enough to allow a clear cell edge to be defined, 
but also within a small enough area to make effective use of beam time. Elemental maps 
of the area shown below take up to 3 hours to be produced by the X-ray beam raster 
scanning across the sample. 
Elemental maps of iron are taken to examine the location of iron rich deposits within and 
around the cell. Chlorine, potassium and zinc maps are acquired to determine the location 
of the cells, due to their high concentrations within cell cytoplasm. These are subsequently 
used to produce overlay images of chlorine and iron to deduce if iron has been 
internalised, and if so its localisation within the cell. 
Elemental maps from samples of MDA-231 cells treated with 100 µM parent metallo 
cylinder for 24 hours are shown in Figure 4.12 and Figure 4.13. The iron maps show low 
levels of iron within the sample. From the overlay images it can be observed that iron 
(shown in blue) accumulates around the edge of the cells but is not observed inside the 
cells. This is the longest treatment time that cells are exposed to the metallo cylinder. Only 
small areas of the sapphire disc area are imaged and cells that have effectively taken up 
the complex may have undergone apoptosis and been washed from the window during 
the PBS washing stage of sample preparation. 
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Figure 4.12 MDA-MB-231 cells, grown on sapphire windows, treated with 100µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 24 h, followed by snap freezing fixation. Camera image of the MDA-231 cells 
to be mapped using XRF microscopy. Elelmntal maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.13 MDA-MB-231 cells grown on sapphire windows, treated with 100µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 24 h followed by snap freezing fixation. Camera image of the MDA-231 cells 
to be mapped using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.14 MDA-MB-231 cells grown on sapphire windows, treated with 100µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 0.5 h followed by snap freezing fixation. Camera image of the MDA-231 cells 
to be mapped using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.15 MDA-MB-231 cells grown on sapphire windows, treated with 100µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 4 h followed by snap freezing fixation. Camera image of the MDA-231 cells to 
be mapped using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.16 MDA-MB-231 cells grown on sapphire windows, treated with 20µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 24 h followed by snap freezing fixation. Camera image of the MDA-231 cells 
to be mapped using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
 
MDA-231 cells were treated with 20 µM parent iron cylinder for 30 minutes. In Figure 
4.17 the iron and chlorine maps are overlaid. It can be observed there is stong 
colocalistaion of iron and chlorine in two of the smaller cells. The cells appear too have 
iron within them and have balled up in to a spherical shape. As observed within the 
camera image. This suggests that the cells that have uptaken the iron complex are entering 
apoptosis, indicated by their loss of enlogated morphology. 
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Figure 4.17 MDA-MB-231 cells grown on sapphire windows, treated with 20µM parent iron(II) 
cylinder [Fe2L3]Cl4 for 0.5 h followed by snap freezing fixation. Camera image of the MDA-231 cells 
to be mapped using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF 
synchrotron microscopy. Overlay of Cl and Fe elemental maps. 
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A2780 cells have also been imaged and mapped after treatment with the metallo cylinder. 
A2780 cells treated with 100 µM parent iron cylinder ([Fe2L3]Cl4) for 30 minutes are 
shown in Figure 4.18, Figure 4.19 and Figure 4.20 and when compared to MDA-231 cells 
treated under the same conditions (Figure 4.14); they show a higher level of iron uptake. 
Over laying the iron and chloride elemental maps shows that the iron is inside the cell, 
this is particularly evident in Figure 4.18. 
 
 
Figure 4.18 A2780 cells grown on sapphire windows, treated with 100µM parent iron(II) cylinder 
[Fe2L3]Cl4 for 0.5 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped 
using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF synchrotron 
microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.19 A2780 cells grown on sapphire windows, treated with 100µM parent iron(II) cylinder 
[Fe2L3]Cl4 for 0.5 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped 
using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF synchrotron 
microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.20 A2780 cells grown on sapphire windows, treated with 100µM parent iron(II) cylinder 
[Fe2L3]Cl4 for 0.5 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped 
using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF synchrotron 
microscopy. Overlay of Cl and Fe elemental maps. 
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Figure 4.21 A2780 cells grown on sapphire windows, treated with 20µM parent iron(II) cylinder 
[Fe2L3]Cl4 for 24 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped 
using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF synchrotron 
microscopy. Overlay of Cl and Fe elemntal maps. 
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Figure 4.22 A2780 cells grown on sapphire windows, treated with 20µM parent iron(II) cylinder 
[Fe2L3]Cl4 for 4 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped 
using XRF microscopy. Elemental maps of Zn, Fe, Cl and K producing using XRF synchrotron 
microscopy. Overlay of Cl and Fe elemental maps. 
Control samples of cells treated with iron(II) chloride were prepared using the procedure 
described previously (4.2.2 Biological sample preparation). Cells were treated with FeCl2 
at 40 µM and 200 µM, double the concentration used for the metallo-cylinder, to account 
for the two metal centers within the iron(II) cylinder.  In A2780 cells treated with iron(II) 
chloride at 40 µM for 24 hours it can be observed that iron is associated around the edges 
of the sample. Samples treated with a high dose of FeCl2 shows an iron distriburtion that 
correlated with zinc distribution, indicating the iron has been taken up into the cell. The 
distribution appears similar to that observed for cells treated with the complex at 100 µM 
(Figure 4.19) 
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Figure 4.23 A2780 cells grown on sapphire windows, treated with 40µM iron(II) chloride FeCl2 for 
24 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped using XRF 
microscopy. Overlay of Zn and Fe elemental maps. 
 
 
 
Figure 4.24 A2780 cells grown on sapphire windows, treated with 200µM iron(II) chloride FeCl2 for 
24 h followed by snap freezing fixation. Camera image of the A2780 cells to be mapped using XRF 
microscopy. Overlay of Zn and Fe elemental maps. 
 
Elemental map overlays of MDA-231 cells treated with FeCl2 at 40 µM for 4 hours shows 
very little correlation between iron and the cellular distribution of zinc. Iron appears to 
be distributed around the cell and hasn’t been internalised within the cell. This 
corresponds with the distribution of iron seen in MDA-MB-231 complex treated samples 
(Figure 4.12 - Figure 4.17).  
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Figure 4.25 MDA-231 cells grown on sapphire windows, treated with 40µM iron(II) chloride FeCl2 
for 4 h followed by snap freezing fixation. Camera image of the MDA-231 cells to be mapped using 
XRF microscopy. Overlay of Zn and Fe elemental maps. 
 
XANES scans were taken through an iron containing area in A2780 cells treated with the 
metallo cylinder [L3Fe2][Cl]4 for 4 hours. The obtained spectra (Graph 4.1) shows a similar 
shape to the iron standards of metallo cylinder bound to ct-DNA and iron (II) phosphate. 
This indicated that iron inside the cell has a 2+ oxidation state and is appears intact within 
the cell. 
During the experiment the cryostat broke, which meant that XANES scan couldn’t be 
obtained, as the process would cause too much damage to the cells at room temperature. 
This meant that iron rich areas in the elemental maps couldn’t be further investigates to 
examine the ions coordination environment and oxidation state, which would allow 
examination of the stability of the complex. 
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Graph 4.1 XANES spectrum, taken of iron(II) standards of iron phosphate, iron metallo cylinder 
bound to ct-DNA and through an iron rich area of an A2780 cell sample treated with metallo cylinder 
for 4 hours at 20 µM. 
 
4.5 Bromine cylinders 
 
Bromine modified cylinders were developed to allow co-localisation experiments of 
bromine and iron to be undertaken. This will give insight into whether the cylinder 
remains intact once inside the cell. A strong correlation in the elemental maps for bromine 
and iron would suggest the complex remains intact. Whereas if no correlation is observed, 
the complex has degraded and the ligand has ‘fallen off’ the metal ion.  
4.5.1 Synthesis of bromine cylinders 
 
5-bromo-2-pyridnecarbldehyde was dissolved in methanol, followed by the dropwise 
addition of 4,4′-methylenedianiline dissolved in methanol ( 
Figure 4.26). The solution was stirred for 20 hours at room temperature; producing a 
white precipitate that was collected by filtration. The ligand (LBr5) was obtained in an 83% 
yield and fully characterised using 13C NMR, MS and 1H NMR (Figure 4.27). In 1H NMR the 
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imine peak (H4) can be observed as a strong singlet, the loss of the aldehyde peak from 
the starting material confirms the condensation reaction has been successful. 
 
 
 
Figure 4.26 Synthesis of bromine functionalised ligand LBr5. 
 
 
Figure 4.27 1H NMR (300 MHz, CDCl3, 298 K) of the pyridylimine ligand functionalised in the 5th with 
bromine LBr5. 
 
 
83% 
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The ligand LBr5 was suspended in methanol and FeCl2 (dissolved in methanol) was added 
dropwise to the stirred ligand. Upon addition of the metal salt, the solution turned a 
characteristic purple colour, showing formation of a metal complex due to the MLCT band 
at 573nm, giving rise to the intense colour. The product was precipitated from solution 
by the addition of ammonium hexafluorophosphate, collected and dried. The product was 
obtained in an 84% yield and fully characterised; the 1H NMR spectra (Figure 4.28) shows 
the formation of the product, indicated by the broad peaks for H5a and H5b. In the ligand 
these hydrogens are equivalent, indicated by the strong singlet peak at 7.26 ppm in the 
1H NMR (Figure 4.27). Upon coordination to the metal, these protons become inequivalent 
and occupy two different environments, shown by the two board singlets in the complex 
1H NMR (Figure 4.28).  
 
Figure 4.28 1H NMR (300 MHz, MeCN, 298 K) of the complex [Fe2LBr53][PF6]4. 
 
To further examine the stability of the complex the bromine functionalised group was also 
synthesised at the 4th positon of the pyridine ring. The ligand, LBr4, was prepared as 
described above using 4-bromo-2-pyridnecarbldehyde and 4,4′-methylenedianiline in a 
2:1 ratio, giving an 88% yield of product ( 
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Figure 4.29). Confirmation of ligand LBr4 formation is shown by the 1H NMR (Figure 4.30), 
appearance the imine peak (H4) and loss of the aldehyde peak, prove the condensation 
reaction was successful. 
 
 
 
Figure 4.29 Synthesis of the bromine functionalised ligand LBr4, with Br in the 4th position of the 
pyridine ring. 
 
 
Figure 4.30 1H NMR (300 MHz, CDCl3, 298 K) of the pyridylimine ligand functionalised in the 4th 
position with bromine.  
88% 
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The ligand LBr4 was reacted with FeCl2 as described above. The 1H NMR of the complex 
(Figure 4.31) shows the aromatic protons have split into two broad peaks (H5a and H5b), 
showing coordination to the metal centres causing them to be inequivalent. 
 
Figure 4.311H NMR (300 MHz, MeCN, 298 K) of the complex [Fe2LBr43][PF6]4. 
 
4.5.2 Stability of bromine cylinders 
 
 
UV-vis stability studies were undertaken to assess if the complexes were stable in an 
aqueous environment, which is essential for effective cellular uptake and treatment.  100 
µM solution of [Fe2LBr53][PF6]4 and [Fe2LBr43][PF6]4 was prepared in 3% 
acetonitrile/water mixture. The acetonitrile was used to dissolve the complex, and diluted 
to 100 µM using ultra-pure milliQ water. A background of acetonitrile/water mixture 
(3:97) was run before experimental measurements were taken. UV-vis spectra were 
taken of the complex solutions over 4 hours, at 1 h time points (Graph 4.2) for complex 
[Fe2LBr53][PF6]4 and over  6 hours for complex [Fe2LBr43][PF6]4. Between measurements 
the complexes was left inside the machine in the dark at room temperature.  
The peak at 575 nm represents the MLCT band of the complex; for this to be present the 
ligand has to be bound to the metal. Observed over time, the intensity of the peak 
decreases for [Fe2LBr53][PF6]4, and after 4 hours the double humped shape of the broad 
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peak has almost flattened out.  The loss of the MLCT band indicates the complex is 
degrading within the time scale of the experiment, in aqueous solution. This indicated 
degradation of the complex and that it is unstable in aqueous solution over. Upon removal 
of the sample from the UV-vis machine the solution has a very faint purple hue compared 
to the deep purple colour observed when the complex is first formed, further confirming 
the degradation of the complex and loss of the MLCT band. 
 
Graph 4.2 Stability of 100 µm Fe(II) bromine-5 cylinder over 4 hours in MeCN/milliQ water (3:97).  
 
The UV-vis stability study was repeated with [Fe2LBr53][PF6]4 with the addition of 30 µM 
ct-DNA. The addition of ct-DNA greatly improves stability of the complex. The defined 
double humped shape from 500-600nm is still observed after 12 hours. This may be due 
to the complex binding to the major groove of DNA and being stabilised by the 
electrostatic forces holding it in place. After 78 hours the MLCT peak at 575nm still has 
an intensity above 1, in comparison to the intensity of the peak after 4 hours without ct-
DNA, where the intensity drops below 0.3. 
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Graph 4.3 Stability of 100 µm Fe(II) bromine-5 cylinder over 78 hours in MeCN/milliQ water (3:97) 
with 30 µm ct-DNA. 
 
 Graph 4.4 Stability of 100 µm Fe(II) bromine-4 cylinder over 6 hours in MeCN/milliQ water (3:97). 
 
The iron(II) bromine functionalised complex [Fe2LBr43][PF6]4 shows increased stability in 
its UV-vis spectrum in acetonitrile/water (3:97), compared to complex [Fe2LBr53][PF6]4 
(Graph 4.4). After 6 hours a well-defined MLCT band is still observed, with maxima at 
590nm. This increase in stability is due to the increased spaced distance between the 
bromide groups at the ends of the complex (Figure 4.32 Structure of LBr4 and LBr5). Any 
repulsion effects caused to the close proximity of three bromine groups has been reduced. 
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Figure 4.32 Structure of LBr4 and LBr5 
 
4.5.3 Synchrotron XRF imaging of bromine cylinders 
 
 
Once the relative stabilities of the bromine cylinders were analysed, synchrotron imaging 
samples were prepared as described previously (4.2.2 Biological sample preparation). 
Except the bromine modified complex was dissolved in MeCN and added to the cell media 
in the 6 well plate. The volume of MeCN was kept at 3% during dilution with cell media. 
Samples were washed after treatment and snap frozen as described above (4.2.2 
Biological sample preparation). Only short treatment periods were undertaken, ranging 
from 30 minutes to 4 hours. This was due to the instability of the complexes in aqueous 
media as discussed in section 4.2.2 . As shown by the UV-vis experiments the complexes 
are stabilised upon binding to DNA. However, in a cellular environment the complex 
needs to enter the cell and reach the nucleus or mitochondria before it is able to bind to 
DNA and increase its stability.  
MDA cells were used due to their large nucleus, this gave a large target area to be mapped 
and deduce if the complex has entered the nucleus. The cells of interest are shown in 
Figure 4.33 and are highlighted in the red box. The redline is the synchrotron beamline 
on the sapphire disc. 
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Figure 4.33 Camera image of MDA cells grown on a sapphire window treated with 100 µm 
[Fe2LBr53][PF6]4 for 30 min, snap frozen and held at liquid nitrogen temperature by a cryostat. The 
image was recorded on I18 at Diamond Light Source. The red box shows the cells used to produce 
elemental maps. 
 
Elemental maps of Zn, Cl, Fe and Br were taken across the sample. The outline of the cells 
can clearly be observed in the Cl and Zn map of the sample and correlates with the cell 
shape observed in the camera image. The elongated shape and morphology of the cells 
observed on the camera image shows that were healthy, adhered and in a healthy state 
before snap freezing. This confirms that the small volume of acetonitrile used to 
administer the complex has had little effect on the cells. The elemental iron map (Figure 
4.34) shows the presence of iron inside the cell after treatment with [Fe2LBr53][PF6]4 for 
30 minutes. The bromide maps also show the presence of bromine inside the cell but also 
in defined clusters around the perimetre of the cell. This suggests that some of the 
complex has degraded before being uptaken by the cells. Although there is iron and 
bromide inside the cell there is no strong co-localisation between the two. This suggests 
that the complex has degraded before reaching the nucleus, where it could have been 
stabilised by binding to the DNA.  
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Figure 4.34 Elemental maps of chlorine, zinc, iron and bromine produced by x-ray synchrotron 
imaging of MDA-MB-231 cells treated with 100 µm [Fe2LBr53][PF6]4 for 30 min, shown above in the 
red box in Figure 4.33. 
 
 
Figure 4.35 The overlay of chlorine and iron elemental maps of MDA-231 cells treated with 100 µm 
[Fe2LBr53][PF6]4 for 30 min, that show iron inside the cell. The overlay of zinc, iron and bromine maps 
showing the presence of bromine inside the cell. The overlay of iron and bromine inside the cell, 
however there seems to be little correlation between the distribution of iron and bromine. 
 
A2780 cells have been treated with the iron bromine complex [Fe2LBr43][PF6]4 at 20 µM 
concentration for 30 minutes, to allow the maps obtained, to be comparable to those 
produced following treatment of [Fe2LBr53][PF6]4. A2780 cells have also been treated with 
the bromine functionalised ligand LBr4, it examine if bromine distribution is comparable 
to that observed in [Fe2LBr43][PF6]4 treated cells. 
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Figure 4.36 A2780 cells grown on sapphire windows, treated with 100 µM [Fe2LBr43][PF6]4 for 0.5 h 
followed by snap freezing fixation. Camera image of the A2780 cells to be mapped using XRF 
microscopy. Overlay of Zn and Fe elemental maps, and Br and Fe elemental maps.  
 
In A2780 cells treated with the complex, there is weak correlation between the 
distribution of bromine and iron throughout the cell. Bromine appears to be distributed 
through the whole cell and shows strong correlation with the distribution of zinc, whilst 
iron is in defined regions. This is surprising due to the greater stability observed by the 
[Fe2LBr43][PF6]4 complex in aqueuos enviroment, in comparison to is 5th position 
counterpart. In UV-vis experiments the complex appears realative stable for up to six 
hours, and the cell sample has only been tretaed for 30 minutes. The complex may have 
been uptake into the cell and broken down inside the cell due to components within the 
cell.  In comparison the bromine distribution in ligand (LBr4) treated cells, at 100 µM for 
30 minutes, appears to bein well defined regions that show little correclation with the 
149 
 
zinc maps, indicating bromine is out side of the cell. This would again suggest that the 
complex enters cells intact, then degrades, leaving bromine inside the cells. 
 
 
Figure 4.37 A2780 cells grown on sapphire windows, treated with 100 µM Ligand-LBr4 for 0.5 h 
followed by snap freezing fixation. Camera image of the A2780 cells to be mapped using XRF 
microscopy. Overlay of Zn and Fe elemental maps, and Br and Zn elemental maps 
 
4.6 Cryo soft x-ray tomographic imaging  
 
4.6.1 Introduction  
 
Beamline B24 is a full field transmission microscope, which allows biological samples to 
be tomographically imaged under near physiological conditions. This technique uses soft 
X-rays around 500eV in the ‘water window’.  The ‘water window’ is the region between 
the K-absorption edges of carbon at 284eV and oxygen at 543eV. Between these two 
energies oxygen is virtually transparent to x-rays, however carbon is highly absorbing. 
This gives rise to natural contrast in the sample between the carbon containing 
organelles/structures of the cell and the vitreous ice surrounding the sample. This allows 
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biological samples to be imaged with a resolution of around 30-40nm. The data collected 
in the water window allows features such as membranes and mitochondria structures to 
be clearly visualised. This technique allows transmission electron miscopy style images 
to be obtained without the need for cell fixation, staining with heavy metals or sectioning. 
Samples are plunge frozen, allowing samples to be ‘fixed’ without the need for chemicals, 
therefore cells can be viewed in as close to a natural physiological state as possible. The 
images obtained are from 3D data collected on whole unstained biological cells.  
4.6.2 Literature examples of cryo soft X–ray tomographic imaging 
 
Cryo soft X-ray tomography (cryo-SXT) provides 3D nanoscale information from 
unstained, cryopreserved whole cells. G361 (malignant melanoma cells) have been cryo 
preserved and imaged using cryo soft X-ray tomography. The images produced show clear 
well defined organelle structures, including the nucleus, cell membrane, mitochondria, 
endoplasmic reticulum, nuclear envelope and nuclear pores[6]. These images show cells 
in as close a natural state as possible, due to removal of chemical fixation.  
 
Figure 4.38 a. Images from a reconstructed tomogram of dividing G361 cells taken using Cryo-SXT 
(Soft X-ray Tomography). The nucleus, cell membrane and intercellular bridge (circled). b. 
magnification of the intercellular bridge. c. mitochondria with christae. d. Endoplasmic reticulum 
(arrows). e. nuclear envelope (white arrows indicate nuclear pores). (Images taken from 
reference[6]).  
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 This technique also allows yeast ultrastructure to be imaged, which has previously 
proved difficult due to its thick cell wall[7]. The cell wall is traditionally removed prior to 
chemical fixation, disrupting the cells native structure[7]. Cryo fixation and soft X-ray 
tomography allows the internal vesicles to be clearly imaged and 3D models of the cell to 
be produced. 
 
Figure 4.39 A. X-ray image of Saccharomyces cerevisiae (arrows show gold fiducial markers used in 
the alignment of tomographic images) B. Reconstructed data of yeast cells (in A. and C) using 
transparent surface analysis showing internal vesicles. C. computer generated image section from 
reconstructed data (dense lipid droplets appear white, organelles and large vacuoles appear dark 
due to their low density. (Image taken from reference[7]). 
 
Cryo-SXT has been used in correlation with cryo-fluorescence microscopy to allow whole 
cell imaging of endosomes and autosomes in mammalian Hek293 cells. Early endosomes 
were located by using an anti-transferrin receptor antibody conjugated to 10nm gold 
nanoparticles; these have been segmented in Figure 4.40, and represented in yellow, with 
the up taken gold nanoparticles visible as black dots inside the endosome[8]. The 
fluorescent marker GFP (green florescent protein) was attached to LC3(Atg8); an 
autophagy specific protein recruited to forming autophagosomes. Red fluorescent protein 
(RFP) was attached to Atg9; an autophagy transmembrane specific protein essential in 
the formation of early autophagosomal structures. GFP-LC3 and RFP-Atg9 were located 
using a cryo-fluorescence stage in the laboratory. Cryo-SXT images were produced at the 
synchrotron to obtain the cellular ultrastructure. The 3D ultrastructure of endocytic and 
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autophagic structure was mapped and showed clusters of omegasomes coming from 
‘hotspots’ on the endoplasmic reticulum[8]. Cryo-SXT and cryo-fluorescence microscopy 
can be used in conjunction with immunogold markers to analyse cellular process that 
would be inaccessible using other imaging modalities[8]. 
 
 
Figure 4.40 Cryo – CLXM of omegasomes in starved HeK293 cells. a. the cryo bright field, 
cryofluorescence GFP-LC3, cryofluorescence RFP-Atg9 image. b. overlay of the fluorescent green and 
red channels (red arrows RFP, green arrows GFP, Quantifoil holes indicated in white). c. 3D 
reconstruction of cryo-SXT data, with features being manually segmented and rendered using Amira 
Software. (Quantifoil holes shown as grey circles, gold fiducials indicted by grey arrows, Atg9-VTC- 
red, LC3-positive omegasomes – green, endosomes – yellow containing anti-TfnR-gold – shows as 
black dots inside the endosome, endoplasmic reticulum – blue)((Images taken from reference [8]) 
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4.6.3 Aims 
 
The aim of this experimental is to obtain whole cell images of cells treated with parent 
metallo iron(II) cylinder. To examine the effects, it has on the morphology of the cell. The 
advantage of this technique is the removal of chemical fixation; allowing cells to be viewed 
in a natural physiological state. This means any changes in the cell morphology can be 
attributed to the metallo cylinder rather than chemical fixation. 
4.6.4 Sample preparation for cryo soft X–ray tomographic imaging 
  
HeLa and MDA-231 cells were seeded into MatTek dishes and left to adhere for 24 hours. 
Cells were stained with the membrane dye DiI and z-stacks were taken of the cells to 
ascertain their thickness. The height of 10 separate cells was taken and used to calculate 
an average thickness for each cell type. MDA -231 cells had an average height of 14 μm, 
and Hela cells an average height of 9μm. This technique has a cell thickness limit of 5-
10μm, which eliminated MDA-231 cells from the experiment. Hela cells were used as they 
were within the thickness limit. 
Cells were grown directly on gold 3mm TEM grids; covered with carbon Quantifoil film, 
with holes of 2 nm, separated by 2 nnm. The TEM grids were sterilised by dipping in 70% 
ethanol, then air dried in a laminar flow hood. One grid was placed in each well of a six 
well plate. Hela cells were seeded at 20,000 cells per well in 3 mL of media, as the grid 
needs to have a final confluence below 20%. Cells were treated with metallo cylinder at 
20 μM concentration for 24 hours or 4-hour time points. The grids were gently washed 
with PBS and fresh media was added. The well plates where then plunge frozen by Paul 
Stanley (University of Birmingham, materials and metallurgy). Each disc was removed 
from the well plate with tweezers and placed in the plunge freezer (Figure 4.41). Samples 
were blotted from behind for 2 seconds to remove excess moisture from the sample that 
was drawn from the front of the sample through the holes in the Quantifoil film. The disc 
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was then plunged into liquid nitrogen cooled liquid ethane for vitrification. Grids were 
transferred into cryo TEM grid storage boxes, which were subsequently placed into a dry 
shipper and at liquid nitrogen temperature. Samples were transported to the Diamond 
Light Source and imaged within 2 days of preparation. 
 
Figure 4.41 Photos of the Cryoplunge 3 used to plunge freezer gold TEM grids in liquid nitrogen 
cooled liquid ethane. 
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4.6.5 Beamline set-up 
 
 
During the experiments, the beam line was still under construction therfore these were 
some of the first experiments to be conducted on beamline B24. As the beamline was still 
under construction it was not connected to the synchrotron; therefore, X-rays were 
generated by a nitrogen plasma source. The schematic setup of the beamline is shown in 
Figure 4.42, the beam passes through the shield wall and is deflected through a variable 
line spacing – plain grating monochromator (VLS-PGM) by a horizontal deflection 
torroidal mirror. The beam is directed to the focal point of the PGMs exit slits. The beam 
is then focused onto the sample grid by a capillary condenser. A 40 nm zone plate then 
refocuses the resulting image onto a CCD direct detector. 
 
Figure 4.42 Schematic layout of beamline B24 at the Diamond Light Source. 
 
The sample is fitted in to the sample holders, which can hold four TEM grids, this is done 
under liquid nitrogen (Figure 4.43). The sample holder arm is then inserted into the 
machine and the chamber is kept at constant cryo-temperature throughout the 
experiment. The sample is then exposed to soft X-rays and the signal obtained at the 
detector is used to generate the image. 
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Figure 4.43 Images of the experimental beamline set up on beamline B24 at the Diamond Light 
Source. 
 
4.6.6 Results of cryo soft X–ray tomographic imaging 
 
Sample preparation for this technique proved challenging, in particular the plunge 
freezing. As observed in Figure 4.44 some samples were covered with a thick layer of ice, 
this is due to inefficient blotting; caused by either over confluent cells or too short a blot 
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time. In other samples where plunge freezing was successful the cells appear to be dying 
as they appear spherical and have lost their defined elongated morphology. 
Unfortunately, the plunge freezing facility is located a distance from the cell incubator, 
meaning cells are out of the incubator for a considerable time prior to plunge freezing. 
Every effort was made to maintain the cells temperature, transporting them in a thick 
walled polystyrene box lined with tin foil, containing filled sealed boxes of warm water in 
an attempt to maintain the temperature. The plunge freezer is also only used sporadically 
and due to the flammable nature of ethane gas, Paul Stanley plunge froze the samples on 
my behalf. This didn’t allow me to develop the technique of plunge freezing for future 
samples.   
Attempts to image the spherical HeLa cells were undertaken, but the cells proved too thick 
for the technique, their increased thickness is probably due to them balling up. A second 
batch of samples was prepared using HeK cells as these are thinner with an average 
thickness 5µm. However, plunge freezing of these samples was also challenging and the 
cells again looked spherical in morphology. 
Beamline B24 is now fully operational and has been joined to the synchrotron. The facility 
now has a dedicate plunge freezer and cell culture facility meaning future samples can be 
cultured, treated and plunge frozen all at one location with expert advice on sample 
preparation at hand. This technique has the ability to produce clear images as seen in the 
literature, with the main draw back for my experiments being plunge freezing. I believe 
this could be overcome by undertaking all stages of the experiment at Diamond Light 
Source. The Hannon group has also recently purchased a cryo stage that can be attached 
to an inverted microscope. This would allow samples to be screened at cryo temperature 
at the university prior to taking samples to Diamond. This would allow good quality 
samples be identified prior to vising Diamond, so that the beam time would be used 
focusing on good quality samples. A fluorescence cube has also been fitted to the beamline 
158 
 
now that it is fully operational. The parent ruthenium cylinder is weakly fluorescent; the 
fluorescence of ruthenium complexes is increased in samples at liquid nitrogen 
temperatures. As these experiments are conducted at cryo temperature, dual experiments 
could be undertaken. Gathering TEM style images showing structural details and 
morphological change as well as fluorescence experiments so that the localisation of the 
cylinder could be observed. 
 
Figure 4.44 A. shows the layer of ice that is covering the TEM grid after plunge freezing with ice 
cracks visible in the sample. B. shows a sample that has been successfully plunge frozen, however, 
the zoom in of this sample C. shows that the cells balled up and have started to go into apoptosis. D. 
shows a zoom in of the ice layer on the TEM grid. 
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4.7 Conclusion and future work 
  
In conclusion elemental maps of MDA-231 and A2780 cells have been successfully 
produced for a variety of complex treatment concentrations and time points. Sample 
preparation on sapphire discs and cell fixation using ‘snap’ freezing in cooled methanol 
has been successful.  
Two novel bromine functionalised ligands have been successfully synthesised and 
characterised using 1H NMR, 13C and mass spectrometry. 
 
 
Figure 4.45 Structure of LBr4 and LBr5 
 
These have been successfully reacted with iron(II) chloride to form two novel complexes, 
which have been characterised using 1H NMR and mass spectrometry. Their stability has 
also been tested in aqueous solution, and an increase in stability occurs by moving 
bromine from the 5th to the 4th position of the pyridine ring. The cellular uptake of these 
complexes has also been explored in MDA-231 and A2780 cell via synchrotron imaging, 
by the production of elemental maps. 
Attempts to prepare TEM-grid sample has also been undertaken, with attempts to image 
these samples using cryo-SXT. Whilst cell growth and treatment was successful, plunge 
freezing was the major down fall in sample preparation. 
In Future work cryo-SXT samples would be prepared at the Diamond Light Source to 
assure plunge freezing was undertaken correctly and eliminate the need to transport 
samples. Cells would also be treated with the ruthenium parent complex [Lp3Ru2][PF6]4, 
which has already been successfully synthesised (Figure 4.46). This would also dual 
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fluorescent and cryo-SXT images to be contained and overlaid. These images would allow 
localisation of the complex and morphological changes, which occur due to complex 
treatment, to be examined at the same time. 
 
Figure 4.46 1H NMR (300 MHz, MeCN, 298 K) of [L3Ru2][PF6]4 
 
More XANES experiment would be undertaken through iron containing areas of cells 
treated with the iron metallo-cylinder, to allow comparison to iron standards. Very few 
XANES measurements were taken during I18 beamline experiments, due to the technical 
difficulties experienced at the facility.   
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5 Experimental 
 
5.1 General experimental 
 
 
All solvents and commercially available reagents were purchased from Sigma-Aldrich, 
Fisher Scientific and VWR and were used without further purification. Deuterated NMR 
solvents were purchased from Goss Scientific and were used without further purification. 
NMR spectra were recorder using a Bruker AVIII300 (300 MHz) and AVIII400 (400 MHz) 
spectrometer. Chemical shift (δ) are reported in parts per million (ppm), spectra are 
calibrated to the reference peak of the deuterated NMR solvent (CDCl3 – 7.26/77.16 ppm, 
CD3CN – 1.94/118.26 ppm, DMSO – 2.50/39.52 ppm, (CD3)2CO – 2.05/29.84 ppm, CD30D 
– 3.31/ 49.00 ppm, 1H and 13C respectively). NMR spectra were assigned based on the 
chemical shift and coupling constants, COSY, NOESY and HSQC experiments were used 
where necessary. Coupling constants (J) are quoted to the nearest 0.1 Hz and peak 
multiplicities are singlet (s), doublet (d) , triplet (t), quartet (q), quintet (qu) and multiplet 
(m). 
Electrospray Ionisation Mass Spectrometry (ESI-MS) was performed on a Micromass LCT 
TOF Mass Spectrometer, with peaks shown as m/z values and reported in Daltons. 
UV-Vis spectra were recoded using a Cary 500 Varian spectrometer, using quartz cuvettes 
with a 1cm path length. 
Fluorescence emission and excitation spectra were recorded using a Shimadzu RF-5301 
PC spectrofluorophotometer, using a quartz cuvettes with a 1cm path length. 
Thin layer Chromatography (TLC) was carried out on pre-coasted aluminium sheets 
(Silica Gel 60 F254), retention factors (Rf) are reported with relation to the solvent used 
to elute the plate, TLC spots were visualised using a hand held UV fluorescence light (254 
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nm). Flash column chromatography was performed using Merck 60 silica gel, with 
particle size 40-63 μm. 
5.1.1 Preparation of 5-trimethylsilylethynyl-2-formyl pyridine 
 
An oven-dried schlenk flask was charged with 5-bromopyridine-2-
carbaldehyde (966 mg, 5.30 mmol), copper iodide (76 mg, 0.40 mmol), 
palladium bistriphenylphosphine dichloride (141 mg, 0.20 mmol) and 
triphenylphosphine (60 mg, 0.22 mmol). Anhydrous triethylamine (30 mL) and 
anhydrous THF (8 mL) were added and the reaction was stirred at room 
temperature under argon for 20 min resulting in a yellow suspension. 
Trimethylsilylacetylene (1 mL, 6.11 mmol) was injected into the flask drop wise at room 
temperature. The reaction was then heated at 60 ᵒC for 5 h under an argon atmosphere. 
The solvent from the crude was removed and the crude extracted with chloroform, 
filtered and concentrated to give a brown solid. The solid was purified by column 
chromatographed on silica gel eluted with DCM. The product containing fractions were 
combined and concentrated to dryness. The solid was extracted with petroleum-ether 
(boiling range 40-60 °C), filtered and the solvent removed to give 5-
Trimethylsilylethynyl-2-formyl pyridine as a pale beige solid (0.741 g, 68%). 1H NMR (300 
MHz, CDCl3): δ 0.28(s, 9H, H9), 7.90 (d, 2H, 4JH-H = 1.3 Hz, H3+4), 8.81 (t, 1H, 14JH-H = 1.4 Hz, 
H6), 10.1 (s, 1H, Hal). 13C {1H} NMR (100 MHz, CDCl3): δ 192.9, 153.2, 151.3, 140.1, 125.0, 
121.2, 103.0, 101.0, 41.7. Rf (DCM) 0.53. ESIMS m/z calculated for 203.08 M+; observed 
203.1 [M+H]+ .The 1H NMR data was consistent with that described in the literature. 
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5.1.2 Preparation of 5-ethynyl-2-formylpyridine 
 
To a solution of 5-trimethylsilylethynyl-2-formyl pyridine (0.700 g, 3.45 mmol) 
in methanol (50 mL) was added potassium carbonate (0.068 g, 0.49 mmol); the 
solution was stirred overnight at room temperature. Ethyl acetate (200 mL) was 
added and the solution washed with water (2 x 25 mL), brine (25 mL), dried 
over MgSO4 and the solvent evaporated to dryness. The crude was purified by column 
chromatography on silica gel eluted with DCM to afford 5-ethynyl-2-formylpyridine as a 
white solid (0.277 g, 61%): 1H NMR (300 MHz, CDCl3): δ 3.42 (s, 1H, H8), 7.94 (d, 2H, 4JH-
H = 0.9 Hz, H3+4), 8.86 (t, 1H, 4JH-H = 1.4 Hz, H6), 10.08 (s, 1H, Hal). 13C {1H} NMR (100 MHz, 
CDCl3): δ 192.5, 153,0, 151.5, 140.1, 123.6, 120.9, 84.0, 79.7. Rf (DCM) 0.57. ESIMS: m/z 
131.04 M+; Observed 154.0 [M+Na]+. The 1H NMR data was consistent with that described 
in the literature. 
5.1.3 Preparation of 4-trimethylsilylethynyl-2-formyl pyridine 
 
An oven-dried schlenk flask was charged with 4-bromopyridine-2-
carbaldehyde (900 mg, 4.84 mmol), copper iodide (80 mg, 0.42 
mmol), palladium bistriphenylphosphine dichloride (140 mg, 0.2 
mmol) and triphenylphosphine (40 mg, 0.15 mmol). Anhydrous 
triethylamine (30 mL) and anhydrous THF (8 mL) were added and the reaction was 
stirred at room temperature under argon for 20 min resulting in a yellow suspension. 
Trimethylsilylacetylene (1 mL, 6.11 mmol) was injected into the flask drop wise at room 
temperature. The reaction was then heated at 60 ᵒC for 5 h under an argon atmosphere. 
The solvent from the crude was removed and the crude extracted with chloroform, 
filtered and concentrated to give a brown solid. The solid was purified by column 
chromatographed on silica gel eluted with DCM. The product containing fractions were 
combined and concentrated to dryness. The solid was extracted with petroleum-ether 
166 
 
(boiling range 40-60 °C), filtered and the solvent removed to give 4-
Trimethylsilylethynyl-2-formyl pyridine as a pale beige solid (0.573 g, 63%). 1H NMR 1H 
NMR (300 MHz, CDCl3): δ 1.57 (s, 1H,), 7.51 (dd, 1H), 7.96 (d, 1H), 8.73 (d, 1H), 10.06 (s, 
1H) . 13C {1H} NMR (100 MHz, CDCl3): δ 193.3, 165.4, 153.1, 150.5, 133.1, 130.0, 124.4, 
102.5, 101.3, 69.9 ESIMS m/z calculated for M+ 203.08 ; observed 203.1 [M+H]+ . 
5.1.4 Preparation of 4-ethynyl-2-formylpyridine 
 
To a solution of 4-trimethylsilylethynyl-2-formyl pyridine (550 mg, 2.71 
mmol) in methanol (50 mL) was added potassium carbonate (60 mg, 0.43 
mmol); the solution was stirred overnight at room temperature. Ethyl 
acetate (200 mL) was added and the solution washed with water (2 x 25 mL), brine (25 
mL), dried over MgSO4 and the solvent evaporated to dryness. The crude was purified by 
column chromatography on silica gel eluted with DCM to afford 4-ethynyl-2-
formylpyridine as a white solid (209 mg, 59%): 1H NMR (300 MHz, CDCl3): δ 3.40 (s, 1H), 
7.52 (dd, 1H), 7.94 (s, 1H) 8.72 (d, 1H), 10.02 (s, 1H). 13C {1H} NMR (100 MHz, CDCl3): δ 
192.7, 152.8, 150.2, 131.8, 129.9, 124.1, 83.6, 80.0. ESIMS: m/z M+ 131.04; Observed 154.0 
[M+Na]+. 
5.1.5 Preparation of 3-nitro-7-diethylamino coumarin 
 
An oven-dried 100 ml three-necked round bottom flask 
equipped with stir bar, argon inlet and condenser was 
evacuated and back filled with argon. The flask was then 
charged with 4-diethylamino salicylaldehyde (1.400 g, 7.20 mmol), ethyl nitroacetate (0.8 
mL, 7.20 mmol) and molecular sieves 4 Å (100 mg) and the flask fitted with a rubber 
septum. Anhydrous 1-butanol (20 mL), piperidine (0.1 mL) and acetic acid (0.2 mL) were 
added and the mixture refluxed for 24 h. Upon cooling room temperature, an orange solid 
formed that was collected by filtration and dissolved in DMF (20 mL) at 80°C.  The 
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solution was filtered to remove the molecular sieved. Ice cold water (100 mL) was added 
to the filtered and precipitated 3-nitro-7-diethylamino coumarin as an orange solid that 
was collect and dried in a desiccator overnight (1.470 g, 77%).1H NMR (300 MHz, CDCl3): 
δ  1.27 (t, 6H, 3JH-H = 7.2 Hz, H11), 3.50 (q, 4H, 3JH-H = 7.2 Hz, H10), 6.48 (d, 1H, 4JH-H = 2.4 
Hz, H9), 6.71 (dd, 1H, 3JH-H = 8.8 Hz, 4JH-H = 2.4 Hz, H7), 7.44 (dd, 1H, 3JH-H = 9.2 Hz, H6), 
8.72 (s, 1H, H4). 13C {1H} NMR (100 MHz, CDCl3): δ 12.58, 45.66, 96.98, 106.35, 111.23, 
132.68, 143.47, 153.58, 154.68, 158.92. ESIMS m/z calculated for 262.10 M+; observed 
263.13 [M+H]+. The 1H NMR data was consistent with that described in the literature 
5.1.6 Preparation of 3-amino-7-diethylamino coumarin 
 
Hydrochloric acid (15 mL, 32%) and stannous chloride 
dehydrate (4.800 g, 21.36 mmol), in order, were added to a 
50 ml round bottom flask equipped with a stir bar. 3-Nitro-
7-diethylamino coumarin (0.800 g, 3.05 mmol) was added to the solution in small 
portions over ten minutes. The reaction was stirred at room temperature for 4 h and then 
poured onto 60 g of ice. The solution was made basic using sodium hydroxide solution (5 
M) and the resulting solution extracted with diethyl ether (2 x 100 mL). The organic layers 
were combined and washed with water (50 mL) dried over anhydrous sodium sulphate 
and concentrated under reduced pressure. The residue was triturated with hexane 
producing a precipitate which was collected and dried to give 3-amino-7-
diethylaminocoumarin as a bright yellow solid (0.540 g, 76%). 1H NMR (300 MHz, CDCl3): 
δ 1.18 (t, 6H, 3JH-H = 7.2 Hz, H11), 3.37 (q, 4H, 3JH-H = 7.2 Hz, H10), 3.85 (bs, 2H, NH2), 6.53 
(d, 1H, 4JH-H = 2.4 Hz, H9), 6.57 (dd, 1H, 3JH-H = 8.8 Hz, 4JH-H = 2.0 Hz, H7), 6.70 (s, 1H, H4), 
7.11 (d, 1H, 3JH-H = 8.8 Hz, H6). 13C {1H} NMR (100 MHz, CDCl3): δ 12.64, 44.79, 98.21, 
109.48, 109.83, 126.09, 127.68, 147.65, 151.78, 160.46. ESIMS m/z calculated for 232.12 
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M+; observed 233.16 [M+H]+. The 1H NMR data was consistent with that described in the 
literature. 
5.1.7 Preparation of 3-azido-7-diethylaminocoumarin 
 
7-Diethylamino-3-amino coumarin (0.300 g, 1.29 mmol) was 
dissolved in hydrochloric acid (12 mL, 16%) and the solution 
cooled to 0 °C. A solution of sodium nitrite (0.090 g, 1.29 
mmol) was slowly added and the reaction mixture stirred at 0 °C for 1 h. A solution of 
sodium acetate (6.000 g) in water (15 ml) was then added to adjust the pH to 4. Sodium 
azide (0.171 g, 2.64 mmol) was added in small portions over ten minutes and the resulting 
solution stirred at 0 °C for 5 h. The reaction was rapidly filtered and the precipitated 
washed with ice cold water and dried under vacuum to give 3-Azido-7-
diethylaminocoumarin as a golden solid (0.25 g, 76%). 1H NMR (300 MHz, CDCl3): δ 1.20 
(t, 6H, 3JH-H = 7.2 Hz, H11), 3.40 (q, 4H, 3JH-H = 7.2 Hz, H10), 6.50 (d, 1H, 4JH-H = 2.4 Hz, H9), 
6.58 (dd, 1H, 3JH-H = 8.8 Hz, 4JH-H = 2.4 Hz, H7), 7.10 (s, 1H, H4), 7.19 (d, 1H, 3JH-H = 8.8 Hz, 
H6). 13C {1H} NMR (100 MHz, CDCl3): δ 12.58, 44.94, 97.54, 108.17, 109.58, 119.76, 
127.73, 128.29, 149.98, 154.32, 158.54. ESIMS m/z calculated for 258.11 M+; observed 
259.2 [M+H]+. The 1H NMR data was consistent with that described in the literature. 
5.1.8 Preparation of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)picolinaldehyde 
 
A mixture of 3-azido-7-
diethylaminocoumarin (0.200 g, 0.77 mmol) 
and 4-ethynyl-1-formylpyridine (0.100 g, 
0.77 mmol) were dissolved in THF and water 
(5:1, 10 mL). A freshly prepared 1 M solution of sodium ascorbate (136 µl, 0.136 mmol) 
in water was added followed by a freshly prepared 7.5% solution of copper (II) sulphate 
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pentahydrate (112 µl, 0.034 mmol) in water. The mixture was stirred in the dark at room 
temperature for 72 h. Ice cold water (50 ml) was added to the reaction and the precipitate 
was rapidly collected by filtration. The solid was washed with ethanol (200 mL), diethyl 
ether (200ml). The product was then washed through into a separate flask with 
chloroform (200 mL) and the solvent evaporated to dryness to afford 4-(1-(7-
(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-yl)picolinaldehyde as a 
yellow solid (218 mg, 73%). 1H NMR (300 MHz, CDCl3): δ 1.26 (t, 6H, 3JH-H = 7.2 Hz, H19), 
3.47 (q, 4H, 3JH-H = 7.2 Hz, H18), 6.58 (d, 1H, 4JH-H = 2.4 Hz, H11), 6.70 (dd, 1H, 3JH-H = 9.0 
Hz, 4JH-H = 3 Hz, H13), 7.45 (d, 1H, 3JH-H = 9.0 Hz, H14), 8.11 (dd, 1H, 3JH-H = 6 Hz, 3JH-H = 3 
Hz H3), 8.40 (s, 1H,  H4), 8.50 (s, 1H, H16), 8.86 (d, 1H, 3JH-H = 6.0 Hz) 9.09 (s, 1H, H8), 
10.14 (s, 1H, Him). 13C {1H} NMR (100 MHz, CDCl3):12.57, 45.22, 97.15, 107.07, 110.40, 
116.35, 118.23, 122.50, 123.93, 130.35, 134.96, 139.49, 144.33, 151.04, 151.99, 153.59, 
156.07,156.96,193.36. δ. ESIMS m/z calculated for 389.15 M+; observed 390.2 [M+H]+ 
5.1.9 Preparation of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)picolinaldehyde 
 
A mixture of 3-azido-7-
diethylaminocoumarin (0.400 g, 0.77 
mmol) and 5-ethynyl-1-formylpyridine 
(0.200 g, 0.77 mmol) were dissolved in THF and water (10 mL, 5:1). A freshly prepared 1 
M solution of sodium ascorbate (272 µL, 0.272 mmol) in water was added followed by a 
freshly prepared 7.5% solution of copper (II) sulphate pentahydrate (224 µL, 0.068 
mmol) in water. The mixture was stirred in the dark at room temperature for 72 h. Ice 
cold water (50 mL) was added to the reaction and the precipitate was rapidly collected 
by filtration. The solid was washed with ethanol (200 mL), diethyl ether (200mL). The 
p4roduct was then washed through into a separate flask with chloroform (200 mL) and 
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the solvent evaporated to dryness to afford 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-
3-yl)-1H-1,2,3-triazol-4-yl)picolinaldehyde as a yellow solid (509 mg, 85%). 1H NMR (300 
MHz, CDCl3): δ 1.26 (t, 6H, 3JH-H = 7.2 Hz, H19), 3.48 (q, 4H, 3JH-H = 7.2 Hz, H18), 6.58 (d, 1H, 
4JH-H = 2.4 Hz, H11), 6.71 (dd, 1H, 3JH-H = 9.0 Hz, 4JH-H = 2.4 Hz, H13), 7.46 (d, 1H, 3JH-H = 9.0 
Hz, H14), 8.07 (d, 1H, 3JH-H = 8.1 Hz, H3), 8.42 (dd, 1H, 3JH-H = 8.1 Hz, 4JH-H = 1.2 Hz, H4), 
8.51 (s, 1H, H16), 9.06 (s, 1H, H8), 9.32 (d, 1H, 4JH-H = 1.2 Hz, H6), 10.12 (s, 1H, Hal). 13C 
{1H} NMR (100 MHz, CDCl3): δ 12.43, 45.08, 97.07, 106.99, 110.29, 121.79, 122.01, 130.21, 
130.57, 133.64, 134.82, 147.38, 151.88, 151.99, 152.08, 153.67, 155.96, 156.89, 192.89. 
ESIMS m/z calculated for 389.15 M+; observed 390.2 [M+H]+ 
5.1.10 Preparation of LC5 
 
5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-yl)picolinaldehyde 
(500 mg, 1.28 mmol) was dissolved in a mixture of chloroform (5 mL) and methanol (10 
mL). A solution of 4,4′-methylenedianiline (128 mg, 0.64 mmol in methanol 4 mL) was 
added dropwise to the stirred reaction. The reaction was stirred for 24 hours in the dark 
at room temperature. The product was collected by filtration, washed with methanol (100 
mL), diethyl ether (100 mL) and dried under vacuum to afford LC5 as a dark brown solid 
(511 mg, 85%). 1H NMR (300 MHz, CDCl3): δ 1.26 (t, 6H), 3.48 (q, 2H), 4.09 (s, 1H), 6.59 
(d, 1H), 6.71 (dd, 1H), 7.29 (s, 4H), 7.46 (d, 1H), 8.33 (m, 2H), 8.50 (s, 1H), 8.68 (s, 1H), 
9.00 (s, 1H), 9.24 (d, 1H). ESIMS m/z calculated for 941.07 M+; observed 942.2 [M+H]+ 
5.1.11 Preparation of [Fe2LC53][PF6]4 
 
Ligand LC5 (100mg, 0.11 mmol) was suspended in methanol (5mL). Fe(II)Cl2·4H2O (30 mg 
0.08 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
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Ligand LC5 solution. Upon addition of the metal salt the solution turned dark green with a 
purple hue. The reaction was stirred for 48 hours in the dark at room temperature. A 
saturated methanolic solution of ammonium hexafluorophosphate was added (1 mL) and 
the complex precipitated from solution. The solid was collected by filtration and washed 
with cold methanol (50 mL) and diethyl ether (50 mL). The green solid was dried under 
reduced pressure to afford [Fe2LC53][PF6]4 (72 mg, 56%). 1H NMR (300 MHz, CD3CN): δ 
1.24 (t, 6H), 3.58 (q, 4H), 4.11 (s, 1H), 5.94 (bs, 2H), 6.63 (s, 1H), 6.88 (d, 1H), 7.12 (bs, 
1H), 7.61 (bs, 1H), 8.41 (s, 1H), 9.00 (s, 1H), 9.09 (d, 1H), 9.42 (s, 1H). ESIMS m/z observed 
[M+H]+4 733.60. 
5.1.12 Preparation of LC4 
 
 
4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-yl)picolinaldehyde 
(150 mg, 0.38 mmol) was dissolved in a mixture of chloroform (5 mL) and methanol (10 
mL). A solution of 4,4′-methylenedianiline (38 mg, 0.19 mmol in methanol 4 mL) was 
added dropwise to the stirred reaction. The reaction was stirred for 24 hours in the dark 
at room temperature. The product was collected by filtration, washed with methanol (100 
mL), diethyl ether (100 mL) and dried under vacuum to afford LC4 as a dark brown solid 
(127 mg, 71%). 1H NMR (300 MHz, CDCl3): 1.26 (t, 3JH-H = 6.0 Hz, 6H), 3.47 (q, 3JH-H = 6.0 
Hz 4H), 4.07 (s, 1H), 6.58, (d, 3JH-H = 6.0 Hz, 1H), 6.70 (dd, 3JH-H = 9.0 Hz, 1H), 7.31 (d, 3JH-H 
= 3 Hz, 4H), 7.45 (d, 3JH-H = 9.0 Hz, 1H),  7.98 (dd, 3JH-H = 6.0 Hz, 1H), 8.50 (s, 1H), 8.63 (s, 
1H), 8.68 (s, 1H), 8.78 (d, 3JH-H = 6.0 Hz, 1H). 9.11 (s, 1H). δ 13C {1H} NMR (100 MHz, CDCl3): 
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δ 12.58 45.21, 97.18, 107.14, 110.34, 115.5, 118.31, 121.38, 121.65, 122.37, 129.96, 
130.31, 134.90, 138.85, 139.99, 145.03, 149.07, 150.51, 151.91, 155.51, 156.05, 159.84. 
ESIMS m/z calculated for 941.07 M+; observed 942.2 [M+H]+. 
5.1.13 Preparation of [Fe2LC43][PF6]4 
 
Ligand LC4 (100mg, 0.11 mmol) was suspended in methanol (5mL). Fe(II)Cl2·4H2O (30 mg 
0.08 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LC4 solution. Upon addition of the metal salt the solution turned dark green with a 
purple hue. The reaction was stirred for 48 hours in the dark at room temperature. A 
saturated methanolic solution of ammonium hexafluorophosphate was added (1 mL) and 
the complex precipitated from solution. The solid was collected by filtration and washed 
with cold methanol (50 mL) and diethyl ether (50 mL). The green solid was dried under 
reduced pressure to afford [Fe2LC43][PF6]4 (74 mg, 58%).1H NMR (300 MHz, CD3CN): 1.20 
(t, 6H), 3.50 (q, 4H), 4.05 (s, 1H), 5.62 (bs, 2H), 6.64 (d, 1H), 6.81 (dd, 1H), 6.97 (bs, 2H), 
7.48 (s, 1H), 7.57 (d, 1H), 8.21 (bs, 1H), 8.44 (s, 1H), 8.95 (bs, 1H), 9.13 (bs, 1H), 9.23 (bs, 
1H). ESIMS m/z observed 733.49 [M+H]4+. 
5.1.14 Preparation of dansyl-PEG3-azide 
 
Dansyl chloride (1000 mg, 3.7 mmol) was dissolved in 
anhydrous dichloromethane (10 mL). Anhydrous 
triethylamine (560 µL, 1.8 mmol) and 11-azido-3,6,9-
trioxaundecan-1-amine (806 µL, 1.1 eq, 4.07 mmol) 
were added and the reaction stirred for 15 h under argon at room temperature in the 
dark. A saturated aqueous solution of NaHCO3 (20 mL) was added and the reaction was 
extracted with dichloromethane (3 x 50 mL). The organic fractions were combined, dried 
over MgSO4, filtered and the solvent evaporated to dryness. The residue was purified 
using column chromatography on silica gel eluted with 2% MeOH in DCM. The product 
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fractions were combined and the solvent evaporated to afford dansyl-PEG3-azide (1.18 g, 
67%) as a bright yellow oil. 1H NMR (300 MHz, CDCl3): δ 8.51(d, 1H, 3JH-H = 8.52), 8.29 (d, 
1H, 3JH-H = 8.67),  8.22 (dd, 1H, 3JH-H = 7.29, 4JH-H = 1.23), 7.52 (m, 2H), 7.16 (d, 1H, 3JH-H = 
7.05 Hz), 5.60 (t, 1H, 3JH-H = 5.88), 4.09 (q, 1H, 3JH-H = 7.14), 3.61 (m, 6H), 3.47 (m, 2H), 3.35 
(m, 6H), 3.08 (q, 2H, 3JH-H = 5.70), 2.86 (s, 6H).δ 13C {1H} NMR (100 MHz, CDCl3): δ 42.87, 
45.22, 50.43, 68.96, 69.80, 69.98, 70.18, 70.35, 115.0, 118.76, 123.11, 129.05, 129.44, 
129.65, 130.12, 135.03, 151.72. MALDI-MS m/z calculated 451.19; observed M+ 451.12, 
[M+Na]+ 474.12, [M+K ]+490.02 
5.1.15 Preparation of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
Dansyl-PEG3-azide (588 mg, 1.3 
mmol) and 5-ethynyl-2-
formylpyridine (143 mg, 1.09 mmol) 
were dissolved in a mixture of 
ethanol and water (5:1 , 20 mL). Sodium ascorbate (400 µl of a 1M solution) and copper 
(II) sulphate pentahydrate (200 µl of a 1M solution) were added and the reaction was 
stirred for 18 h in the dark at room temperature under an argon atmosphere. The reaction 
was diluted with water (15 mL) and the solution extracted with dichloromethane (3 x 
50mL).  The organic fractions were combined, dried over MgSO4 and concentrated to 
dryness. The residue was purified by column chromatograph on silica gel eluted with 
DCM. The product containing fractions were combined, evaporated to dryness to afford 
the product as a yellow oil (425 mg, 67%). 1H NMR (300 MHz, CDCl3): δ δ 8.51(d, 1H, 3JH-
H = 8.52), 8.29 (d, 1H, 3JH-H = 8.67),  8.22 (dd, 1H, 3JH-H = 7.29, 4JH-H = 1.23), 7.52 (m, 2H), 
7.16 (d, 1H, 3JH-H = 7.05 Hz), 5.60 (t, 1H, 3JH-H = 5.88), 4.09 (q, 1H, 3JH-H = 7.14), 3.61 (m, 6H), 
3.47 (m, 2H), 3.38 (m, 6H), 3.09 (q, 2H, 3JH-H = 5.70), 2.85 (s, 6H). 13C {1H} NMR (100 MHz, 
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CDCl3): δ 42.00, 44.4, 49.4, 68.2, 69.3 69.2, 69.3, 69.4, 114.1, 117.9, 122.2, 127.1, 128.3, 
128.6, 128.6, 129.4, 130.0, 132.4,134.1, 142.5, 146.2, 150.9, 191.8 ESIMS m/z calculated 
M+ 582.6, observed [M+H]+ 583.6 
5.1.16 Preparation of 4-(dimethylamino)-N-(2-(2-(2-(2-(4-(2-
formylpyridin-4-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
Dansyl-PEG3-azide (100 mg, 0.22 
mmol) and 4-ethynyl-2-
formylpyridine (30 mg, 0.22 mmol) 
were dissolved in a mixture of ethanol 
and water (5:1 , 20 mL). Sodium ascorbate (200 µl of a 1M solution) and copper (II) 
sulphate pentahydrate (100 µl of a 1M solution) were added and the reaction was stirred 
for 18 h in the dark at room temperature under an argon atmosphere. The reaction was 
diluted with water (15 mL) and the solution extracted with dichloromethane (3 x 50mL).  
The organic fractions were combined, dried over MgSO4 and concentrated to dryness. The 
residue was purified by column chromatograph on silica gel eluted with DCM. The product 
containing fractions were combined, evaporated to dryness to afford the product as a 
yellow oil (75mg, 59%). 1H NMR (300 MHz, CDCl3): δ 2.77 (s, 6H), 3.02 (m, 2H), 3.31 (m, 
4H), 3.39 (m, 2H), 3.50 (m, 2H), 3.57 (m, 2H), 3.86 (t, 2H), (4.57 (t, 2H), 6.13 (t, 1H), 7.05 
(dd, 1H), 7.41 (dt, 2H), 7.94 (dd, 1H), 8.14 (dd, 1H), 8.19 (d, 1H), 8.23 (d, 1H), 8.29 (s, 1H), 
8.42 (d, 1H), 8.68 (dd, 1H),  10.00 (s, 1H). ESIMS m/z calculated M+ 582.6, observed 
[M+H]+ 583.7 
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5.1.17 Preparation of  LD5 
 
 
5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy) ethyl)naphthalene-1-sulfonamide (300 mg, 0.51 mmol) was 
dissolved in a mixture of chloroform (5 mL) and methanol (10mL). A solution of 4,4′-
methylenedianiline (51 mg, 0.25 mmol in 2 mL methanol) was added dropwise to the 
stirring reaction. The reaction was stirred for 24 h at room temperature in the dark. 
Methanol (10 mL) was added to the reaction and the solution was sonicated for 5 minutes 
to dissolve an oily residue that has built up on the side of the glass, the solution was stirred 
for a further 2 hours at room temperature in the dark. Diethyl ether (50 mL) was added 
to precipitate the product. The product was collected by filtration and dried under 
vacuum to afford LD5 as a brown solid (216 mg, 65%). 1H NMR (300 MHz, CDCl3): δ 2.85 
(s, 6H), 3.13 (m, 2H), 3.37 (m, 4H), 3.44 (m, 2H), 3.60 (m, 2H), 3.67 (m, 2H), 3.95 (t, 2H), 
4.03 (s, 1H), 4.66 (s, 2H), 6.32 (t, 1H), 7.12 (dd, 1H), 7.27 (s, 4H), 7.46 (ddd, 2H), 8.25 (m, 
3H), 8.32 (m, 2H), 8.50 (d, 1H), 8.72 (s, 1H), 9.09 (dd, 1H). 13C {1H} NMR (100 MHz, CDCl3): 
δ 43.18, 45.56, 50.49, 69.45, 70.22, 70.38, 70.51, 70.55, 115.27, 119.20, 121.71, 122.11, 
122.35, 123.32, 128.26, 129.31, 129.93, 130.42, 133.56, 146.84, 159.54.  
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5.1.18 Preparation of [Fe2LD53][PF6]4 
 
Ligand LD5 (100 mg, 0.075 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O 
(9.98 mg, 0.05 mmol) was dissolved in methanol (2 mL), this was added dropwise to the 
stirred Ligand LD5 solution. Upon addition of the metal salt the solution turned purple.  
The reaction was stirred for 24 hours in the dark at room temperature. A saturated 
methanolic solution of ammonium hexafluorophosphate was added (1 mL) and the 
complex precipitated from solution. The solid was collected by filtration and washed with 
cold methanol (50 mL) and diethyl ether (50 mL). The purple solid was dried under 
reduced pressure to afford [Fe2LD53][PF6]4 (95 mg, 82%). 1H NMR (300 MHz, CD3CN): δ 
2.83 (s, 6H), 2.93 (m, 2H), 3.26 (m , 4H), 3.33 (m, 2H), 3.43 (m, 2H), 3.51 (m, 2H), 3.81 (t, 
2H), 3.93 (s, 4H), 4.48 (t, 2H), 5.58 (bs, 2H), 5.99 (t, 1H), 6.90 (bs, 2H), 7.20 (d, 1H), 7.52 
(m, 2H), 8.06 (d, 2H), 8.18 (d, 1H), 8.32 (s, 1H), 8.50 (d, 1H), 8.64 (d, 1H), 8.77 (d, 8.77), 
8.89 (s, 1H). ESIMS m/z observed at 1023.8 [M+H]4+. 
5.1.19 Preparation of LD4 
 
 
4-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy) ethyl)naphthalene-1-sulfonamide (50 mg, 0.08 mmol) was 
dissolved in a mixture of chloroform (5 mL) and methanol (10mL). A solution of 4,4′-
methylenedianiline (7.5 mg, 0.04 mmol in 2 mL methanol) was added dropwise to the 
stirring reaction. The reaction was stirred for 24 h at room temperature in the dark. 
Methanol (10 mL) was added to the reaction and the solution was sonicated for 5 minutes 
to dissolve an oily residue that has built up on the side of the glass. The reaction was 
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stirred for a further 2 hours at room temperature in the dark. Diethyl ether (50 mL) was 
added to precipitate the product. The product was collected by filtration and dried under 
vacuum to afford LD4 as a brown solid (36 mg, 68%). 1H NMR (300 MHz, CDCl3): δ 2.85 (s, 
6H), 3.07 (t, 2H), 3.37 (t, 2H), 3.41 (m, 2H), 3.48 (m, 2H), 3.61 (m, 2H), 3.67 (m, 2H), 3.96 
(t, 2H), 4.05 (s, 1H), 4.65 (t, 2H), 5.70 (t, 1H), 7.13 (d, 1H), 7.21 (s, 1H), 7.26 (s, 4H), 7.48 
(t, 3H, 7.92 (s, 2H), 8.21 (dd, 1H), 8.28 (d, 1H), 8.31 (2, 1H), 8.50 (d, 1H). 13C {1H} NMR 
(100 MHz, CDCl3): δ 43.20, 45.54, 50.64, 69.37, 69.50, 70.27, 70.42, 70.60, 115.29, 118.37, 
119.04, 121.56, 128.37, 129.47, 129.95, 130.53. 
5.1.20 Preparation of [Fe2LD43][PF6]4 
 
Ligand LD4 (30 mg, 0.02 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O (3 mg, 
0.015 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LD4 solution. Upon addition of the metal salt the solution turned purple. The 
reaction was stirred for 24 hours in the dark at room temperature. A saturated methanolic 
solution of ammonium hexafluorophosphate was added (1 mL) and the complex 
precipitated from solution. The solid was collected by filtration and washed with cold 
methanol (50 mL) and diethyl ether (50 mL). The purple solid was dried under reduced 
pressure to afford [Fe2LD43][PF6]4 (25 mg, 72%). 1H NMR (300 MHz, CD3CN): δ 2.77 (s, 
2H), 2.91 (m, 2H), 3.23 (m, 4H), 3.31 (m, 2H), 3.47 (m, 2H), 3.57 (m, 2H), 3.90 (m, 2H), 
4.65 (m, 2H), 5.50 (bs, 2H), 6.15 (s, 1H), 6.70 (bs, 2H), 7.14 (s, 1H), 7.46 (s, 2H), 8.04 (s, 
2H), 8.17 (s, 2H), 8.43 (s, 1H). ESIMS m/z observed at 1169.7 [M+H]4+. 
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5.1.21 Preparation of LBr5 
 
To a solution of 5-bromopydrinde-2-
carboxaldehye (200 mg, 1.07 mmol) 
in methanol (30 mL) was added 
dropwise a solution of  4,4′-methylenedianiline (102 mg, 0.52 mmol  in 2 mL methanol). 
The reaction was stirred at room temperature for 20 h. A white precipitate formed which 
was collected by filtration, washed with cold methanol (100 mL), diethyl ether (50 mL) 
and dried under vacuum to afford LBr5 as a white powder (230 mg, 83%). 1H NMR (300 
MHz, CDCl3): δ 4.04 (1H, s), 7,26 (4H, s)7.94 (1H, dd, , 3JH-H = 9 Hz,  4JH-H = 3 Hz), 8.11 (1H, 
d, 3JH-H = 9 Hz), 8.57 (1H, s), 8.76 (1H, s). 13C {1H} NMR (100 MHz, CDCl3): δ 41.26, 121.57, 
122.95, 129.97, 139.49, 150.93, 158.95. ESIMS m/z observed at 535.00. 
5.1.22 Preparation of [Fe2LBr53][PF6]4 
 
 Ligand LBr5 (100mg, 0.18 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O (24 
mg, 0.12 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LBr5 solution. Upon addition of the metal salt the solution turned purple.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
solution. The solid was collected by filtration and washed with cold methanol (100 mL) 
and diethyl ether (50 mL). The purple solid was dried under reduced pressure to afford 
[Fe2LBr53][PF6]4 (115mg, 84%). 1H NMR (300 MHz, CD3CN): δ 4.08 (s, 1H), 5.51 (bs, 2H), 
6.97 (bs, 2H), 7.66 (s, 1H), 8.59 (m, 2H), 9.17 (s, 1H).   
5.1.23 Preparation of LBr4 
 
To a solution of 4-bromopydrinde-2-
carboxaldehye (100 mg, 0.54 mmol) 
in methanol (10 mL) was added 
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dropwise a solution of 4,4′-methylenedianiline (50 mg, 0.25 mmol in 2 mL methanol). The 
reaction was stirred at room temperature for 20 h. A white precipitate formed which was 
collected by filtration, washed with cold methanol (100 mL), diethyl ether (50 mL) and 
dried under vacuum to afford LBr4 as a white powder (117 mg, 88%). 1H NMR (300 MHz, 
CDCl3): δ  4.05 (1H, s), 7.27 (4H, s) 7.52 (1H, dd, 3JH-H = 6 Hz, 4JH-H = 3 Hz ), 8.40 (1H, d, 3JH-
H = 1.5 Hz), 8.50 (1H, d, 3JH-H = 6 Hz), 8.57 (1H, s). 13C {1H} NMR (100 MHz, CDCl3): δ 41.26, 
121.63, 152.17, 128.30, 129.99, 150.42, 158.65. ESIMS m/z observed at 535.00  
5.1.24 Preparation of [Fe2LBr43][PF6]4 
 
Ligand LBr4 (100mg, 0.18 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O (24 
mg, 0.12 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LBr4 solution. Upon addition of the metal salt the solution turned purple.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
solution. The solid was collected by filtration and washed with cold methanol (50 mL) and 
diethyl ether (50 mL). The purple solid was dried under reduced pressure to afford 
[Fe2LBr43][PF6]4 (109 mg, 79%). 1H NMR (300 MHz, CD3CN): δ 4.04 (s, 1H), 5.53 (bs, 1H), 
6.96 (bs, 1H), 7.25 (s, 1H), 7.99 (s, 1H), 8.73 (s, 1H), 8.92 (s, 1H).  
5.1.25 Preparation of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde 
 
To a mixture of imidazole-2-carboxaldehyde (300mg, 3.12 mmol) and 
potassium carbonate (431 mg, 2.98 mmol) in anhydrous DMF (13 
mL) was added propargyl bromide (80% w.v in toluene stabilised 
with MgO). The reaction was stirred at room temperature under an argon atmosphere for 
18 h. The suspension was filtered and the filtrate diluted with water (20 mL). The solution 
was extracted with diethyl ether (3 x 50 mL), the organic layer dried over MgSO4, filtered 
and the solvent evaporated to provide 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde 
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as a yellow oil (288 mg, 69 %). 1H NMR (300 MHz, CDCl3): δ 2.49 (1H, t, , 4JH-H = 3 Hz), 5.15 
(2H, d, , 4JH-H = 3 Hz), 7.20 (1H, s), 7.39 (1H, s), 9.69 (1H, s). 13C {1H} NMR (100 MHz, 
CDCl3): δ 182.1, 142.6, 131.6, 125.5, 76.1, 75.4, 37.2. ESIMS m/z calculated 134.13; observed 
134.1 M+, 135.1 [M+H]+ 
5.1.26 Preparation of LTBim 
 
To a solution of 1-(prop-2-yn-1-
yl)-1H-imidazole-2-
carbaldehyde (150 mg, 0.84 
mmol) dissolved in methanol (10 mL) was added dropwise a solution of 4,4′-
methylenedianiline (83 mg, 0.42 mmol in 2 mL methanol). The reaction was stirred at room 
temperature for 18 h. A white precipitate formed that was collected by filtration, washed with 
cold methanol (50 mL) and diethyl ether (50 mL). The product was dried under vacuum to 
afford LTBim as a white powder (148 mg, 82%). 1H NMR (300 MHz, CDCl3): δ 3.34 (1H, t, 4JH-
H = 3 Hz), 3.97 (1H, s), 5.46 (1H, d, 4JH-H = 3 Hz), 7.17 (1H, s), 7.26 (4H, q, 3JH-H = 9 Hz), 7.53 
(1H, s), 8.49 (1H, s). 13C {1H} NMR (100 MHz, CDCl3): δ 150.7, 148.8, 142.5, 140.3, 130.5, 
130.1, 125.4, 121.7, 79.4, 76.4, 44.6, 39.4 ESIMS m/z calculated 430.19, observed 431.2 
[M+H]+, 453.2 [M+Na]+ 
5.1.27 Preparation of [Fe2LTBim3][PF6]4 
 
Ligand LTBim (50 mg, 0.12 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O 
(16mg, 0.08 mmol) was dissolved in methanol (2 mL), this was added dropwise to the 
stirred Ligand LTBim solution. Upon addition of the metal salt the solution turned dark red.  
The reaction was stirred for 24 hours at room temperature. A saturated methanolic 
solution of ammonium hexafluorophosphate was added (1 mL) and the complex 
precipitated from solution. The solid was collected by filtration and washed with cold 
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methanol (50 mL) and diethyl ether (50 mL). The red solid was dried under reduced 
pressure to afford [Fe2LTBim3][PF6]4 (44 mg, 56%). ESIMS m/z observed at 350.81 [M+H]4+ 
5.1.28 Preparation of [Ni2LTBim3][PF6]4 
 
Ligand LTBim (50 mg, 0.12 mmol) was suspended in methanol (10 mL). Ni(II)Cl2·6H2O (19 
mg, 0.08 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LTBim solution. Upon addition of the metal salt the solution turned orange.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
solution. The solid was collected by filtration and washed with cold methanol (50 mL) and 
diethyl ether (50 mL). The orange solid was dried under reduced pressure to afford 
[Ni2LTBim3][PF6]4 (36 mg, 45%). ESIMS m/z observed at 352.13 [M+H]4+ 
5.1.29 Preparation of 3-azidopropan-1-ol 
 
3-Chlororpropanol-1-ol (5g, 52.8 mmol) and sodium azide (8.5g, 
130.7 mmol) were dissolved in water (65 mL). The solution was heated at 90 ᴼC for 20 h. 
The solution was cooled to room temperature and diluted with diethyl ether (200 mL) 
and brine (200 mL). The organic fraction was separated, dried over Na2SO4 and carefully 
concentrated to afford 3-azidopropan-1-ol as colourless oil (4.47g, 82%). 1H NMR (300 
MHz, CDCl3): δ 1.85 (2H, qu, 3JH-H = 6 Hz), 3.45 (2H, t, 3JH-H = 6 Hz)) 3.5 (1H, s, OH), 3.71 
(2H, t , 3JH-H = 6 Hz)). ESIMS m/z calculated 101.11, observed 102.22 [M+H]+ 
5.1.30 Preparation of 3-azidopropyl methanesulfonate 
 
3-Azidopropan-1-ol (1.219 g, 12.1 mmol) was dissolved in a 
mixture of dry THF (25 mL) and triethylamine (2.5 mL), the 
solution was cooled to 0ᵒC under argon. Mesyl chloride (1.5 mL) was added dropwise to 
the cooled solution and the mixture stirred for 1 h at 0 °C. The reaction mixture was then 
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slowly warmed to room temperature and stirred for 16 h. DCM (100 mL) and a saturated 
sodium bicarbonate solution (50 mL) were added to the reaction mixture. The organic 
layer was separated and washed with saturated sodium bicarbonate (2 x 50 mL), brine 
(50 mL) and dried over Na2SO4. The solvent was carefully removed to give 3-azidopropyl 
methanesulfonate as a colourless oil (1.647 mg, 76%). 1H NMR (300 MHz, CDCl3): δ 2.28 
(2h, qu, 3JH-H = 6 Hz), 3.31 (3H, s), 3.75 (2H, t, 3JH-H = 6 Hz), 4.58 (2H, t, 3JH-H = 6 Hz). δ ESIMS 
m/z [M+H]+ 180.2 
5.1.31 Preparation of 1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde 
 
To a mixture of imidazole-2-carboxaldehyde (300mg, 3.125 
mmol) and potassium carbonate (500 mg, 3.6 mmol) in 
anhydrous DMF (10 mL) was added 3-azidopropyl 
methanesulfonate. The reaction was stirred at room temperature under an argon 
atmosphere for 18 h. The suspension was filtered and the filtrate was diluted with water 
(20 mL). The solution was extracted with diethyl ether (3 x 50 mL), the organic layer dried 
over MgSO4, filtered and the solvent evaporated to provide 1-(3-azidopropyl)-1H-
imidazole-2-carbaldehyde as a yellow oil (374 mg, 67%). 1H NMR (300 MHz, CDCl3): δ 
1.95 (2H, qu, 3JH-H = 6 Hz) 3.22 (2H, t, 3JH-H = 6 Hz), 4.37 (2H, t, 3JH-H = 6 Hz), 7.13 (1H, s), 
7.19 (1H, s), 9.58 (1H, 2).  
5.1.32 Preparation of LimN 
 
 
To a solution of 1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde (150 mg, 0.84 mmol) 
dissolved in ethanol (10 mL) was added dropwise a solution of 4,4′-methylenedianiline (83 
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mg, 0.42 mmol in 2 mL ethanol). The reaction was stirred at room temperature for 18 h. A 
white precipitate formed that was collected by filtration, washed with cold methanol (100 mL) 
and diethyl ether (50 mL). The product was dried under vacuum to afford LimN as a white 
powder (140mg, 64%). 1H NMR (300 MHz, CDCl3): δ 2.25 (q, 2H), 3.45 (t, 2H), 4.12 (s, 1H), 
4.75 (t, 2H), 7.17 (s, 1H), 7.30 (d, 4H), 7.36 (s, 1H), 8.64 (s, 1H). 13C {1H} NMR (100 MHz, 
CDCl3): δ 30.09, 45.27, 48.49, 115.49, 121.25, 124.93, 129.80, 129.94, 130.49, 139.77, 
149.08, 150.61. 
5.1.33 Preparation of [Fe2LimN3][PF6]4 
 
Ligand LimN (50 mg, 0.09 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O (12 
mg, 0.06 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LimN solution. Upon addition of the metal salt the solution turned dark red.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
solution. The solid was collected by filtration and washed with cold methanol (50 mL) and 
diethyl ether (50 mL). The red solid was dried under reduced pressure to afford 
[Fe2LimN3][PF6]4 (23 mg, 34%). 1H NMR (300 MHz, CD3CN): δ 3.09 (bs), 3.37 (s), 3.89 (s), 
4.44 (s), 4.64 (bs), 6.58 (d), 6.90 (d), 7.26 (s), 8.49 (bs), 9.72 (s), 11.84 (bs), 15.17 (s), 
17.32 (s), 53.14 (bs), 58.20 (bs), 96.78 (bs). ESIMS m/z observed at 418.02 [M+H]4+. 
5.1.34 Preparation of [Ni2LimN3][PF6]4 
 
Ligand LimN (50 mg, 0.09 mmol) was suspended in methanol (10 mL). Ni(II)Cl2·6H2O (14 
mg, 0.06 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand LimN solution. Upon addition of the metal salt the solution turned orange.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
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solution. The solid was collected by filtration and washed with cold methanol (50 mL) and 
diethyl ether (50 mL). The orange solid was dried under reduced pressure to afford 
[Ni2LimN3][PF6]4 (28 mg, 42%). ESIMS m/z observed at 419.80 [M+H]4+. 
5.1.35 Preparation of L 
 
 
4,4′-Methylenedianiline (500 mg, 2.52 mmol) was dissolved in ethanol (50 mL), 2-
pyridinecarbaldehyde (0.5 mL, 5.04 mmol) was added dropwise. A cream suspension formed 
and the reaction was stirred for 22 h at room temperature. The precipitate was collected by 
filtration, washed with methanol (50 mL), diethyl ether (20 mL) and dried under vacuum to 
afford L as a pale cream solid (872 mg, 92%). 1H NMR (300 MHz, CDCl3): δ 4.05 (s, 1H), 7.26 
(s, 4H), 7.39 (ddd, 1H), 7.81 (dt, 1H), 8.20 (d, 1H), 8.62 (s, 1H), 8.71 (d, 1H). ESIMS m/z 
[M+H]+ 377.6. 
5.1.36 Preparation of [Fe2L3]Cl4 
 
Ligand L (100 mg, 0.26 mmol) was suspended in methanol (10 mL). Fe(II)Cl2·4H2O (35 
mg, 0.17 mmol) was dissolved in methanol (2 mL), this was added dropwise to the stirred 
Ligand L solution. Upon addition of the metal salt the solution turned purple.  The reaction 
was stirred for 24 hours at room temperature. A saturated methanolic solution of 
ammonium hexafluorophosphate was added (1 mL) and the complex precipitated from 
solution. The purple solid was collected by filtration and washed with cold methanol (50 
mL) and diethyl ether (50 mL). The purple solid was suspended in methanol (20 mL) and 
stirred with dowex to exchange the counter ion. The solution was stirred for 6 hours at 
room temperature, then filtered to remove the dowex beads. The solution was 
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concentrated under vacuum, to a small volume ~ 2 mL. Diethyl ether (50 mL) was added 
to precipitate the complex from solution. The precipitate was collected by filtration and 
dried under reduced pressure to afford [Fe2L3][Cl]4 as a purple solid (97 mg, 81%). 1H 
NMR (300 MHz, MeOD): δ 4.05 (s, 1H), 5.61 (bs, 2H), 7.03 (bs, 2H), 7.44 (d, 1H), 7.84 (t, 
1H), 8.48 (t, 1H), 8.68 (d, 1H), 9.14 (s, 1H).  
5.1.37 Preparation of Lim 
  
 
Imadazole-2-carboxaldehyde (500 mg, 5.2 mmol) was dissolved in methanol (20 mL). A 
solution of 4,4′-methylenedianiline (514 mg, 2.6 mmol) dissolved in methanol (2 mL) was 
added dropwise to the stirred solution forming a suspension. The reaction was stirred for 
18 h at room temperature and the precipitate was collected by filtration, washed with 
cold methanol (50 mL) and diethyl ether (20 mL) and dried under vacuum to afford Lim 
as a white solid (874 mg, 95%). 1H NMR (300 MHz, DMSO): 3.99 (s, 1H), 7.25 (d, 1H), 7.27 
(s, 1H), 7.32 (s, 1H), 7.32 (d, 1H), 8.41 (s, 1H), 13.07 (bs, 1H).δ 13C {1H} NMR (100 MHz, 
DMSO): δ 154.4, 150.4, 131.2, 130.1, 121.6, 120.6, 40.6. ESIMS m/z (M+H)+ 355.2 
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5.1.38 Preparation of 1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-
yl)-1H-1,2,3-triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde 
 
 
A mixture of 3-azido-7-diethylaminocoumarin (96 mg, 0.37 mmol) and 1-(prop-2-yn-1-
yl)-1H-imidazole-2-carbaldehyde (50 mg, 0.37 mmol) were dissolved in THF and water 
(5:1, 10 mL). A freshly prepared 1 M solution of sodium ascorbate (34 µl, 0.034 mmol) in 
water was added followed by a freshly prepared 7.5% solution of copper (II) sulphate 
pentahydrate (28 µl, 0.0085 mmol) in water. The mixture was stirred in the dark at room 
temperature for 72 h. Ice cold water (20 ml) was added to the reaction and the precipitate 
was rapidly collected by filtration. The solid was washed with ethanol (20 mL), diethyl 
ether (20ml). The product was then washed through into a separate flask with chloroform 
(20 mL) and the solvent evaporated to dryness to afford 1-((1-(7-(diethylamino)-2-oxo-
2H-chromen-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde as a 
yellow solid (48 mg, 33%). 1H NMR (300 MHz, CDCl3): δ 1.18 (t, 6H), 3.39 (q, 4H), 3.42 (s, 
2H), 5.73 (s, 2H), 6.49 (d, 1H), 6.60 (dd, 1H), 7.33 (d, 1H), 8.26 (s, 1H), 8.52 (s, 1H), 9.80 
(bs, 1H). 13C {1H} NMR (100 MHz, CDCl3): δ 12.4, 42.3, 45, 97.1, 106.9, 110.1, 116.6, 124.0, 
130.1, 135.1, 142.2, 142.7, 143.9, 151.7, 155.9, 156.8, 182.4.  
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5.1.39 Preparation of LimC 
 
1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-1H-
imidazole-2-carbaldehyde (20 mg, 0.05 mmol) was dissolved in methanol (5 mL). 4,4′-
Methylenedianiline (5 mg, 0.025 mmol) was dissolved in methanol (1 mL), and added 
dropwise to the stirred solution forming a suspension. The reaction was stirred for 18 h 
at room temperature and the precipitate was collected by filtration, washed with cold 
methanol (50 mL) and diethyl ether (20 mL) and dried under vacuum to afford LimC as a 
yellow solid (19 mg, 82%). 1H NMR (300 MHz, CDCl3): δ 1.23 (t, 6H), 3.44 (q, 4H), 4.04 (s, 
1H), 6.03 (s, 2H), 6.53 (s, 1H), 6.65 (d, 1H), 7.28 (s, 4H), 7.38 (d, 1H), 8.32 (s, 1H), 8.62 (s, 
1H). 13C {1H} NMR (100 MHz, CDCl3): δ12.42, 41.09, 45.00, 97.04, 106.95, 110.04, 116.72, 
121.30, 123.85, 129.91, 130.01, 134.90, 139.68, 151.64, 155.85, 156.82. ESIMS m/z 
calculated 946.41, observed 947.4 [M+H]+. 
5.1.40 Preparation of [Fe2LimC3][PF6]4 
 
Ligand LimC (8 mg, 0.008 mmol) was suspended in methanol (5 mL). Fe(II)Cl2·4H2O (1 mg, 
0.005) was dissolved in methanol (1 mL), this was added dropwise to the stirred Ligand 
LimC solution. Upon addition of the metal salt the solution turned dark red.  The reaction 
was stirred for 24 hours at room temperature. A saturated methanolic solution of 
ammonium hexafluorophosphate was added (100 µ) and the complex precipitated from 
solution. The solid was collected by filtration and washed with cold methanol (5 mL) and 
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diethyl ether (5 mL). The red solid was dried under reduced pressure to afford 
[Fe2LimC3][PF6]4 (4.1 mg, 43%). ESIMS m/z observed at 738.23 [M+H]4+. 
5.1.41 Preparation of [Ni2LimC3][PF6]4 
 
Ligand LimC (8 mg, 0.008 mmol) was suspended in methanol (5 mL). Ni(II)Cl2·6H2O (1.3 
mg 0.005) was dissolved in methanol (1 mL), this was added dropwise to the stirred 
Ligand LimC solution. Upon addition of the metal salt the solution turned orange.  The 
reaction was stirred for 24 hours at room temperature. A saturated methanolic solution 
of ammonium hexafluorophosphate was added (100 µl) and the complex precipitated 
from solution. The solid was collected by filtration and washed with cold methanol (5 mL) 
and diethyl ether (5 mL). The orange solid was dried under reduced pressure to afford 
[Ni2LimC3][PF6]4 (3.8 mg, 40%). ESIMS m/z observed at 739.65 [M+H]4+. 
5.1.42 Preparation of dasnyl _C3_N3 
Dansyl chloride (200 mg, 0.74 mmol) was dissolved in anhydrous 
DCM (5 mL) and anhydrous triethylamine (103 µl, 0.74 mmol). The 
solution was cooled to 0 ᵒC under argon before the addition of 3-
azidopropylamine (300 µl). The reaction was stirred for 1 h at 0 ᵒC 
before warming to room temperature and string for an additional 2 hours. The solvent 
was removed in vacuo and the crude product was purified by flash chromatograph on 
silica gel using DCM/MeOH (49:1) as eluent, to afford the product as a yellow oil (141.9 
mg, 58 %). 1H NMR (300 MHz, CDCl3): δ 1.62 (2H, qu, 3JH-H = 6.6 Hz), 2.88 (6H, s), 2.97 
(2H, q, 3JH-H = 6.6Hz), 3.22 (2H, t, 
3JH-H = 6.3 Hz), 5.38 (1H, t, 
3JH-H = 6.3 Hz), 7.17 (1H, d, 
3JH-H = 7.5 Hz), 7.53 (2H, m), 8.25 (1H, dd, 
3JH-H = 7.5 Hz, 
4JH-H = 1.2 Hz), 8.31 (1H, d, 
3JH-H 
= 8.4 Hz), 8.54 ( 1H, d, 3JH-H = 8.4 Hz).  
13C {1H} NMR (100 MHz, CDCl3): δ 28.82, 40.70, 
45.44, 48.70, 115.30, 118.62, 123.21, 128.53, 129.56, 130.63, 134.46, 152.09.  ESMS m/z 
calculated 333.13, found [M+H]+ at 334.1. 
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5.1.43 Preparation of FITC_C3_N3 
Fluorescein isothiocyanate isomer I (100 mg, 0.257 
mmol) was suspended in anhydrous DCM (5mL) and 
anhydrous triethylamine (70 µl, 0.502 mmol). 3-
Azidopropylamine (300 µl) was added dropwise, the 
solution was stirred under argon at room temperature 
for 48 h.  The solvent was removed under reduced pressure and the residue purified using 
flash chromatography on silica gel using DCM/MeOH (9/1). The residue was dried under 
vacuum overnight to afford the product as an orange powder (66 mg, 53%) 1H NMR (300 
MHz, CD3OD): δ 1.88 (2H, qu, 3JH-H = 6.6 Hz), 3.27 (1H, qu, 4JH-H = 1.8 Hz), 3.38 (2H, t, 3JH-
H = 6.6 Hz), 3.66 (2H, t, 
3JH-H = 6.9 Hz), 6.49 (1H, d,
  4JH-H = 2.4 Hz), 6.52 (1H, d, 
4JH-H = 2.4 
Hz), 6.63 (1H, s), 6.64 (1H, s), 6.67 (1H, s), 6.70 (1H, s), 7.11 (1H, d, 3JH-H = 8.1 Hz), 7.69 (1H, 
dd, 3JH-H = 8.1 Hz, 
4JH-H = 1.8 Hz), 8.07 (1H, d, 
4JH-H = 1.8 Hz). 
13C {1H} NMR (100 MHz, 
CD3OD): δ 29.33, 43.06, 50.31, 103.56, 111.89, 114.33, 120.60, 126.16, 130.08, 130.19, 
130.53, 131.50, 131.59, 142.27, 148.20, 154.60, 162.67, 171.37, 182.99.  ESMS m/z calculated 
489.11, found [M+H]+ at 490.1. 
5.1.44 Preparation of FITC_PEG3_N3 
 Fluorescein isothiocyanate isomer I (100 
mg, 0.257 mmol) was suspended in 
anhydrous DCM (5mL) and anhydrous 
triethylamine (100 µl, 0.717 mmol). 11-
azido-3,6,9-trioxaundecan-1-amine (200 
µl, mmol) was added dropwise, the 
solution was stirred under argon at room temperature for 36 h.  The solvent was removed 
under reduced pressure and the residue purified using flash chromatography on silica gel 
using DCM/MeOH (6/1). The residue was dried under vacuum overnight to afford the 
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product as an orange powder (75 mg, 48%)1H NMR (400 MHz, CD3OD): δ 3.28-3.26 (2H, 
m), 3.55-3.66 (14H, m), 3.76 (2H, bs), 6.49 (1H, d, 4JH-H = 2.4Hz), 6.51 (1H, d, 
4JH-H = 2.8 Hz), 
6.67 (1H, 2), 6.641 (1H, s), 6.644 (1H, s), 7.10 (1H, d, 3JH-H = 8.0 Hz), 7.73 (1H, d, 
3JH-H = 8.0 
Hz), 8.14 (1Hy, d, 4JH-H = 1.6 Hz). 
13C {1H} NMR (100 MHz, CD3OD): δ 45.45, 51.66, 62.14, 
70.15, 70.99, 71.27, 71.39, 71.43, 71.47, 71.55, 103.55, 111.66, 113.67, 113.73, 113.99, 119.90, 
125.89, 129.45, 130.16, 130.29, 130.41, 131.34, 131.44, 142.35, 148.68, 148.75, 154.32, 
161.96, 171.23, 182.73. 
5.1.45 Preparation of LTB5 
 
 
 
5-Ethynyl-2-formylpyridine (100 mg, 0.76 mmol) was dissolved in ethanol (20 mL). A 
solution of 4,4′-methylenedianiline (75 mg, 0.38 mmol) dissolved in ethanol (2 mL) was 
added dropwise to the stirred solution forming a suspension. The reaction was stirred for 
18 h at room temperature and the precipitate was collected by filtration, washed with 
cold methanol (50 mL) and diethyl ether (20 mL) and dried under vacuum to afford LTB5 
as a white solid (135 mg, 84%). 1H NMR (300 MHz, CDCl): 3.34 (s, 1H), 4.05 (s, 1H), 7.25 
(s, 4H), 7.88 (dd, 1H), 8.19 (dd, 1H), 8.61 (s, 1H), 8.79 (dd, 1H).  
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5.2 Cell culture experimental 
5.2.1 General cell culture 
DMEM (Dulbeccos Modified Eagles Medium with 4500mg glucose/L, 110mg sodium 
pyruvate/L, pyridioxine.HCl and NaHCO3 and phenol red), PBS (Phosphate Buffered 
Saline – without sodium and magnesium chloride), FBS (Fetal Bovine Serum – heat 
inactivated, sterile filtered), L-Glutamine 200mM, Penicillin-Streptomycin - 10,000 units 
penicillin and 10 mg streptomycin/mL, trypsin-EDTA (0.5% trypsin, 0.2% EDTA, x 10 
concentration) were all purchased from Sigma Aldrich and used as received. RPMI 1640 
(Roswell Park Memorial Institute with 2000 mg glucose/L, Glutathione 1.0 mg/L and 
phenol red) and McCoys 5A media (3000 mg glucose/L, Bacto-Peptone 600mg/L 
Glutathione 0.5mg/L and phenol red) were purchased from GIBCO life technologies and 
used as received. All cell culture was performed in a sterile cell culture laminar flow cell 
culture hood. All solutions were warmed to 37 °C in a water bath prior to use.   
5.2.2 Cell lines  
MDA-231 human Caucasian breast adenocarcinoma (92020424) cultured using DMEM, 
A2780 human ovarian carcinoma (93112519) cultured using RPMI, U-2 OS Human 
Osteosarcoma (92022711) cultured using McCoys 5A, HeLa Human cervix epitheloid 
carcinoma (93021013) cultured using DMEM, HeK-293 Human Embryo Kidney 
(85120602) cultured using DMEM. All cell lines were obtained fro the European collection 
of cell culture (ECACC). 
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5.2.3 Cell media preparation 
DMEM and RPMI were supplemented with FBS (10% v/v), penicillin (100 U/ml), 
streptomycin (100 µg/mL) and L-glutamine (2mM). McCoys 5A was supplemented with 
FBS (10% v/v), penicillin (100 U/ml) and streptomycin (100 µg/mL). 
5.2.4 Cell culture passage  
Cells were passaged once they reached 80% confluence. Media, Trypsin-EDTA and PBS 
were warmed to 37°C in a water bath. Old media was removed carefully, cells were then 
gently rinsed with PBS (10 mL), and the PBS removed. Trypin-EDTA (2 mL of a x1 
solution) was added and then flask was returned to the incubater for 5 minutes. Cell 
detachment was monitored using a Leica DMIL light microscope. Once cells were fully 
detached, media was added to inhibit the trypsin-EDTA. The contents of the flask was 
transferred to a 15 mL falcon tube. The cell suspension was subjected to centrifugation in 
a Falcon 6/300 refrigerated centrifuge for 5 minutes at 1500 rpm at 20 °C. The 
supernatant was discarded and the cell pellet was resuspended in 1 mL of media. Fresh 
media (15 mL) was added to a new T75 flask along with 200 μL of the cell suspension. 
The flask was swirled gently to evenly distribute cells. The flask was then placed in an 
incubator at 37 °C with a 5% CO2 atmosphere. 
5.2.5 Cryopreservation of cells 
Cell lines were preserved for future use by following cell passage up to centrifugation. The 
cell pellet was resuspended into 3 mL of freezing media (FBS and DMSO 10%  v/v). 1 mL 
aliquots were placed into o-ring cryovials. Samples were placed in the -80°C freezer for 
24 h and then transferred to a vapour phase liquid nitrogen tank for longterm storage. 
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5.2.6 Cell counting 
The steps for cell passage were followed up to cell centrifugation and resuspension in 1 
mL of media. 20 μL of the cell suspension was added to 180 μL of media in an eppindorf. 
A Hawksley BS.748 Neubauer haemocytometer with a 0.1 mm depth was sterilised with 
70% ethanol along with a cover slip that was placed on top of the haemocytometer. 10 μL 
of the cell aliquot was pipetted onto each side of the haemocytometer. Cells were counted 
in the central square of the grid on both sides and an average was taken. The volume 
required for the desired number of cells was then calculated using the equation. 
5.2.7 Sapphire disc sample preparation 
35 mm Round sapphire discs (knights optical) were sterilised by placing them in a 70 % 
ethanol solution for 5 minutes, the air drying in a sterilpetri disc in a laminar flow hood. 
The discs were then dipped into PBS twice, followed by the applicable media for the cell 
type being used. One disc was then placed into each well in a sterile 6 well plate. Cells 
were counted using the above procedure and 300,000 cells were placed in each well and 
the total volume made up to 3 mL with media. The plates were then placed in an incubator 
at 37°C with 5% CO2 for 24 hours to allow cells to adhere to the disc. Cells were the treated 
with the compound at the required concentration for the desired length of time. The 
media was then removed and the discs were gently washed twice with PBS to remove any 
residual media. The discs were then snap frozen using a dry ice and methanol slurry that 
had been allowed to cool down to -70°C. discs were firstly bolted from the side to remove 
the majority of PBS on the surface by capillary action. Discs where then hovered over the 
surface of the bath for a few seconds, submerged into the bath for 5 seconds, then placed 
into labelled 6 wells plates kept on a bed of dry ice. Samples where then stored in a -80°C 
freezer until use, when they were shipped to the diamond light source on dry ice.  
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5.2.8 TEM grid sample preparation 
Gold TEM grids covered with an R2/2 quantifoil carbon film were sterilised by dipping in 
a 70% ethanol solution and then leaving them on a sterile surface to dry, until the ethanol 
had fully evaporated. One TEM grid was placed in each well of a 6 well plate. Cells were 
counted using the above procedure and 50,000 cell were placed into each well and the 
total volume made up to 3 mL using media. Plates were placed into and incubator at 37°C 
with 5% CO2 for 24h for cells to adhere. Cells were then treated with compound at varying 
concentrations for the required length of time. Sampled were plunge frozen using a Joel 
Cy3 plunge freezer. Grids were removed from the well extremely carefully using 
opposable tweezers so as to not damage the quatifoil film. The sample were placed in the 
plunge freezer, blotted from behind for 2 seconds and then plunged in a solution of liquid 
nitrogen cooled liquid ethane. The sample was then transferred into cyro grid boxes 
whilst still submerged in liquid nitrogen. Sample grid boxes were stored at liquid nitrogen 
temperature in a dry shipper. 
5.2.9 MatTek dish preparation 
MatTek dishes were seeded with 300,000 cells per well and cells were left to adhere for 
24 hours. The media was removed, cells were washed with PBS and clear media was 
added (without phenol red). The dish was transferred to the microscope, focused and an 
image taken before treatment. The complex was then added and an imaging time course 
was under taken. 
 
 
 
 
 
Appendix 
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6 Appendix 
 
6.1 NMR spectra of 5-trimethylsilylethynyl-2-formyl pyridine 
 
Figure 6.47 1H NMR spectrum of 5-trimethylsilylethynyl-2-formyl pyridine in CDCl3 
 
 
Figure 6.48 13C NMR spectrum of 5-trimethylsilylethynyl-2-formyl pyridine in CDCl3 
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6.2 NMR spectra of 5-ethynyl-2-formylpyridine 
 
Figure 6.49 1H NMR spectrum of 5-ethynyl-2-formylpyridine in CDCl3 
 
 
Figure 6.50 13C NMR spectrum of 5-ethynyl-2-formylpyridine in CDCl3 
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6.3 NMR spectra of 4-trimethylsilylethynyl-2-formyl pyridine 
 
Figure 6.51 1H NMR spectrum of 4-trimethylsilylethynyl-2-formyl pyridine in CDCl3 
 
Figure 6.52 13C NMR spectrum of 4-trimethylsilylethynyl-2-formyl pyridine in CDCl3 
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6.4 NMR spectra of 4-ethynyl-2-formylpyridine 
 
 
Figure 6.53 1H NMR spectrum of 4-ethynyl-2-formylpyridine in CDCl3 
 
 
 
Figure 6.54 13C NMR spectrum of 4-ethynyl-2-formylpyridine in CDCl3 
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6.5 NMR spectra of 3-nitro-7-diethylamino coumarin 
 
 
Figure 6.55 1H NMR spectrum of 3-nitro-7-diethylamino coumarin in CDCl3 
 
 
Figure 6.56 13C NMR spectrum of 3-nitro-7-diethylamino coumarin in CDCl3 
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Figure 6.57 COSY NMR spectrum of 3-nitro-7-diethylamino coumarin in CDCl3  
 
 
Figure 6.58 HSQC NMR spectrum of 3-nitro-7-diethylamino coumarin in CDCl3 
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6.6 NMR spectra of 3-amino-7-diethylamino coumarin 
 
Figure 6.59 1H NMR spectrum of 3-amino-7-diethylamino coumarin in CDCl3 
 
Figure 6.60 13C NMR spectrum of 3-amino-7-diethylamino coumarin in CDCl3 
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Figure 6.61 COSY NMR spectrum of 3-amino-7-diethylamino coumarin in CDCl3 
 
Figure 6.62 HSQC NMR spectrum of 3-amino-7-diethylamino coumarin in CDCl3 
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6.7 NMR spectra of 3-azido-7-diethylaminocoumarin 
  
Figure 6.63 1H NMR spectrum of 3-azido-7-diethylaminocoumarin in CDCl3 
 
Figure 6.64 13C NMR spectrum of 3-azido-7-diethylaminocoumarin in CDCl3 
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Figure 6.65 COSY NMR spectrum of 3-azido-7-diethylaminocoumarin in CDCl3 
 
Figure 6.66 HSQC NMR spectrum of 3-azido-7-diethylaminocoumarin in CDCl3 
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6.8 NMR spectra of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)picolinaldehyde 
 
Figure 6.67 1H NMR spectrum of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-
4-yl)picolinaldehyde in CDCl3 
 
Figure 6.68 13C NMR spectrum of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-
4-yl)picolinaldehyde in CDCl3 
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Figure 6.69 13C NMR spectrum of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-
4-yl)picolinaldehyde in CDCl3 
 
 
Figure 6.70 HSQC NMR spectrum of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)picolinaldehyde in CDCl3 
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Figure 6.71 COSY NMR spectrum of 4-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)picolinaldehyde in CDCl3 
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6.9 NMR spectra of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)picolinaldehyde 
 
 
Figure 6.72 1H NMR spectrum of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-
4-yl)picolinaldehyde in CDCl3 
 
Figure 6.73 13C NMR spectrum of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazol-
4-yl)picolinaldehyde in CDCl3 
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Figure 6.74 COSY NMR spectrum of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)picolinaldehyde in CDCl3 
 
Figure 6.75 HSQC NMR spectrum of 5-(1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)picolinaldehyde in CDCl3 
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6.10 NMR spectra of LC5 
 
Figure 6.76 1H NMR spectrum of LC5 in CDCl3 
  
212 
 
6.11 NMR spectra of [Fe2LC53][PF6]4 
 
Figure 6.771H NMR spectrum of [Fe2LC53][PF6]4 in CD3CN 
 
Figure 6.78 COSY NMR spectrum of [Fe2LC53][PF6]4 in CD3CN  
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6.12 NMR spectra of LC4 
 
Figure 6.79 1H NMR spectrum of LC4 in CDCl3 
 
Figure 6.80 13C NMR spectrum of LC4 in CDCl3 
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Figure 6.81 HSQC NMR spectrum of LC4 in CDCl3 
 
 
Figure 6.82 COSY NMR spectrum of LC4 in CDCl3 
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Figure 6.83 NOESY NMR spectrum of LC4 in CDCl3  
6.13 NMR spectra of [Fe2LC43][PF6]4 
 
Figure 6.84 1H NMR spectra of [Fe2LC43][PF6]4 in CD3CN 
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6.14 NMR spectra of dansyl-PEG3-azide 
 
 
Figure 6.85 1H NMR spectrum of dansyl-PEG3-azide in CDCl3 
 
Figure 6.86 13C NMR spectrum of dansyl-PEG3-azide in CDCl3 
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Figure 6.87 13C NMR spectrum of dansyl-PEG3-azide in CDCl3 
 
Figure 6.88 HSQC NMR spectrum of dansyl-PEG3-azide in CDCl3 
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Figure 6.89 COSY NMR spectrum of dansyl-PEG3-azide in CDCl3 
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6.15 NMR spectra of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-
formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
Figure 6.90 1H NMR spectrum of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide in CDCl3 
  
Figure 6.91 13C NMR spectrum of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide in CDCl3 
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Figure 6.92 HSQC NMR spectrum of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide in CDCl3 
 
Figure 6.93 COSY NMR spectrum of 5-(dimethylamino)-N-(2-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide in CDCl3 
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6.16 NMR spectra of 4-(dimethylamino)-N-(2-(2-(2-(2-(4-(2-
formylpyridin-4-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 
 
Figure 6.94 1H NMR spectra of 4-(dimethylamino)-N-(2-(2-(2-(2-(4-(2-formylpyridin-4-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide in CDCl3 
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6.17 NMR spectra of LD5 
 
 
Figure 6.95 1H NMR spectrum of LD5 in CDCl3 
 
  
Figure 6.96 13C NMR spectrum of LD5 in CDCl3 
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Figure 6.97 13C NMR spectrum of LD5 in CDCl3 
 
Figure 6.98 HSQC NMR spectrum of LD5 in CDCl3 
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Figure 6.99 COSY NMR spectrum of LD5 in CDCl3 
 
Figure 6.100 NOESY NMR spectrum of LD5 in CDCl3 
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6.18 NMR spectra of [Fe2LD53][PF6]4 
 
 
Figure 6.101 1H NMR spectrum of [Fe2LD53][PF6]4 in CD3CN 
 
 
Figure 6.102 COSY NMR spectrum of [Fe2LD53][PF6]4 in CD3CN 
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6.19 NMR spectra of LD4 
 
Figure 6.1031H NMR spectrum of LD4 in CDCl3 
 
Figure 6.104 13C NMR spectrum of LD4 in CDCl3 
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Figure 6.105 13C NMR spectrum of LD4 in CDCl3 
 
Figure 6.106 HSQC NMR spectrum of LD4 in CDCl3 
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Figure 6.107 COSY NMR spectrum of LD4 in CDCl3 
6.20 NMR spectrum of [Fe2LD43][PF6]4 
 
Figure 6.108 1H NMR spectrum [Fe2LD43][PF6]4 of  CD3CN 
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6.21 NMR spectra of LBr5 
 
 
Figure 6.109 1H NMR spectrum of LBr5 in CDCl3 
 
Figure 6.110 13C NMR spectrum of LBr5 in CDCl3 
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6.22 NMR spectrum of [Fe2LBr53][PF6]4 
 
Figure 6.111 1H NMR spectrum of [Fe2LBr53][PF6]4 in CD3CN 
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6.23 NMR spectra of LBr4 
 
Figure 6.112 1H NMR spectrum of LBr4 in CDCl3 
 
 
Figure 6.113 13C NMR spectrum of LBr4 in CDCl3 
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6.24 NMR spectra of [Fe2LBr43][PF6]4 
 
Figure 6.114 1H NMR spectrum of [Fe2LBr43][PF6]4 in CD3CN 
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6.25 NMR spectra of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde 
 
Figure 6.115 1H NMR spectrum of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde in CDCl3 
 
 
Figure 6.116 13C NMR spectrum of 1-(prop-2-yn-1-yl)-1H-imidazole-2-carbaldehyde in CDCl3 
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6.26 NMR spectra of LTBim 
 
Figure 6.117 1H NMR spectrum of LTBim in DMSO 
 
Figure 6.118 13C NMR spectrum of LTBim in DMSO 
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6.27 NMR spectrum of 3-azidopropan-1-ol 
 
Figure 6.119 1H NMR spectrum of 3-azidopropyl methanesulfonate in CDCl3 
6.28 NMR spectrum of 3-azidopropyl methanesulfonate 
 
Figure 6.120 1H NMR spectrum of 3-azidopropyl methanesulfonate in CDCl3 
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6.29 NMR spectra of 1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde 
  
Figure 6.121 1H NMR spectrum of 1-(3-azidopropyl)-1H-imidazole-2-carbaldehyde in CDCl3 
6.30 NMR spectra of LNim 
 
 
Figure 6.122 1H NMR spectrum of LNim in CDCl3 
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Figure 6.123 13C NMR spectrum of LNim in CDCl3 
 
Figure 6.124 13C NMR spectrum of LNim in  
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6.31 NMR spectrum of [Fe2LNim3][PF6]4 
 
 
Figure 6.125 1H NMR spectrum of [Fe2LNim3][PF6]4 in CD3CN 
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6.32 NMR spectra of 1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-
1H-1,2,3-triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde
 
 
Figure 6.126 1H NMR spectrum of 1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde in CDCl3 
 
Figure 6.127 13C NMR spectrum of 1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde in CDCl3 
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Figure 6.128 HSQC NMR spectrum of 1-((1-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-
triazol-4-yl)methyl)-1H-imidazole-2-carbaldehyde in CDCl3 
 
6.33 NMR spectra of LimC 
 
Figure 6.129 1H NMR spectrum of LimC in CDCl3 
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Figure 6.130 13C NMR spectrum of LimC in CDCl3 
 
Figure 6.131 HSQC NMR spectrum of LimC in CDCl3 
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6.34 NMR spectrum of L 
 
Figure 6.132 1H NMR spectrum of L in CDCl3 
 
6.35 NMR spectrum of [Fe2L3]Cl4 
 
Figure 6.133 1H NMR spectrum of [Fe2L3]Cl4 in CD3CN 
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6.36 NMR spectra of Lim 
 
 
Figure 6.134 1H NMR spectrum of Lim in DMSO 
 
 
Figure 6.135 13C NMR spectrum of Lim in DMSO 
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Figure 6.136 HSQC spectrum of Lim in DMSO 
  
6.37 NMR spectra of dansyl _C3_N3 
 
Figure 6.137 1H NMR spectrum of Dansyl _C3_N3 in CDCl3 
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Figure 6.138 13C NMR spectrum of Dansyl _C3_N3 in CDCl3 
 
6.38 NMR spectra of FITC_C3_N3 
 
Figure 6.139 1H NMR spectrum of FITC _C3_N3 in MeOD 
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Figure 6.140 13C NMR spectrum of FITC_C3_N3 in MeOD 
 
 
Figure 6.141 COSY NMR spectrum of FITC _C3_N3 in MeOD 
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Figure 6.142 HSQC NMR spectrum of FITC _C3_N3 in MeOD 
6.39 NMR spectra of FITC_PEG3_N3 
 
Figure 6.143 1H NMR spectrum of FITC_PEG3_N3 in MeOD 
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Figure 6.144 13C NMR spectrum of FITC_PEG3_N3 in MeOD 
 
 
Figure 6.145 13C NMR spectrum of FITC_PEG3_N3 in MeOD 
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Figure 6.146 HSQC NMR spectrum of FITC_PEG3_N3 in MeOD 
  
Figure 6.147 COSY NMR spectrum of FITC_PEG3_N3 in MeOD 
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6.40  NMR spectrum of LTB5 
 
Figure 6.148 1H NMR spectrum of LTB5 in CDCl3 
